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Background: There is increasing evidence that trauma exposure is associated with impulsive 
behaviour and difficulties regulating affect. The findings of recent studies implicate the 
disruption of neurobiological mechanisms, particularly those involving the neurotransmitter 
serotonin, in both impulsivity and affect regulation.  
Method: This thesis interrogated the link between maladaptive responses to childhood 
trauma, affect-regulation and impulsivity, using a four-pronged approach.  Firstly, a 
systematic meta-analysis of pharmacotherapy for disorders associated with poor impulse 
control and aggression in children and adolescents provided a basis for the argument that 
developmental disruptions of the serotonergic system are common to both. The extent to 
which serotonin is involved in difficulties regulating emotion in traumatised adults was
subsequently investigated via a meta-analysis of the efficacy of selective serotonin-reuptake 
inhibitors (SSRIs) in treating posttraumatic stress disorder (PTSD). The neural circuitry
underlying behavioural impulsivity and affect regulation was identified by conducting an
Activation Likelihood Estimation meta-analysis of fMRI data from 51 studies employing the 
Go/NoGo paradigm. Finally, an empirical investigation of the hypothesis that the relationship 
between childhood trauma exposure and subsequent difficulties in emotion regulation and
impulsivity might be mediated by impaired opioid neurotransmission was conducted by
comparing performance on an emotion recognition paradigm in 40 trauma-exposed and
healthy students from the University of Cape Town who participated in a placebo-controlled 
study of the partial mu-opioid agonist buprenorphine.
Results: This thesis observed evidence that (a) the reduction of aggression symptoms in 
disruptive behaviour disorders might be mediated by serotonergic pathways, (b) that the 
SSRIs are effective in treating PTSD, (c), that the GNG paradigm reliability elicits neural 














of childhood trauma demonstrate impairments in affect regulation, including the avoidance of 
angry faces, and that buprenorphine was effective in normalising trauma-associated deficits 
in the recognition of fearful faces.  
 
Conclusion: Collectively, the results obtained through a combination of multiple 
methodologies, including the analysis of data from a pharmacological challenge study as 
well as that collected through meta-analysis, point to possible clinical and research 
implications for the serotonergic manipulation of childhood-trauma associated impairments in 
impulsivity and affect regulation. Moreover, the GNG paradigm appears to be a suitable 
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As many as 80-100% of people will be exposed to a potentially traumatising event during 
their lifetimes (Breslau et al., 1998; Frans, Rimmö, Aberg, & Fredrikson, 2005). There is 
evidence of a robust relationship between psychological trauma incurred in childhood and 
deficits in emotion regulation. For example, childhood interpersonal traumas but not adult 
traumas were recognised in a large sample (N=620) of non-clinical subjects as representing 
a vulnerability factor for poor affect regulation (Briere & Rickards, 2007). Additionally, 
cumulative childhood trauma but not adult trauma predicted the likelihood of deficits in self-
regulation (including affect dysregulation) and posttraumatic stress disorder (PTSD) 
symptoms in a sample of 582 women who presented at trauma clinics (Cloitre et al., 2009). 
The replication of this latter finding with respect to a sample of children suggests that it 
cannot be explained solely by the effects of mood in adults on retrospective self-reporting 
measures of child trauma (Cloitre et al., 2009). Finally, disordered eating and self-injurious 
behaviours in females, frequently associated with childhood maltreatment, has been 
theorised to be moderated by difficulties regulating emotions (Hund & Espelage, 2006; 
Paivio & McCulloch, 2004).  
  
The majority of evidence for an association between trauma exposure, affect dysregulation 
and impulsivity can be found in the clinical literature on posttraumatic stress disorder 
(PTSD). PTSD is observed in approximately 5-9% of individuals who have been exposed to 
traumas (Breslau et al., 1998; Frans et al., 2005; Kessler et al., 2005), has been 
conceptualised as fundamentally involving deficits in affect regulation (Frewen & Lanius, 
2006), and frequently presents with symptoms of impulsive aggression (Olatunji, Ciesielski, 
& Tolin, 2010; Orth & Wieland, 2006). PTSD is defined in the latest edition of the Diagnostic 
and Statistical Manual (DSM-IV) as the psychological sequelae of exposure to "actual or 











which "the person's response involved intense fear, helplessness or horror" (American 
Psychiatric Association, 1994). It is characterised by symptoms of intrusiveness/re-
experiencing, avoidance/numbing, and hyperarousal, and results in enormous personal and 
societal costs (Brunello et al., 2001; S. D. Solomon & Davidson, 1997). 
A substantial body of evidence implicates poor emotion regulation as a core component of
PTSD (Chemtob, Novaco, Hamada, Gross, & Smith, 1997; Cloitre, Koenen, Cohen, & Han,
2002; Cloitre, Stovall-McClough, Miranda, & Chemtob, 2004; Frewen, Pain, Dozois, &
Lanius, 2006). For instance, Frewen et al. (2006) conceptualised PTSD as essentially a 
disorder of poor affect regulation that is characterised by either a failure to inhibit a state of 
hyperarousal in response to traumatic memories, or the overly efficient inhibition of arousal
(in the dissociative form of PTSD), with associated correlates in fear-related neurocircuitry
(L. M. Shin & Handwerger, 2009). PTSD is particularly strongly associated with difficulties
regulating anger. A meta-analysis of 39 studies of trauma exposed adults observed an
overall association across traumatic events between anger and PTSD (Pearson r = 0.48),
with the effect largest for military veterans (Orth & Wieland, 2006). In addition, a subsequent 
meta-analysis detected greater impairments amongst mostly treatment seeking veterans
with PTSD in anger control and anger-out and anger-in dimensions, relative to a composite
group of studies consisting of all other anxiety disorders (Olatunji et al., 2010)1.
Characterising adverse trauma-responses in terms of poor emotion regulation is consistent 
with the emphasis in current diagnostic taxonomies of PTSD on the emotional response to 
1  It should be noted that a examination of US population-based survey  data from the National Comorbidiy 
Survey - Replication study (Kessler et al., 2005) found the association of anger expression and experience to 
be less robust for PTSD than the other anxiety disorders (Hawkins & Cougle, 2010). This may be due to 
differences between community and treatment-seeking samples, or differences in trauma type. For instance, 
the most common traumatic event associated with PTSD diagnosis in the NCS-R data was “death of a loved 














the traumatic event rather than any inherent quality of the event itself (American Psychiatric 
Association, 1994). It also resonates with the proposal of a diagnostic category of Disorders 
of Extreme Stress-Not Otherwise Specified (DESNOS), which is frequently associated with 
early-life adversity, poor affect regulation and dissociative tendencies (Bessel A van der Kolk, 
Roth, Pelcovitz, Sunday, & Spinazzola, 2005). 
 
Early childhood adversity has been associated with increases in impulsive behaviour. For 
instance, clinically depressed patients who had experienced child abuse were more likely to 
be impulsive and aggressive (Brodsky et al., 2001). In addition, early life trauma in a military 
sample was associated with the development of personality styles characterised by poor 
impulse control (Rademaker, Vermetten, Geuze, Muilwijk, & Kleber, 2008). The association 
between trauma exposure and poor impulse control extends to PTSD, with large-scale 
epidemiological studies reporting significant increases in patients with PTSD in the 
prevalence of comorbid substance abuse (Mills, Teesson, Ross, & Peters, 2006) and 
suicidality (Nock et al., 2009). Impulsivity has also been associated with the emergence of 
re-experiencing symptoms characteristic of maladaptive post-traumatic responses in adults 
(Aidman & Kollaras-Mitsinikos, 2006), and with PTSD symptoms more generally (Joseph, 
Dalgleish, Thrasher, & Yule, 1997). Finally, the observation that acts of impulsive aggression 
may predict a diagnosis of PTSD in veterans (Teten et al., 2010) provides an explicit link 
between trauma exposure, deficits in inhibiting impulsive behaviour, and emotion regulation 
difficulties.  
         1.1  Characterising the relationship between emotion regulation and impulsivity 
 
Emotion regulation has been described as “the processes by which individuals influence 
which emotions they have, when they have them, and how they experience and express 
these emotions” (Gross, 1998, pg. 275).  In a recent review and meta-analysis of the 











6 emotion regulation strategies which have been consistently identified in the literature. Half 
of these are regarded as protective of psychopathology (re-appraisal, problem-solving and 
acceptance), whereas the remainder (suppression, avoidance, rumination) are regarded as 
vulnerability factors for the development of psychopathological states, including depression, 
eating and substance-related disorders.  Although PTSD studies were excluded from this 
review, studies of community and clinical samples have generally found that suppression of 
emotional expression and cognitive re-appraisal are associated with increases and 
reductions in trauma-related symptoms, respectively (Amstadter & Vernon, 2008; Eftekhari, 
Zoellner, & Vigil, 2009; Moore, Zoellner, & Mollenholt, 2008). 
There is a general consensus that understanding of the role of emotion regulation in 
psychopathology would be advanced by experimental studies using laboratory-based 
measures of behaviour. Gratz & Roemer (2004) provide a broad  definition of emotion 
regulation that is well-suited for this purpose. They characterise emotion regulation as
involving the monitoring and modulation of emotions in an adaptive fashion, particularly with 
respect to achieving particular goals whilst experiencing negative emotion. The emphasis in
this conceptualisation is on the functional nature of emotions, and on managing emotions in 
the service of performing behaviour, rather than controlling the emotion itself. It also 
bypasses controversies in the literature regarding the distinction between emotion regulation 
and reactivity (Lewis, Zinbarg, & Durbin, 2010).
There is evidence suggesting that the functional schema of emotion regulation proposed by 
Gratz & Roemer (2004) has utility in describing maladaptive responses to psychological 
trauma. For instance, Tull and colleagues (2007) were able to detect significantly higher 
impairment in impulse-control, access to effective emotion regulation strategies, and 
emotional clarity amongst 108 University students with scores on the PTSD Checklist (PCL) 














confounds of negative affect and difference in income. The importance of access to effective 
emotion regulation strategies in preventing trauma-related psychopathology (reviewed with 
respect to general psychopathology by Aldao et al. 2009) was recently illustrated by the 
finding that women who were exposed to traumatic events were more likely to experience 
symptoms of anxiety, depression and PTSD if they reported infrequently or ineffectively 
regulating their emotions  (Eftekhari et al., 2009). 
 
The literature on alexithymia provides further evidence of the association between trauma 
exposure and impairments in affect regulation. Alexithymia is most commonly defined 
operationally using the 20-item Toronto Alexithymia Scale (TAS-20) as being characterized 
by deficits in identifying and describing  internal emotions (Bagby, Parker, & Taylor, 1994).  
There is ample evidence for a relationship between early life adversity and alexthymia, 
particularly with respect to emotional neglect/abuse and sexual abuse (Frewen, Lanius et al., 
2008; McCaslin et al., 2006; McLean, Toner, Jackson, Desrocher, & Stuckless, 2006; 
Zlotnick, Mattia, & Zimmerman, 2001).  Evidence of a relationship between childhood 
adversity and impaired emotion regulation is consistent with theoretical frameworks 
postulating that stressful interaction with caregivers during childhood impacts, via its effects 
on attachment relationships, on abilities to regulate affect and develop positive relationships 
in later life (Schore, 2002; B. A. van der Kolk & Fisler, 1994).  
 
A number of studies have also identified elevated symptoms of alexithymia in patients 
diagnosed with PTSD (Frewen et al., 2006; Fukunishi, Sasaki, Chishima, Anze, & Saijo, 
1996; Yehuda et al., 1997). The association between PTSD symptoms and alexithymia was 
revealed in a meta-analysis as being relatively robust (Frewen, Dozois, Neufeld, & Lanius, 
2008). Alexithymia has been conceptualised as most strongly related to  avoidance and 
emotional "numbness" symptoms in PTSD (Badura, 2003), though empirical support for an 














Lanius et al., 2008; Fukunishi et al., 1996). Nevertheless, these studies indicate that 
difficulties in recognising emotions may be one important aspect of poor affect regulation 
characterising maladaptive sequelea of exposure to psychological trauma.  
 
The association of early life adversity and PTSD with alexithymia supports the use of a 
measure of effect regulation in populations exposed to trauma that tests the ability to 
recognise emotions. One such measure is the Difficulties in Emotion Regulation Scale 
(DERS), which contains two dimensions that are particularly relevant in this regard (“lack of 
clarity of emotions” and  “emotional awareness”)(Gratz & Roemer, 2004). The DERS has 
demonstrated sensitivity to age-related differences in emotional control in healthy individuals 
(Orgeta, 2009), and has identified deficits in behavioural aspects of emotion regulation in 
clinical populations, including borderline personality disorder (Glenn & Klonsky, 2009) and 
substance abuse populations (Fox, Axelrod, Paliwal, Sleeper, & Sinha, 2007; Fox, Hong, & 
Sinha, 2008). The close link between emotion regulation and impulsivity is apparent in the  
observation that two of the six dimensions c ntained within the DERS relate to impulsivity: 
(1) difficulties engaging in goal-directed behaviours when experiencing negative emotions, 
and (2) impulse-control difficulties when experiencing negative emotions (Gratz & Roemer, 
2004).  
  
Conversely, poor affect regulation forms a core component of an influential conceptualisation 
of impulsivity proposed by Whiteside & Lynam (2001). Whiteside and Lynam (2001) provided 
an empirical formulation of impulsivity by factor analysing data collected from 437 
undergraduates on a variety of impulsivity scales. This analysis identified four dimensions of 
impulsivity that were subsequently operationalised as the UPPS Impulsive Behaviour Scale; 
urgency, lack of perseverance, lack of planning and sensation seeking. The impulsivity 
dimension of urgency is most clearly related to affect regulation, describing as it does the 















Differences in scores on the urgency subscale of the UPPS have consistently predicted 
impulsive behaviours, including bulimia symptoms, cigarette craving and drinking alcohol to 
cope (Anestis, Selby, & Joiner, 2007; Billieux, der Linden, & Ceschi, 2007; Fischer, Smith, & 
Anderson, 2003). Further work has distinguished between negative urgency, which is 
identical to the original conceptualisation of urgency and positive urgency, where positive 
emotions contribute to the likelihood of engaging in rash behaviour (Cyders et al., 2007). 
Positive urgency has been shown to uniquely predict elevations in pathological gambling, as 
well as risky sexual behaviour, alcohol and drug use during the 1st year of college (Cyders & 
Smith, 2008a; Zapolski, Cyders, & Smith, 2009).   
 
         1.2  The neurobiology of emotion regulation and trauma exposure 
 
Neural correlates of the regulation of emotional response have been obtained from studies 
employing brain imaging technologies, including functional magnetic resonance imaging 
(fMRI) and positron emission tomography (PET). fMRI and PET provide measures of blood 
oxygenation and glucose metabolism, respectively, that are interpreted as indices of neural 
activity in response to task demands. fMRI studies have reported an inverse relationship 
between activation of the frontal cortex (ventrolateral and ventromedial PFC) and the 
amygdala in the context of the active regulation of emotion  (Ochsner, Bunge, Gross, & 
Gabrieli, 2002; Urry et al., 2006). Emotion regulation paradigms employing the labelling of 
emotional expressions versus control conditions have documented the same inhibitory 
cortical-subcortical coupling in the emotion identification condition, both in normal controls 
(Hariri, Bookheimer, & Mazziotta, 2000; Lieberman et al., 2007) and subjects who had been 















The similarity between the findings from imaging studies of emotion regulation and models of 
functional neural pathology in PTSD are suggestive. A dominant model of the neurocircuitry 
of PTSD involves impaired inhibition of limbic activity by the prefrontal cortex (Rauch, Shin, 
& Phelps, 2006; L. Shin et al., 2004). Evidence for such abnormalities comes in the form of 
covariation in activity of the anterior cingulate cortex (ACC) and the amygdala in patients 
with PTSD on exposure to emotional facial expressions (L. Shin et al., 2005; Williams et al., 
2006). Symptom severity also correlated positively with amygdala activation and negatively 
with activation of the medial prefrontal cortex in PTSD patients asked to imagine traumatic 
events while listening to a personalised script (L. Shin et al., 2004). Although the amygdala is 
a component of the fear circuitry that is engaged in healthy individuals as well as across a 
range of anxiety disorders, a meta-analysis of brain imaging studies of patients with social 
anxiety disorder, specific phobia or PTSD who had been exposed to affective stimuli 
detected frontal deactivation in the PTSD group only (Etkin & Wager, 2007).  
 
Studies of particular genetic polymorphisms have also implicated frontal-limbic pathology in 
emotion regulation. Hariri (2002) found increased activation of the amygdala of carriers of 
the short variant (S) of the serotonin transporter gene, associated with less efficient 
transcription of serotonin, within an emotion induction paradigm, relative to people 
homologous for the long variant (L) of this gene (Hariri et al., 2002). This finding has 
subsequently been replicated in a larger sample (Hariri et al., 2005). Indeed, the association 
between 5HTTLPR polymorphisms and amygdala activation to a variety of aversive stimuli 
has been confirmed in a recent meta-analysis of 14 studies  (Munafò, Brown, & Hariri, 2008). 
Although functional or structural measures of the  amygdala alone has not always been 
strongly predictive of an S allele effect on emotional behaviour,  one study found that 
functional coupling between the pregenual anterior cingulate cortex (pACC) and the 
amygdala accounted for almost 30% of the variance in anxious temperament  (Pezawas et 














in carriers of the short allele. This finding mirrors the coupling detected during the 
presentation of aversive pictures between activity in the ventral medial prefrontal cortex and 
bilateral amygdala for healthy participants homologous for the L allele (Heinz et al., 2005). 
 
1.3  Involvement of neurotransmitters in the relationship between trauma and affect 
dysregulation  
 
There is growing evidence for rather specific dysregulations of neurotransmitter systems 
(including the serotonin, noradrenaline, and dopamine systems) and neuroendocrine 
systems (including the hypothalamus-pituitary-adrenal axis) in PTSD (Charney, Deutch, 
Krystal, Southwick, & Davis, 1993; Connor & Davidson, 1998; Ravindran & Stein, 2009). A 
large body of clinical evidence suggests that medications that selectively block the reuptake 
of serotonin at synapse terminals, collectively known as selective serotonin reuptake 
inhibitors (SSRIs), are particularly effective in treating PTSD symptoms. This has been 
confirmed in meta-analyses (Mooney, Oakley, Ferriter, & Travers, 2004; D. J. Stein, Ipser, & 
Seedat, 2006), and the use of SSRIs as first line agents in treating PTSD has been 
incorporated into clinical practice guidelines (Asnis, Kohn, Henderson, & Brown, 2004; 
Bandelow et al., 2008).  
 
Low serotonergic activity is also associated with maladaptive acts of aggression in 
naturalistic studies of people and non-human primates. In a review of studies investigating 
the relationship between violence and serotonin, Krakowski et al. (2003) describes studies 
that have experimentally manipulated serotonin availability via tryptophan precursor dosing, 
and demonstrated an increase in prosocial behaviour with increasing serotonin and 
increases in hostility/aggression with reduced levels of serotonin. This effect was especially 
pronounced in individuals who are predisposed to aggression, suggesting that serotonergic 














Indeed, van Honk and colleagues argue in their Triple Imbalance Hypothesis of reactive 
aggression that an imbalance between testosterone and cortisol results in acts of impulsive 
aggression, but only against the background of lower levels of serotonin (van Honk, Harmon-
Jones, Morgan, & Schutter, 2010).  
 
Similarly, the association of abnormal dopamine levels with emotion regulation and 
impulsivity has been considered in the context of its interaction with serotonin. For instance, 
Cyders et al. (2008b) suggest that serotonin inhibits the risky, approach behaviours 
associated with high levels of dopamine, such that individuals with high levels of dopamine 
and low serotonin levels might be particularly likely to behave impulsively in response to 
negative emotional state. The high density of dopamine and serotonin receptors in the 
amygdala and the prefrontal cortex suggest that one mechanism by which this might take 
place is via the PFC-amygdala pathway.  
 
Conceptualising certain forms of impulsivity, such as negative urgency, as arising within the 
context of negative effect, suggests that other neurotransmitters besides serotonin that may 
mediate the relationship between childhood trauma and affect regulation might also have 
implications with regards to impulsive behaviour.  As decribed below there are both 
theoretical and empirical grounds for believing that one such class of neurotransmitters are 
represented by the opioids.  There is accumulating evidence that mu-opioids in particular are 
involved in regulating negative emotions.  
 
From a neurodevelopmental perspective, animal research has demonstrated that mu-opioids 
are secreted endogenously in circumstances in which social attachments such as infant-
mother bond are formed, and that they may have a role in regulating separation distress 














the evolutionary co-opting of neural circuits involved in pain regulation, as suggested by 
evidence that endogenous and exogenous opioids reduce activation in areas implicated in 
pain sensitivity, emotion regulation and reward sensitivity, including the anterior cingulate 
cortex (ACC), orbitofrontal cortex (OFC), insula, amygdala, caudate and periaqueductal gray 
(see Stein et al. 2007, and Bruehl et al. 2009 for reviews). Further support for this theory 
comes in the form of evidence that opioid dysregulation appears to mediate the relationship 
between the tendency to “act out” feelings of anger and increased sensitivity to pain (Bruehl 
et al., 2009).  
 
Dysregulation of the opioid system may also characterise pathological responses to 
psychological trauma. Heat and cold pain thresholds were significantly increased in both 
combat veterans with and without PTSD, with subjective reports of pain as more intense in 
PTSD populations once the threshold is achieved (Kraus et al., 2009).  Additional research 
suggests that PTSD may be associated with the failure of a compensatory response in the 
opioid system to trauma. In a PET study employing the mu-opioid receptor radioligand [11C] 
carfentanil, significant down-regulation of mu-opioid receptor binding potential was observed 
in regions implicated in emotion egulation in both PTSD patients and combat exposed 
controls relative to normal controls (insula, nucleus accumbens, anterior cingulate cortex and 
extended amygdala) (Liberzon et al., 2007). Reductions in opioid binding were observed in 
the orbitofrontal cortex (OFC) and subgenual ACC in the combat-exposed groups, relative to 
the healthy controls. Interestingly, these differences were  more apparent in the OFC in the 
combat controls than the PTSD patients, suggesting a compensatory mechanism in 
response to neural changes changes induced by trauma-exposure that was not harnessed in 















1.4  The behavioural measurement of impulsivity and affect regulation 
 
Both impulsivity and affect regulation are multi-dimensional constructs (Fineberg et al., 
2010). Investigations of the relationship between these constructs are complicated by the 
plethora of mostly self-rated questionnaires to select from in their measurement. The validity 
of these questionnaires is also frequently questionable, especially given the continuing 
debates regarding how to define impulsivity and affect regulation (Lewis et al., 2010).  
 
An alternative approach to using self-report questionnaires to assess emotion regulation and 
impulsivity is to use performance on a behavioural measure as a proxy for these constructs, 
with the advantage that brain regions involved in the performance of affect-drive impulses 
can also be identified. One such task that may be particularly suitable in this respect is the 
Go-NoGo (GNG) task. The GNG task is one of the most extensively validated motor 
inhibition tasks, and is frequently employed as a behavioural proxy for impulsivity in both 
research and clinical settings. There is also some evidence that performance and neural 
activation on the GNG correlates with self-rating measures of impulsivity in healthy subjects 
(Brown, Goltz, Vilis, Ford, & Everling, 2006; though see Horn, Dolan, Elliott, Deakin, & 
Woodruff, 2003), and in measures related to impulsivity, such as absent-mindedness, 
assessed using the Cognitive Failures Questionnaire (Broadbent, Cooper, FitzGerald, & 
Parkes, 1982; Garavan, Hester, Murphy, Fassbender, & Kelly, 2006),.  
 
In the traditional GNG task, participants are presented with  a series of distinct stimuli on a 
computer screen, one or more of which are designated as targets (``Go'' trials). Subjects are 
instructed to press a response button as quickly as possible when presented with the 'Go' 
stimuli, and to withhold responding on presentation of other distractor stimuli (``NoGo'' trials). 














ability to inhibit motor responses. This paradigm has been successfully adapted for brain 
imaging studies, suggesting that it might have utility in investigating the neural correlates of 
impulsivity. Prior meta-analyses of response inhibition that have incorporated GNG studies 
reported reliable patterns of activation in cortical and subcortical brain structures, including 
the  inferior frontal gyrus (IFG), dorsolateral prefrontal cortex (DLPFC),  anterior cingulate 
cortex (ACC),  sensory motor association areas, the parietal cortex, basal ganglia (putamen, 
caudate) and insula (see Buchsbaum et al. 2005, Nee et al. 2007, Simmonds et al. 2008, 
Swick et al. 2011 and Levy et al. 2011 for reviews). 
 
The conceptual and empirical overlap between impulsivity and emotion regulation suggests 
that behavioural measures of response inhibition might be more sensitive to impulsivity 
following trauma exposure if they include an affective component. This seems plausible 
given the observation that the same  genes involved in affect regulation are also implicated 
in impulse control (5HTT & MAO-A) (Passamonti et al., 2006; Passamonti et al., 2008). A 
similar conclusion was reached by Gay and colleagues (2008) in their discovery that 
(negative) urgency was specifically related to errors in prepotent response inhibition using a 
Go/NoGo paradigm, leading the authors to suggest that urgency may be even more strongly 
related to inhibition of automatic motor responses in conditions in which emotional stimuli are 
used. 
 
A number of research teams have modified the GNG to include affective stimuli, in efforts to 
distinguish between subjects suffering from clinical disorders characterised by impaired 
affect regulation and healthy controls. This approach has been validated, with the affective 
GNG (AGNG) revealing differences in performance in a range of clinical populations, 
including patients diagnosed with borderline personality disorder and premenstrual dysphoric 














of errors on negative NoGo trials (Silbersweig et al., 2007) while healthy female subjects 
demonstrated faster reaction times to neutral as opposed to negative or positive target 
words, an effect that was not observed for subjects with premenstrual dysphoric disorder 
(Protopopescu et al., 2008). The affective version of the GNG has also been successfully 
employed in separating clinical from normal populations in terms of brain activity, even in 
cases where behavioural performances in the two groups were equivalent.  For instance, 
Wessa et al. (2007)  detected increased BOLD signal in the right medial and left superior 
OFC, the right precuneus (extending to the posterior cingulate cortex), the left insula and the 
caudate (bilaterally) in euthymic bipolar disorder patients relative to normal controls on the 
comparison of emotional versus neutral distracters (despite comparable performance in 





























The literature reviewed provides evidence that increased impulsivity and affect 
dysregulation, as well as associated neurobiological abnormalities, may characterise the 
long-term negative sequelae experienced by some individuals who have been exposed to 
psychological trauma, both in childhood and later in life. It also suggests that the GNG 
paradigm might be usefully employed in investigating neural correlates of impulsivity and 
affect regulation. This evidence forms the basis of the four-fold strategy in investigating the 
relationship between trauma, impulsivity and affect regulation outlined below.  
 
The first two components of this thesis will attempt to use systematically compiled evidence 
for the efficacy of serotonergic agents to gauge the extent to which serotonergic pathways 
are involved in impaired impulse control and affect regulation, as well as pathological 
responses to psychological trauma. This strategy takes the converse approach to that 
employed recently by Serretti et al. (2007), who were able to confirm from a meta-analysis of 
pharmacogenetic studies that polymorphisms of the serotonin transporter predict response 
to antidepressants (Serretti et al., 2007). 
  
In the first part of this dissertation, the importance, from a developmental perspective, of the 
serotonergic system in affect regulation and impulse control will be identified by conducting a 
systematic review and meta-analysis of pharmacotherapy for disruptive behaviour disorders 
(DBDs) in children and adolescents. The DBD group of disorders includes oppositional 
defiant disorder (ODD) and conduct disorder (CD), and was selected as it is relatively well-
characterised, and represent a form of psychopathology that involves aspects of both 
impulsive behaviour and poor affect regulation. Moreover, paediatric patients presenting with 
DBD's frequently have a history of maltreatment (Ford et al., 2000), suggesting a role for 
psychological trauma and/or neglect in the difficulties that they have in regulating negative 















The second part of the dissertation will involve an investigation of the neurobiological 
systems that mediate the relationship between trauma and impulsivity/affect regulation. This 
will be achieved through a systematic comparison of the efficacy of serotonergic agents in 
not only reducing global PTSD symptom severity, but also the intrusion, hyperarousal and 
numbing/avoidance symptom clusters from which this disorder is constituted. It is anticipated 
that this will provide insight into the extent to which serotonin mediates disruptions in affect 
following trauma exposure. The hyperarousal and avoidance/numbing clusters are likely to 
be particularly informative in this regard, given their centrality in the characterisation of PTSD 
as a disorder of affect regulation  (Frewen & Lanius, 2006).  
 
The third component of this dissertation will investigate the utility of a laboratory measure of 
response inhibition in identifying regions of the brain th t subserve impulsivity and affect 
regulation. Brain regions that are involved in inhibition of motor responses, with and without 
the requirement to regulate affect, will be identified by synthesising data from functional 
magnetic resonance imaging (fMRI) studies of the Go/NoGo paradigm. This will be achieved 
through conducting an Activation Likelihood Estimation (ALE) meta-analysis of coordinates 
corresponding to regions of the brain that are activated in healthy adults while correctly 
inhibiting motor responses (Laird et al., 2005; Turkeltaub, Eden, Jones, & Zeffiro, 2002).  A 
formal statistical comparison of data from versions of this task that employ affective stimuli 
versus versions that do not will help pinpoint potential sites of impairment in disorders 
characterised by affective impulsivity.  
 
Finally, the hypothesis that a history of childhood trauma will impact negatively on the 
regulation of aversive emotions, and that these effects are mediated by the opioid system, 
will be investigated within the context of a pharmacological challenge study. Specifically, 














and childhood trauma and alexithymia in particular, leads to the prediction that University 
students with a history of childhood adversity will be poorer in recognising the emotions 
displayed in fearful and angry faces. The extent to which the modulation of particular 
biological systems can normalise these deficits will be investigated through the placebo-















3. SYSTEMATIC REVIEW OF PHARMACOTHERAPY OF DISRUPTIVE BEHAVIOUR 




The disruptive behaviour disorders consist of the diagnoses of conduct disorder (CD) and 
oppositional defiant disorders (ODD). The DSM-IV-TR defines ODD as a pattern of 
negativistic, hostile and defiant behaviour, often directed towards authority figures (American 
Psychiatric Association, 1994). Conduct disorder, on the other hand, is described as a 
persistent and recurrent pattern of behaviour in which age-appropriate social norms and the 
rights of others are violated. Disruptive behaviour disorders (DBDs) are often characterised 
by the poor control of impulsive behaviour (Hollander, Baker, Kahn, & Stein, 2006), with 
impulsivity being demonstrated as highly predictive of conduct disorder in adolescents 
(Askenazy et al., 2003; Vitacco & Rogers, 2001). 
 
Although disruptive behavioural disorders have been characterised by some as primarily 
involving premeditated aggressive acts (Fahim et al., 2011), this may be more true of CD 
than ODD, for which 3 of the 8 DSM-IV symptom criteria for the diagnosis of this condition 
are more closely allied to impulsive forms of aggression (“often loses temper”, “is often 
touchy or easily annoyed by others”, “is often angry and resentful”)(American Psychiatric 
Association, 1994). A comparison of grey matter density in 8 year old children with disruptive 
behavioural disorders revealed differences between those diagnosed with conduct disorders 
and/or ODD, relative to healthy controls (Fahim et al., 2011). Interestingly, a specific effect 
was observed for ODD in the left OFC, a region that has been identified as a major site in 















The following chapter reviews pharmacotherapy for DBDs with the intent of determining the 
relative efficacy of different agents in treating this class of disorders. It will be re-examined 
with the intent of extracting information on the underlying serotonergic abnormalities that 
may characterise these disorders.  
 
3.2  Introduction 
 
This paper provides a systematic review of the pharmacotherapy of disruptive behaviour 
disorders (DBDs) in children and adolescents. Disruptive behaviour disorders are prevalent 
in the community, and result in significant personal impairment and socio-economic costs. In 
the National Comorbidity Survey Replication, impulse control disorders (including both 
disruptive behaviour disorders and intermittent explosive disorder) had a higher lifetime 
prevalence than mood or substance abuse disorders at 24.8%, with a median initial age-of-
onset of 11 years (Kessler et al. 2005). Public service utilisation costs were 10 times as large 
in the UK in 1998 in patients with conduct disorder than those without (Scott et al. 2001).  
Pediatric DBDs are likely to be particularly disruptive, as they impair academic and social 
performance during a period of mental and behavioural maturation (Burke et al. 2002). It has 
been estimated that disruptive behaviour problems (including Attention Deficit/Hyperactivity 
Disorder (ADHD)) account for over 50% of pediatric referrals to mental health practices 
(Waschbusch et al. 2002). 
 
Disruptive behaviour disorders are composed of conduct disorder (CD), oppositional 
defiance disorder (ODD), and disruptive behavior disorders not otherwise specified (DBD-
NOS). While oppositional defiance disorder is defined by the DSM-IV-TR as a pattern of  
antisocial behaviour that is frequently directed towards authority figures, conduct disorder 














others are repeatedly violated  (American Psychiatric Association, 1994). In the case of 
conduct disorder these behaviours have been categorised in the DSM-IV-TR as aggression 
to people and animals, destruction of property, deceitfulness or theft, and the serious 
violation of rules. The criteria for the diagnosis of oppositional defiance disorder and conduct 
disorder are provided in Tables 1 & 2. 
 
Table 1. DSM-IV-TR behavioural criteria for oppositional defiant disorder 
1) often loses temper  
2) often argues with adults  
3) often actively defies or refuses to comply with adults' requests or rules  
4) often deliberately annoys people  
5) often blames others for his or her mistakes or misbehavior  
6) is often touchy or easily annoyed by others  
7) is often angry and resentful 
8) is often spiteful or vindictive  
             A minimum of 4 of the behaviours listed must have been performed for a period 
             of at least 6 months before a diagnosis of oppositional defiant disorders can be   




Table 2. DSM-IV-TR behavioural criteria for conduct disorder 
1) often bullies, threatens, or intimidates others 
2) often initiates physical fights  
3) has used a weapon that can cause serious physical harm to others  
4) has been physically cruel to people  
5) has been physically cruel to animals  
6) has stolen while confronting a victim 
7) has forced someone into sexual activity  
8) has deliberately engaged in fire setting with the intention of causing   
    serious damage  
9) has deliberately destroyed others' property   (other than by fire setting) 
10) has broken into someone else's house, building, or car  
11) often lies to obtain goods or favors or to avoid obligations  
12) has stolen items of nontrivial value without confronting a victim  
13) often stays out at night despite parental prohibitions, beginning before 
      age 13 years  
14) has run away from home overnight at least twice while living in  
      parental or parental surrogate home  
15) is often truant from school, beginning before age 13 years  
             A minimum of 3 of behaviours listed must have been performed over the  
             previous year, with at least 1 criterion present over the past 6 months, before a  


















Disruptive behaviour disorders are associated with a high degree of comorbidity, with 
depression, substance abuse and ADHD frequently co-occuring in patients with conduct 
disorder (Loeber et al. 2000). As many as 50% of children referred to clinics with ADHD are 
also diagnosed with conduct disorder (Newcorn et al. 2001), a pattern of comorbidity 
associated with a poorer outcome (Lahey et al. 2002;Satterfield and Schell 1997), as well as 
an earlier onset of  conduct disorder (Biederman et al. 1996;Loeber et al. 1995). The odds 
that children and adolescents with conduct disorder also present with comorbid impulse 
control disorders during their lifetimes were found in the National Comorbidity Survey 
Replication to be over 7 times greater than for those participants without conduct disorder 
(Nock et al. 2006). This is consistent with evidence that impulsivity is highly predictive of 
conduct disorder in adolescents (Askenazy et al. 2003;Vitacco and Rogers 2001).   
 
The negative behavioural and criminal sequelae of conduct disorder have been well 
established  (Fergusson et al. 2005;Foley et al. 1996). Oppositional defiant disorders feature 
prominently in the developmental trajectory of conduct disorder, which, in turn, has been 
associated with the subsequent development of antisocial personality disorder (APD). Risk 
factors identified by Burke (2002) as implicated in the development of disruptive behaviour 
disorders include (a) biological factors, such as a genetic predisposition (suggested by family 
and twin studies), impaired neuroanatomy and functioning (specifically deficits in the 
functioning of the frontal lobes and the amygdala), underarousal of the autonomic system, 
low levels of serotonin, and the presence of neurotoxins, (b) childhood functional factors, 
such as temperament, poor maternal attachment, reading problems, impulsivity/behavioural 
inhibition,  and poor social skills, and (c) psychosocial factors, such as poor parenting, 
selective mating, child abuse, peer interaction (including peer rejection and association with 















Most children’s first contact with clinicians is through their referral for disruptive and 
aggressive behaviour (Steiner and Karnik 2003). Many of these children are subsequently 
diagnosed with conduct disorder. The exact diagnosis assigned depends on the 
classification system employed. The DSM-IV-TR subsumes conduct disorder and 
oppositional defiant disorder as distinct entities within the broader classification of disruptive 
behaviour disorders, with sub-clinical presentations of these disorders diagnosable as 
disruptive behaviour not otherwise specified.  The most recent version of the International 
Classification of Diseases (ICD-10), on the other hand, defines oppositional defiant disorder 
as a milder form of conduct disorder. In addition, while the DSM-IV-TR allows concurrent 
diagnoses of ADHD and conduct disorder, the ICD-10 defines hyperkinetic disorder (which is 
analogous to the DSM-IV diagnosis of ADHD) as a disruptive behaviour disorder, and hence 
as an exclusionary criteria for the diagnosis of CD.  
 
3.2.1  Treatment 
 
There are to date no registered medications for the treatment of disruptive behaviour 
disorders. Children with disruptive behaviours represent a difficult to treat population, as they 
are non-compliant almost by definition. The frequent co-occurrence of a number of 
biological, functional and psychosocial risk factors for the development of CD suggests a 
need for multi-modal interventions (Burke et al. 2002). A recent clinical practice guideline on 
the treatment of ADHD with or without comorbid conduct disorder recommended that 
psychotherapy be employed as first line treatment for conduct disorder, and that concurrent 
pharmacotherapy be reserved for severe or treatment resistant cases (Kutcher et al. 2004).  
 
The presence of comorbidity in disruptive behaviour disorders also has treatment 














for treating ADHD, the presence of CD symptoms has typically been regarded as a 
contraindication for this medication, given the greater perceived risk of abuse by children 
with conduct disorder (Fischer and Barkley 2003). The efficacy of stimulants in treating 
ADHD with comorbid conduct disorder also needs to be determined, as there is evidence 
that the combination of these disorders is physiologically distinct from either diagnosis on its 
own (Banaschewski et al. 2003).  
 
In this paper we will focus on the role of pharmacotherapy in pediatric disruptive behaviour 
disorders.  We systematically retrieved randomised controlled trials (RCTs) in this area for 
review and conducted a meta-analysis of trials meeting strict inclusion criteria to determine 
the efficacy and tolerability of pharmacotherapy in treating these disorders. A narrative 
review of those RCTs which were not included in the meta-analysis was also conducted. To 
our knowledge, this is the first systematic review of pharmacotherapy for pediatric disruptive 




The electronic databases, PubMed (1966 - May 2006), psycINFO (1972-2006 PART A) and 
the Cochrane Library (2006, Issue 1) were searched for all randomised controlled trials of 
disruptive behaviour disorders. The search query included the following terms:  "Conduct 
Disorder", "Attention Deficit and Disruptive Behavior Disorders", Disruptive behaviour", 
"Oppositional defiant disorder", "aggression", "adolescent", and "child" (contact author for full 
search strategy). These terms were appended to a sensitive search strategy for PubMed 
devised by Robinson and Dickersin (2002)  for the retrieval of RCTs. Similar search 
strategies were devised for the psycINFO and Cochrane Library databases. Unpublished 














and through contacting pharmaceutical companies and experts in the field.  
 
All randomised controlled trials of children (0-10 years) and adolescents (11-18 years) who 
have been diagnosed with disruptive behaviour disorders according to DSM or ICD criteria 
were considered for inclusion in the review. With regards to the meta-analysis, only trials 
published after the release of the DSM-III (1980) (American Psychiatric Association 1980) 
were included, in order to ensure homogenous diagnostic criteria. The presence of comorbid 
substance use, depression, hyperkinetic conduct disorder (in which features of both 
hyperkinetic disorder and conduct disorder are present) or ADHD were not used as 
exclusion criteria, given the high co-occurence of these disorders with disruptive behaviour 
disorders. Publication in other languages besides English and the failure to report outcome 
data were also not grounds for excluding studies from the meta-analysis. Trials including 
pediatric patients with sub-average IQs were included, provided the majority of the sample 
was not diagnosed with mental retardation (IQ <= 70). Trials of participants with a diagnosis 
of hyperkinetic disorder were excluded from the meta-analysis, as were trials in which an 
augmenting medication was used in addition to the medication under study.  
 
Treatment response and reduction in global symptom severity were the primary outcomes of 
interest. Treatment response was determined by calculating the relative risk of difference 
(RR) for outcome, as assessed on the improvement item of the Clinical Global Impressions 
(CGI-I) or related scale. The number needed to treat (NNT) was also calculated. This 
provides an indication of the number of patients who require treatment with medication 
before a single additional patient in the medication group responds to treatment, relative to 
the control group. Reduction in global symptom severity was assessed by means of 
computing standardised mean difference (SMD) scores on the severity item of the Clinical 















SMD scores were calculated using Hedges adjusted g, a variant of the Cohen d estimate of 
effect size that controls for small group bias (Rosenthal and Rosnow 1991).  Cohen's d is 
calculated by dividing the difference between the mean summary score at trial endpoint for 
the medication and comparison groups by the pooled standard deviation of the means 
(Cohen 1988). Summary statistics for categorical and continuous measures were obtained 
using the DerSimonian and Laird random effects model (DerSimonian and Laird 1986). The 
random effects model includes both within-study sampling error and between-studies 
variation in determining the precision of the overall effect size.  The contribution of each of 
the trials to the overall effect size was weighed by the inverse of the variance of each trial. 
 
Secondary outcomes included the efficacy of medication in reducing aggression on scales 
validated for this purpose (such as the modified Overt Aggression Scale (Malone et al. 
1994a)), as well as the number of patients who discontinued treatment due to drug-related 
adverse events. The chi-square test was also used to calculate whether there were 
differences in the proportion of such events reported for the medication and comparison 
groups. All drug-related adverse events occurring in more than 10% of patients in the trials 
included in the meta-analysis, or which were significantly more frequent following medication 
treatment in these trials, are described in the narrative review. 
 
The order of preference for the retrieval of summary statistics in trials utilising multiple 
sources of information (teachers, parents and clinicians) was to select clinician rating 
outcomes first, followed by teacher and parent ratings. This strategy was adopted on the 
basis of evidence for the greater validity of teacher to parent ratings in assessing impairment 
due to disruptive behaviour disorders (Hart et al. 1994). In the case of data from trials 














summary statistics for multiple groups against the same placebo control was avoided by 
pooling the means and standard deviations across all of the treatment arms as a function of 
the number of participants in each arm. 
 
The extent of differences in treatment response across studies was determined by means of 
the chi-square test of heterogeneity, with a significance level of less than 0.10 interpreted as 
evidence of heterogeneity, given the low power of the chi squared statistic when the number 
of trials is small (Deeks et al. 2005). A specially designed data collection form was used for 
data abstraction, with analyses conducted using the RevMan software (The Cochrane 
Collaboration 2005).  
 
Studies were stratified by medication class (stimulants, antipsychotics, anticonvulsants and 
other medications), with a separate category created for lithium. All summary statistics were 
expressed in terms of an average effect size and 95% confidence intervals (CIs). The small 
number of trials included in the quantitative comparisons have been supplemented with a 
qualitative description of all of the RCTs retrieved in the literature search.  
 
We also decided to conduct a brief review of pediatric impulse control disorders, given the 
observation that both DBDs and impulse control disorders may be characterised by the poor 
control of impulsive behaviour (Hollander et al. 2006).  A similar search strategy to that 
described above was employed, with the queries modified to retrieve all clinical trials of 
pediatric intermittent explosive disorder, kleptomania, pathological gambling, pyromania and 
















3.4  Results 
 
3.4.1  Meta-analysis 
 
A total of 14 (823 participants) of the 30 short-term trials identified as eligible for inclusion in 
the review were included in the meta-analysis. Twelve of the trials were placebo-controlled. A 
flow diagram of the trial selection procedure is provided in Figure 1, with descriptive data for 
the RCTs considered for inclusion presented in Table 3. Two ongoing studies were also 
identified from the controlled-trials database: a trial of divalproex in the treatment of 
disruptive behaviour disorder and explosive tempers in adolescents and adults (ID: 
NCT00218114), and a relapse prevention trial of children and adolescents with conduct and 
other disruptive behaviour disorders who responded to initial open-label treatment of 
risperidone (ID: NCT00236444). 
















Table 3. Descriptive data for pediatric RCTs included in the review 
Principal 
Author 
Year Medication Duration Dosage
b 








    Steiner 2003 divalproex 7 1000 vs 125 
mg/d (mode) 
CGI-I high dose > low 
dose 
  Patients:  71 with CD (14-18 years) 
 





med > placebo 
  Patients: 20 with DBDs (10-18 years) 
 
   Cuevaa 1996 carbamazepine 6 683 mg/d GCJS med = placebo 
  Patients: 24 with CD (5-12 years) 
 
    Looker 1970 diphenyl-
hydantoin 
4 100 - 200 
mg/d 
CTRS med = placebo 
  Patients: 17 with temper tantrums (6-15 years) 
 
Antipsychotics 






med > placebo 
  Patients: 235 with CD or ODD or ODD (NOS), comorbid ADHD in 68% (5-17 
years) 
 
    Aman 2002 risperidone 6 1.16 mg/d NCBRF  med > placebo 
  Patients: 119 (sub-average IQs) with DBDs (5-12 years) 
 
    Snyder 2002 risperidone 6 0.98 mg/d NCBRF  med > placebo 
  Patients: 110  (sub-average IQs) with DBDs (5-12 years) 
 
    van    
    Bellinghen 
2001 risperidone 4 0.01 - 0.09 
mg/kg/d 
CGI-I med = placebo 
  Patients: 13 (sub-average IQs) disruptive behaviour (6-14 years) 
 
    Buitelaara 2001 risperidone 6 2.9 mg/d CGI-S med > placebo 
  Patients: 38 (sub-average IQs) with DBDs and comorbid ADHD (6-14 years) 
 
    Findlinga 2000 risperidone 10 0.75-1.5 
mg/d 
RAAPP  med > placebo 
  Patients: 20 with CD (6-14 years) 
 
    Greenhilla 1985 molindone & 
thioridazine 
4 26.8 mg/d & 
169.9 mg/d 
CRS (mol = thi) > 
placebo  
  Patients: 31 with CD (6-11 years) 
 
    Campbella 1984 haloperidol & 
lithium 
4 2.95 mg/d & 
1166 mg/d 














  Patients: 61 with CD (5-13 years) 
 
  Cunningham 1968 haloperidol 4 0.5 - 3 mg/d behav. 
ratings 
med > placebo 
  Patients: 12 with disruptive behaviour (8-13 years) 
 
    Barker 1968 haloperidol 3 0.05 mg/kg/d  med > placebo 
  Patients: 16 with disruptive behaviour (4-15 years) 
 
Lithium 
    Malonea 2000 lithium 4 900 - 2100 
mg/d 
GCJCS med > placebo 
  Patients: 40 with CD (10-17 years) 
 
   Rifkina 1997 lithium 2 -- OAS med = placebo 
  Patients: 33 with CD (12-17 years) 
 
   Campbella 1995 lithium 4 1,248 mg/d GCJS med > placebo 
  Patients: 50 with CD (5-12 years) 
 
Stimulants 
    Spencera 2006 MAS XRd 4 10 - 40 mg/d CGI-I  med > placebo 
  Patients: 308 with ODD or ODD & ADHD (6-17 years) 
  
    Riggsa 2004 pemoline 12 37.5 - 112.5 
mg/d 
CGI-I med > placebo 
  Patients: 69 with ADHD, SUDe & CD (13-19 years) 
 
   Kolkoa  1999 low & high dose 
methyl-phenidate 
6 0.3 vs 0.6 
mg/kg 
IOWA O/D med > placebo 
  Patients: 22 with ADHD & DBDs (6-13 years) 
 
   Kleina 1997 methyl- 
phenidate 
5 41.3 mg/d CPRS & 
QRBC 
med > placebo 
  Patients: 83 with CD (6-15 years; 51/74 completers with ADHD) 
 
    Klorman  1994 methyl- 
phenidate 
3 22.3 mg/d IOWA A/O med > placebo 
(ADD/O) 
  Patients: 107 with ADD or ADD + aggression/oppositionality (5-12 years) 
 
    Vitiello 1991 diphen-
hydramine 
as needed 25 or 50 mg 
p.r.n. 
CGI-I med = placebo 
  Patients: 21 with ADHD and/or CD or MD (5-13 years) 
 
    Kaplan 1990 methyl-phenidate 3 0.47 mg/kg AABC med > placebo 
  Patients: 6 with ADHD & CD (13-16 years) 
 




(high = low dose) > 
placebo 
  Patients: 11 with ADHD & aggression (5-12 years) 
 
    Taylor 1987 methyl-phenidate 7 5 - 30 mg/d global CD 
severity  
med > placebo 
















    Newcorn 2005 atomoxetine 8 1.2 & 1.8 
mg/kg/d 
CPRS-RS med (all doses) > 
placebo 
(ADHD + ODD) 
  Patients: 293 with ADHD & ODD (8-18 years) 
 
    Hazell 2003 clonidine 6 -- Cr-PTRC med > placebo 
  Patients: 67 with ADHD & DBDs (6-14 years) 
 
   Connora 2000 clonidine, methyl-
phenidate 
12 0.17 & 32.5 
mg/d 
DBS clon = methyl = 
placebo 
  Patients: 24 with ADHD & DBDs (6-16 years) 
 
       aTrials included in meta-analysis 
       bDosages are provided as ranges or means, depending on the availability of the information 
       cWhere categorical treatment response not defined, indicates efficacy on primary outcome  
      measure 
       dMAS XR = mixed amphetamine salts extended release 
       eSUD = substance use disorder 
     Acronyms for primary outcomes: AABC: Adolescent Antisocial Behavior Checklist; CGI-I:   
     Clinical Global Impressions - Improvement item; CPRS: Children's Psychiatric Rating Scale;  
     CPRS-RS: Connor’s Parent Rating Scale - Revised Short form; CrPTRC: Connor’s revised  
     Parent and Teacher Rating Checklist; CRS: Connor’s Rating Scale; DBS: Disruptive Behavior  
     Scale; GCJS: Global Clinical Judgements Scale; IOWA A/O: IOWA Conners  
     Aggression/Oppositionality subscale; IOWA O/D: IOWA Conners Oppositional/Defiant  
     subscale; NCBRF: Nisonger Child Behavior Rating Form (conduct problem subscale); MOAS:  
     Modified Overt Aggression Scale; OAS: Overt Aggression Scale; RAAPP: Rating of  
     Aggression Against People and/or Property Scale; SCL-90: Symptom Checklist - 90 item scale 
 
The majority of the trials (8/14) in the meta-analysis were restricted to participants with 
conduct disorder. Comorbid ADHD was present in 5 of the studies, one of which contained 
patients diagnosed with substance abuse disorder (Riggs et al. 2004). Only one trial 
investigated pharmacotherapy for pediatric oppositional defiant disorder (Spencer et al. 
2006). The most common reason for excluding trials from the meta-analysis was failure to 
diagnose disruptive behaviour disorders according the relevant diagnostic criteria (see 
Figure 1). The trials included in the meta-analysis tested the following medications: 
stimulants (3 methylphenidate, 1 mixed amphetamine salts extended release, 1 pemoline), 
antipsychotics (1 haloperidol, 1 molindone, 2 risperidone), lithium (4 trials), the 
anticonvulsants (1 carbamazepine, 1 divalproex), the selective adrenergic agonist clonidine 
and the dopamine antagonist thioridazine (1 trial each). Only one trial included a comparison 















Treatment response was significantly greater following treatment with medication than 
placebo across the 4 trials of disruptive behaviour disorders that provided data on the CGI-I 
and the Global Clinical Judgements Scale (relative risk (RR) of response = 2.39, 95%CI = 
1.1 to 5.21, n = 136) (see Figure 2). Approximately 3 patients with DBDs would have to be 
treated with medication before one could expect to witness an additional response, relative 
to placebo (NNT = 3.1). A significantly larger proportion of patients responded to lithium than 
placebo (N = 2, RR = 4.22, 95%CI = 1.83 to 9.74, n = 90). Risperidone was effective in 
reducing overall symptom severity by 2.19 points on the CGI-S (N = 2, 95%CI = -3.07 to -
1.31, n = 58)(Figure 3).  
 
There was limited evidence for the effectiveness of medication in reducing aggression (N=4, 
SMD = -1.93, 95%CI = -3.88 to 0.02, n = 172), despite significant variation in the efficacy of 
the different agents (Figure 4). The tendency of medication to reduce aggression was largely 
attributable to the reduction of aggression scores in the single trial of methylphenidate (Klein 
et al. 1997). Differences were also apparent for the two trials of risperidone (Chi = 10.59, p < 
0.01), with significantly less reduction of aggression observed in the trial of adolescents with 






















Review: Pharmacotherapy for impulse control and disruptive behavior disorders in children and adolescents
Comparison: 01 Primary outcomes                                                                                           
Outcome: 01 Treatment response (CGI-I or similar)                                                                      
Study  Treatment  Control  RR (random)  Weight  RR (random)
or sub-category  n/N  n/N  95% CI  %  95% CI
01 Anticonvulsants
 Cueva 1996                 3/11               3/11         21.18      1.00 [0.26, 3.91]        
Subtotal (95% CI) 11                 11  21.18      1.00 [0.26, 3.91]
Total events: 3 (Treatment), 3 (Control)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.00 (P = 1.00)
02 Lithium
 Campbell 1995             10/25               1/25         12.33     10.00 [1.38, 72.39]       
 Malone 2000               14/20               4/20         32.75      3.50 [1.39, 8.80]        
Subtotal (95% CI) 45                 45  45.08      4.22 [1.83, 9.74]
Total events: 24 (Treatment), 5 (Control)
Test for heterogeneity: Chi² = 0.98, df = 1 (P = 0.32), I² = 0%
Test for overall effect: Z = 3.38 (P = 0.0007)
03 Stimulants
 Spencer 2006               8/13               4/11         33.75      1.69 [0.69, 4.13]        
Subtotal (95% CI) 13                 11  33.75      1.69 [0.69, 4.13]
Total events: 8 (Treatment), 4 (Control)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.16 (P = 0.25)
Total (95% CI) 69                 67 100.00      2.39 [1.10, 5.21]
Total events: 35 (Treatment), 12 (Control)
Test for heterogeneity: Chi² = 5.20, df = 3 (P = 0.16), I² = 42.3%
Test for overall effect: Z = 2.19 (P = 0.03)
 0.01  0.1  1  10  100
 Favours control  Favours treatment  
Figure 2. Response to pharmacotherapy treatment on the CGI-I 
 
 
Review: Pharmacotherapy for impulse control and disruptive behavior disorders in children and adolescents
Comparison: 01 Primary outcomes                                                                                           
Outcome: 02 Clinical global impressions symptom severity                                                               
Study  Treatment  Control  WMD (random)  Weight  WMD (random)
or sub-category N Mean (SD) N Mean (SD)  95% CI  %  95% CI
01 Antipsychotics
Findling 2000           10      2.32(0.30)          10      4.92(0.68)      54.52     -2.60 [-3.06, -2.14]      
Buitelaar 2001          19      2.70(1.20)          19      4.40(1.00)      45.48     -1.70 [-2.40, -1.00]      
Subtotal (95% CI)     29                          29 100.00     -2.19 [-3.07, -1.31]
Test for heterogeneity: Chi² = 4.41, df = 1 (P = 0.04), I² = 77.3%
Test for overall effect: Z = 4.89 (P < 0.00001)
Total (95% CI)     29                          29 100.00     -2.19 [-3.07, -1.31]
Test for heterogeneity: Chi² = 4.41, df = 1 (P = 0.04), I² = 77.3%
Test for overall effect: Z = 4.89 (P < 0.00001)
 -10  -5  0  5  10
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Review: Pharmacotherapy for impulse control and disruptive behavior disorders in children and adolescents
Comparison: 02 Secondary outcomes                                                                                         
Outcome: 01 Aggression scales                                                                                          
Study  Treatment  Control  SMD (random)  Weight  SMD (random)
or sub-category N Mean (SD) N Mean (SD)  95% CI  %  95% CI
01 Antipsychotics
Findling 2000           10      2.24(0.42)          10      3.54(0.56)      23.81     -2.52 [-3.75, -1.28]      
Buitelaar 2001          19      6.70(6.30)          19      8.10(6.90)      25.60     -0.21 [-0.85, 0.43]       
Subtotal (95% CI)     29                          29  49.41     -1.30 [-3.56, 0.96]
Test for heterogeneity: Chi² = 10.59, df = 1 (P = 0.001), I² = 90.6%
Test for overall effect: Z = 1.13 (P = 0.26)
02 Lithium
Malone 2000             20      2.29(2.65)          20      4.31(4.26)      25.61     -0.56 [-1.19, 0.07]       
Subtotal (95% CI)     20                          20  25.61     -0.56 [-1.19, 0.07]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.73 (P = 0.08)
03 Stimulant
Klein 1997              37      6.00(0.50)          37      8.30(0.50)      24.98     -4.55 [-5.43, -3.67]      
Subtotal (95% CI)     37                          37  24.98     -4.55 [-5.43, -3.67]
Test for heterogeneity: not applicable
Test for overall effect: Z = 10.13 (P < 0.00001)
Total (95% CI)     86                          86 100.00     -1.93 [-3.88, 0.02]
Test for heterogeneity: Chi² = 72.53, df = 3 (P < 0.00001), I² = 95.9%
Test for overall effect: Z = 1.94 (P = 0.05)
 -10  -5  0  5  10
 Favours treatment  Favours control  
Figure 4. Reduction of symptoms of aggression following treatment with medication 
 
Although it was originally the intention of the authors to conduct an a priori comparison of 
patient withdrawals due to drug-related adverse events, there were insufficient data for this 
purpose. Instead, overall dropout rates in the medication and placebo groups were 
calculated as a proxy measure of medication tolerability. Total patient dropout for trials 
included in the meta-analysis was equivalent in the placebo and medication groups across 
the 8 studies for which dropout data was available (RR = 0.97, 95%CI = 0.60 to 1.55, n = 
631). Dropout rates were not significantly higher following treatment for any of the 
medication groups. It was not possible to conduct an a priori subgroup analysis to test for the 
differential effect of medication in early versus late-onset CD due to lack of data on the 
breakdown of patient samples by age-group.  
     
3.4.2  Narrative review 
 
Efficacy of medication in treating disruptive behaviour disorders 
 
There have been several open-label studies providing preliminary evidence of the efficacy of 














al. 1998), lithium (Malone et al. 1994b), reboxetine (Mozes et al. 2005) and trazodone 
(Zubieta and Alessi 1992).  The psychostimulant, methylphenidate, has been particularly well 
studied, with both open label (Serra-Pinheiro et al. 2004) and controlled studies (Gadow et 
al. 1990; Kaplan et al. 1990; Klein et al. 1997; Klorman et al. 1994; Kolko et al. 1999; Taylor 
et al. 1987) supporting the usefulness of this agent.  
 
In the first placebo-controlled trial of methylphenidate for behaviour problems, approximately 
a third of the boys who were treated were classified as "much improved" after 3 weeks of 
treatment (Taylor et al. 1987). Behavioural hyperactivity, younger age and the absence of 
affective symptoms were better predictors of treatment response than a diagnosis of ADHD. 
Children diagnosed with attention deficit disorder and high levels of 
aggression/oppositionality demonstrated decreased symptoms of oppositionality, as well as 
improved performance on cognitive tasks after 3 weeks of treatment with methylphenidate 
(Klorman et al. 1994). Methylphenidate was also successful in reducing aggression in a 
crossover study of 6 patients with conduct disorder and comorbid ADHD (Kaplan et al. 
1990). Ratings of antisocial behaviour were reduced in a similar population following 
treatment with methylphenidate, even after controlling for the severity of comorbid ADHD 
(Klein et al. 1997).   
 
There is little evidence of the effectiveness of other stimulants besides methylphenidate in 
treating disruptive behaviour disorders. A recent 12 week placebo-controlled trial of pemoline 
failed to detect a reduction in symptoms of CD in 69 adolescents with comorbid ADHD and 
substance abuse (Riggs et al. 2004). In addition, the use of pemoline is not generally 
recommended, as it carries a risk of hepatoxicity and thus requires frequent monitoring of 
liver enzyme levels. Negative results were also obtained in a small controlled trial of the 














(Vitiello et al. 1991), including conduct disorder. Nevertheless, a recent large multicentre 
RCT of mixed amphetamine salts extended release (MAS XR) in treating oppositional 
defiant disorder demonstrated efficacy and tolerability for higher doses of this medication (30 
and 40 mg/d) in the pediatric population (Spencer et al. 2006). Despite this finding, evidence 
of treatment response was not observed when the analysis was limited to the minority of 
patients (21%) without comorbid ADHD. 
 
Lithium has well-known anti-aggressive properties, and has been used extensively in 
treating pediatric aggression. Lithium and haloperidol demonstrated equivalent efficacy in 
reducing symptom severity in a placebo-controlled trial for 61 treatment-resistant 
hospitalised children with CD (Campbell et al. 1984). Lithium performed better than 
haloperidol on a global scale of improvement and in reducing explosiveness in conduct 
disorder. It was also more effective in reducing CGI side effect scores and resulted in less 
cognitive impairment (Platt et al. 1984). The efficacy of lithium on measures of global 
improvement and aggressivity has been confirmed in subsequent placebo-controlled trials 
(Campbell et al. 1995; Malone et al. 2000). The findings of the only controlled trial to date to 
report that lithium was not more effective than placebo in reducing conduct disorder 
symptoms may be attributable to the short duration of this trial (2 weeks) (Rifkin et al. 1997). 
 
Antipsychotics have also been used in clinical practice for the treatment of childhood 
aggressivity (Kaplan et al. 1994). Children treated with haloperidol displayed significantly 
less disobedience and aggression towards adults than when they were provided with 
placebo, both when used as monotherapy (Barker and Fraser 1968) and in adjunction with 
behavioural treatment (Cunningham et al. 1968). The antipsychotic molindone hydrochloride 
and the dopamine antagonist thioridazine were equally effective in reducing aggression and 














Low doses of the atypical antipsychotic risperidone (0.5 mg/d - 3 mg/d) resulted in 
significantly greater reductions on a scale assessing aggression against people and/or 
property than placebo for children and adolescents diagnosed with CD, many of whom had 
previously failed community-based treatment with methylphenidate (Findling et al. 2000). A 
double-blind trial of children and adolescents with disruptive behaviour disorders detected 
significantly lower relapse rates in the medication than placebo group after 6 months of 
maintenance treatment with risperidone (Reyes et al. 2006). 
 
The effectiveness of risperidone in treating disruptive behaviour in the mentally-impaired 
pediatric population has also been assessed. At the end of a trial comparing 6 weeks of 
double-blind risperidone and placebo treatment for 38 mentally impaired children with 
aggression-related psychiatric disorders (CD, ODD or ADHD) (Buitelaar et al. 2001), 21% of 
those receiving risperidone were rated as "markedly" or "severely" disturbed on the CGI-S, 
compared to 84% of the placebo control group. Equivalent magnitudes of response were 
observed in a placebo-controlled pilot study of risperidone for low IQ children with persistent 
behavioural disturbances (Van Bellinghen and De Troch 2001).  Reductions in symptom 
severity were also demonstrated in two large multi-centre placebo-controlled trials of 
risperidone for disruptive behavior disorders in low IQ children, even after controlling for the 
sedative effect induced by the medication (Aman et al. 2002a;Snyder et al. 2002). Significant 
improvements in behaviour were detected as early as 1 week after treatment initiation. The 
interpretation of these findings is complicated, however, by that fact that many of children 
were receiving concurrent psychotropic medication. 
 
Although anticonvulsants are increasingly being used to treat affective disorders, mixed 
results have been obtained in placebo-controlled trials of their use to treat disruptive 














adolescents with disruptive behaviour (tantrums), failed to detect a significant difference in 
parent and teacher ratings between medication and placebo (Looker and Conners 1970). 
Carbamazepine also failed to demonstrate effectiveness on any of the outcomes measures 
employed in a study of children with conduct disorder (Cueva et al. 1996). On the other 
hand, greater response to divalproex than placebo was observed in participants diagnosed 
with explosive tempers, mood lability, and disruptive behaviour disorders (Donovan et al. 
2000), as well as in adolescents with conduct disorders who had at least one criminal 
conviction (Steiner and Karnik 2003). In the latter study, symptom severity and global 
improvement ratings were more favourable after administration of high doses (500 - 1500 
mg/d) than low doses (up to 250 mg/d) of divalproex. 
 
The selective adrenergic agonist clonidine has shown some promise in augmenting 
pharmacotherapy for disruptive behaviour disorders with comorbid ADHD. Clonidine is 
implemented widely in clinical practice as an add-on to treatment for psychostimulants 
(Hazell et al. 1996).  In a controlled trial over half (21/37) of patients receiving clonidine as 
augmentation improved on a conduct scale compared to 21% (6/29) of those receiving 
placebo (Hazell and Stuart 2003). Interestingly, in this trial clonidine seemed to reduce some 
of the side effects associated with psychostimulants, but not insomnia, a common indication 
for its prescription. A comparison of clonidine and methylphenidate monotherapy and 
treatment combining both agents revealed few differences in the efficacy and tolerability of 
these medications for a group of children and adolescents (Connor et al. 2000). Preliminary 
data on newer agents, such as atomoxetine, are promising.  A recent placebo-controlled trial 
of this selective noradrenaline uptake inhibitor in children with ADHD found that symptom 
reductions occurred in children with ADHD and comorbid oppositional defiance at higher (1.8 














Drug-related adverse events in trials included in meta-analysis 
 
Treatment of conduct disorder with lithium resulted in significantly more nausea (Campbell et 
al. 1995) and vomiting (Malone et al. 2000) than placebo. Of the anticonvulsants included in 
the meta-analysis, carbamazepine (Cueva et al. 1996) and divalproex (Donovan et al. 2000) 
resulted in increased levels of dizziness and appetite, respectively. Four out of 13 of the 
patients receiving carbamazepine experienced moderate, but transient leukopenia, with 2 
children experiencing marked symptoms of this condition. Equivalent levels of subjective 
distress and mild side effects were reported in one of the excluded trials for both high (500 - 
1500 mg/d) and low dose (up to 250 mg/d) divalproex (Steiner and Karnik 2003).  
 
Few of the trials of stimulants included in the meta-analysis provided information on side 
effects. In the escalated dose placebo-controlled trial of mixed amphetamine salts extended 
release (MAS XR) (Spencer et al. 2006), anorexia/decreased appetite, insomnia, headache 
and abdominal pain were relatively common in all dosage groups (10, 20, 30 & 40 mg/d). 
Anorexia/decreased appetite and insomnia occurred significantly more frequently in those 
patients given 20, 30 or 40 mg/d of MAS XR than placebo, and led more often than other 
side effects to trial discontinuation. In the study of pemoline (Riggs et al. 2004), stomach-
aches, insomnia and skin-picking were significantly more common in the medication than the 
placebo group. Higher rates of drowsiness and dizziness were observed relative to placebo 
following augmentation of stimulants with clonidine (Hazell and Stuart 2003). Prescription of 
this medication requires careful monitoring, as it is associated with adverse cardiovascular 
events, self-poisoning, and sudden death in children. 
 
A significantly greater number of patients receiving the neuroleptic haloperidol experienced 
sedation than those receiving lithium or placebo (Campbell et al. 1984), with  medication 














antagonist thioridazine resulted in elevated levels of sedation and dizziness (Greenhill et al. 
1985). There was, however, no difference in the overall tolerability of thioridazine when 
compared to molindone, despite high levels of dystonia following treatment with the 
antipsychotic.   
 
Significant increases in drowsiness, vomiting, weight gain, and the extrapyramidal symptom 
of parkinsonism were observed following double-blind treatment with risperidone (Buitelaar 
et al. 2001). Amongst the trials excluded from the meta-analysis, somnolence was reported 
as significantly more frequent in two trials of risperidone for children with sub-average IQs 
(Aman et al. 2002a;Snyder et al. 2002;Aman et al. 2002b). Adverse events in the acute 
phase of a large augmentation trial of risperidone for children with oppositional defiant 
disorders (Reyes et al. 2006) had largely subsided by the end of the 6 month double-blinded 
maintenance component of this trial. Nevertheless, adverse events resulting from treatment 
with risperidone suggest caution in its use for pediatric DBDs, especially given the absence 
of efficacy comparisons between risperidone and other more established treatment 
modalities (Keenan 2005).  
 
Impulse control disorders 
 
We were not able to find any clinical trials of pharmacotherapy for pediatric impulse control 
disorders. Although the SSRIs and mood stabilizers have been recognised as first line 
agents in the treatment of intermittent explosive disorder in adults (Coccaro and Danehy 
2006), there is little controlled evidence for the efficacy of these agents in other impulse 

















The meta-analysis detected an overall effect of short-term pharmacotherapy on treatment 
response in patients diagnosed with conduct disorder. The similar number of dropouts in the 
medication and placebo groups, both overall, and when stratified by medication class, 
suggests that the medications employed in these studies were relatively well tolerated. 
Nevertheless, certain side effects, such as sedation, dizziness and nausea are common. The 
potential emergence of serious drug-related adverse events, such as extrapyramidal 
symptoms with antipsychotics, are particularly worrisome.  
 
There are a number of factors limiting the conclusions that can be drawn from this review. 
Firstly, few of the trials of disruptive behavior disorders that were retrieved provided sufficient 
data for inclusion in the meta-analysis, with many employing ad-hoc, non-standardised rating 
scales. As a result, the meta-analysis possessed limited power to detect treatment effects, a 
problem compounded by the small sample sizes employed in the individual studies. In 
addition, although efforts were made to be as inclusive as possible, the requirement that 
trials included in the meta-analysis examine comparable patient populations places 
constraints on the applicability of its findings to the complex cases that typically present 
within clinical practice.   
 
Despite these shortcomings, this review found lithium and risperidone to be effective in 
treating CD on global measures of treatment response and symptom severity, respectively. 
Lithium treatment has the drawback of requiring constant monitoring to prevent the 
emergence of serious side effects. The effectiveness of low-dose risperidone, on the other 
hand, is consistent with the recommendation in a recent consensus statement that low 














psychosocial intervention (Kutcher et al. 2004).2 
 
The new generation of atypical antipsychotics are regarded as possessing a more 
favourable side effect profile than traditional neuroleptics (Connor et al. 2001). Nevertheless, 
substantial increases in somnolence and weight gain have been observed in the trials of 
risperidone in pediatric DBDs conducted to date. There also remain significant concerns 
about the possibility of extrapyramidal symptoms, with low rates of parkinsonism observed in 
a few of the trials (Buitelaar et al. 2001;Reyes et al. 2006). In the light of the serious nature 
of these adverse events, and evidence that low doses of risperidone present a stimulant 
effect (Alcantara and Barcia 1999), additional trials comparing risperidone with more 
established psychostimulants would be useful (Keenan 2005).3 Further, although treatment 
with risperidone over longer periods was well tolerated in the only long-term trial included in 
this review (Reyes et al. 2006) long-term effectiveness data are needed in order to 
comprehensively evaluate the risk-benefit ratio for this medication.   
 
The presence of aggressive behaviour in youth with primary conduct disorder has been 
recognised as indicating augmentation of psychosocial treatment with medication (Kutcher et 
al. 2004). This review revealed a great deal of variability between trials of pediatric disruptive 
behaviour disorders in the effectiveness of medication in treating aggression.  Despite this, 
aggressive behaviour was significantly reduced in patients with normal intellectual 
functioning in single trials of methylphenidate (Klein et al. 1997) and risperidone (Findling et 
al. 2000).  
 
Psychostimulants, and in particular, methylphenidate, appear effective in treating children 
                                                            
2 A consensus statement sponsored by Johnson & Johnson, the manufacturers of risperidone 
3 though see Aman et al. (2004)  for evidence that combined risperidone/stimulant treatment may be 














and adolescents with disruptive behaviour disorders. The majority of the controlled trials of 
this medication are for children and adolescents diagnosed with CD and comorbid ADHD.  
Nevertheless, a meta-analysis of 28 studies of ADHD with aggression found a dissociation 
between the effects of stimulants on aggression-related behaviours and ADHD symptoms 
(Connor et al. 2002). Methlyphenidate was also effective in reducing antisocial behaviour in 
a trial of children and adolescents with conduct disorders, after controlling for the severity of 
comorbid ADHD symptoms (Klein et al. 1997). The optimum dosage of this medication still 
needs to be determined, however, with dose control trials demonstrating effects of dosage in 
some trials (eg. Kolko et al 1999), but not in others (eg. Gadow et al. 1990).  Evidence for 
the efficacy of anticonvulsants in treating disruptive behaviour disorders is mixed, with the 
most evidence for efficacy being observed for divalproex (Donovan et al. 2000;Steiner and 
Karnik 2003). 
 
The role of serotonin in behaviour inhibition, and the reduction of impulsive and aggressive 
behaviour with the administration of serotonin reuptake inhibitors (Cherek et al. 2002) 
suggests that serotonin dysregulation plays a role in disruptive behaviour disorders. There is 
a need for more controlled trials of SSRIs in treating impulse control and disruptive 
behaviour disorders in pediatric patients, despite the favourable side-effect profile of the 
SSRIs relative to older antidepressants.  
 
The presence of comorbid psychiatric diagnoses has implications for the pharmacotherapy 
of pediatric disruptive behaviour disorders. This is particularly the case for patients with 
comorbid ADHD, which is not only prevalent in children and adolescents with conduct 
disorder, but is also associated with early onset CD, a particularly severe and treatment-
resistant form of the disorder. A recent consensus statement (Kutcher et al. 2004) 














combined with pharmacotherapy in the treatment of ADHD with comorbid CD.  This patient 
subgroup also appears to respond preferentially to higher doses of medication such as 
stimulants (Gadow et al. 1990) and atomoxetine (Newcorn et al. 2005). The development of 
slow-release formulations of medication should increase the effectiveness of 
pharmacotherapy for this difficult-to-treat population (Kutcher et al. 2004).  
 
In clinical practice different modalities of treatment are often combined.  However, only a few 
trials incorporating psychotherapy and pharmacotherapy have been conducted to date. A 
controlled trial of pediatric ADHD and comorbid ODD or CD found main effects for 
methylphenidate and behaviour modification on their own, but little evidence for an 
incremental increase in effectiveness through combining these interventions (Kolko et al. 
1999). Analyses of data from the NIMH  Collaborative Multisite Multimodal Treatment Study 
of Children with Attention Deficit/Hyperactivity Disorder suggests that the addition of 
psychosocial to medication therapy increases response rates in children with ADHD and 
comorbid ODD by up to 21% (Swanson et al. 2001).   
 
We were only able to find one controlled trial of the long-term treatment of disruptive 
behaviour disorders. The finding of reduced relapse rates after 6 months of maintenance 
therapy amongst responders to acute risperidone treatment (Reyes et al. 2006) is consistent 
with the suggestion that children with conduct disorder should receive pharmacotherapy for 
a minimum of half a year before discontinuing treatment (Buitelaar et al. 2003). Little 
research has been conducted on pharmacotherapy for pediatric ODD. The high proportion of 
patients with ODD and comorbid ADHD in the trial demonstrating the efficacy and tolerability 
of mixed amphetamine salts (Spencer et al. 2006) supports the recommendation that 
medication only be used for ODD comorbid with other psychiatric diagnoses that are 














Further research should be conducted into promising medications for the treatment of 
disruptive behaviour disorders, such as naltrexone (Kim et al. 2001). The influence of gender 
on the effectiveness of medication in treating disruptive behaviour disorders should also be 
assessed, as there is some evidence to suggest that females who are diagnosed with CD 
have a poorer prognosis than males (Dalsgaard et al. 2002). Finally, studies of resilience to 
risk factors associated with the subsequent development of DBDs, including trials 
investigating genetic predisposition for antisocial behaviour (Caspi et al. 2002;Jaffee et al. 
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Data provided by randomised controlled trials (RCTs) on differences in the efficacy of 
medication agents for treating PTSD provides one way to interrogate the involvement of 
serotonin in difficulties with regulating emotion following psychological trauma. Frewen et 
al.’s (2006) conceptualisation of PTSD draws attention to the arousal and numbing symptom 
clusters as particularly pertinent in this regard. Indeed, Davidson predicted that tricyclic 
antidepressants that target the serotonergic system would be more effective in treating 
numbing symptoms, and noradrenergic agents intrusion symptoms (Davidson 1992). This is 
consistent with the findings from an early trial of the SSRI fluoxetine, in which a reduction 
was observed after 5 weeks in hyperarousal and numbing symptoms, but not re-experiencing 
or active avoidance symptoms (B. van der Kolk et al., 1994).  
 
The feasibility of using symptom cluster response profiles to infer the involvement of 
particular biochemical pathways in pathological responses to trauma is also suggested by 
findings from a meta-analysis that the effects of treating PTSD with atypical antipsychotic 
agents (employed as monotherapy or augmentation agents in randomised controlled trials) 
were restricted to intrusion symptoms (Pae et al., 2008). The following chapter describes a 
systematic review and meta-analysis of the effects of pharmacotherapy in treating PTSD. In 
line with the emphasis of this thesis, the focus of the review was not only on the reduction of 
overall PTSD symptom severity, but also on comparing the effects of serotonergic agents on 















4.2  Introduction 
 
It is estimated that as many as 80% to 100% of all people are exposed to traumatic events 
during their lifetimes (Breslau et al., 2005; Frans et al., 2005). Depending on the nature of the 
trauma, approximately 5-9% of the general population go on to develop posttraumatic stress 
disorder (PTSD), a condition characterised by the experience of persistent flashbacks of the 
event (re-experiencing/intrusion symptoms), a state of high arousal when exposed to 
reminders of the trauma (hyperarousal symptoms), and concomitant avoidance/emotional 
numbing in response to these reminders (avoidance/emotional numbing symptoms) (Breslau 
et al., 1998; Frans et al., 2005; Kessler et al., 2005). This constellation of symptoms satisfy 
the criteria for PTSD when they extend beyond a month after exposure to the trauma and 
cause clinically significant functional disability, as conceptualised in current psychiatry 
diagnostic systems such as the Diagnostic and Statistical Manual of Mental Disorders, 4th 
edition (DSM-IV) (American Psychiatric Association, 1994). 
 
PTSD is frequently chronic and associated with significant morbidity, poor quality of life, and 
high personal, social and economic costs. It additionally represents a risk factor for 
developing other mood and anxiety disorders, as well as substance use disorders. It has 
been estimated that the US economy alone loses in the region of 3 billion dollars annually 
due to PTSD-related loss in productivity (Brunello et al., 2001).  
 
PTSD is characterised by a range of neurobiological disruptions, including changes in the 
hypothalamus-pituitary-adrenal axis, as well as alterations in the serotonergic, and 
noradrenergic neurotransmitter systems. Chemical modulation of these systems by means of 
medication therefore holds promise as a treatment for this disorder. Conversely, reports of 
the efficacy of the selective serotonin reuptake inhibitors, or SSRIs, in treating PTSD 
implicates involvement of the serotonin system in its aetiology. Indeed, on the basis of both 














have recommended the SSRIs as first line agents in treating PTSD. The SSRIs paroxetine 
and sertaline are currently the only medications approved by the Federal Drug Agency in the 
United States for the treatment of PTSD. 
 
Despite the general acceptance of SSRIs as first-line medication interventions for treating 
PTSD, a recent analysis of clinical practice treatment guidelines revealed considerable 
variability in conclusions regarding their efficacy (Stein et al., 2009).  This is reflected in a 
review conducted by the Institute of Medicine, in which it was concluded that there is 
insufficient evidence that any of the SSRIs reduce PTSD symptom severity (Institute of 
Medicine (IOM), 2009). In addition, there is recognition that not all patients with PTSD 
respond to the SSRIs, leading to the need for augmentation or combination treatment 
strategies, and to interest in agents such as tiagibine that employ novel mechanisms of 
action. A comprehensive review of the efficacy of medication in treating PTSD is therefore 
warranted.  
 
Accordingly, a narrative review was conducted of the effectiveness of medication in reducing 
PTSD symptoms, as reported by randomised controlled trials (RCTs) of pharmacotherapy for 
PTSD. Efficacy data was synthesised across trials as part of an update of a prior meta-
analysis of PTSD pharmacotherapy, using the guidelines established by the Cochrane 
Collaboration (Higgins and Altman, 2008). Finally, a review of pharmacotherapy RCTs for 
treatment resistant patients was also conducted. 
 
This review addresses the following questions: 
1) is medication effective in treating PTSD? 
2) are some agents more effective than others? 
3) how long should medications be administered? 














4.3  Method 
 
Inclusion of studies in this review was restricted to all placebo-controlled randomised 
controlled trials (both published and unpublished) of pharmacotherapy for adults (18 – 64 
years) diagnosed with PTSD, according to DSM-III+ or ICD-9+ criteria. Assessment of RCTs 
for inclusion in this review was conducted independently by 2 raters. Concurrent treatment of 
the majority of patients with medication (=> 50%)  as part of standard care were grounds for 
exclusion. Concurrent psychotherapy was permitted, on the condition that it was (a) not 
trauma-focused, or (b) had been initiated at least 3 months prior to the beginning of the trial. 
RCTs of medication prophylaxis for PTSD were not eligible. Finally, studies were restricted to 
those in which the objective was to treat all symptom clusters defining PTSD, rather than 
specific subsets, such as sleep disturbances.  
 
Eligible RCTs were identified in February, 2010 by systematically searching the following 
databases:  MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials, the 
Cochrane Collaboration Depression, Anxiety and Neurosis Controlled Trials Register and the 
National PTSD Center Pilots database. Database-specific search queries were designed 
(see the supplementary material for full syntax), and included the terms "posttraumatic stress 
disorder" and "randomized controlled trial". Additional unpublished studies were located by 
searching the bibliographies of published articles and contacting experts in the field.  Where 
study data was missing, or in cases in which there was concern regarding publication of 
multiple reports on the same trial, the reviewers contacted investigators by email in an 
attempt to obtain more information. The selection procedure for trials that were eligible for 
inclusion in the review is presented in Figure 1. Study characteristics and outcomes are 



















Figure 1. Selection flowchart for RCTs included in the review 
 
4.4  Narrative review of the findings of RCTs of pharmacotherapy for PTSD 
 
4.4.1  Mono-amine oxidase inhibitors 
 
The Mono-amine oxidase inhibitors (MAO-I) were one of the first class of agents to be tested 
in RCTs for treating PTSD.  The mono-amine oxidase A enzyme is a deaminater of both 
norepinephrine and serotonin, neurotransmitters that have been implicated in PTSD (Baker 
et al., 1995). Two RCTs of phenelzine, a mono-amine oxidase inhibitor (MAO-I), provide 
mixed evidence for its efficacy in treating this patient population. No differences were 
detected in a 5 week cross-over RCT (Shestatzky et al., 1988), with over half of the 
participants (7/13) withdrawing during the course of the study while receiving phenelzine. A 














60 male combat veterans reported a significant decrease after 3 weeks of treatment with 
phenelzine in the score on the primary PTSD symptom severity scale, the self-rated Impact 
of Event Scale (IES) (Horowitz et al., 1979; Kosten et al., 1991). 
 
4.4.2  Reversible inhibitors of monoamine oxidase A (RIMAs) 
 
The clinical utility of the MAO-Is is limited by the potential for serious drug-related adverse 
events, such as hypertensive crises, and stringent dietary restrictions that reduce the 
likelihood of compliance. These shortcomings have been largely overcome in the case of the 
reversible inhibitors of monoamine oxidase A (RIMAs) a class of agents that temporarily 
inhibit the functioning of the monoamine oxidase A enzyme.  
 
Nevertheless, results from two placebo-controlled trials of the RIMA brofaromine have been 
disappointing. In the first, Katz et al (1994) observed no evidence of reductions in the total 
score of the gold-standard observer-rated measure of symptom severity, the Clinician 
Administered PTSD scale (CAPS)(Blake et al., 1995), following 14 weeks of treatment. A 
significant treatment effect did emerge, however, when restricting the sample of 60 patients 
to those diagnosed for at least one year. A larger 12 week study of 118 patients failed to 
detect difference on the CAPS following a similar dosing regimen (Baker et al., 1995). More-
over, although RIMAs are relatively safe compared to the MAO-Is, their potential for harmful 



















4.4.3  Selective Serotonin Reuptake Inhibitors 
 
The SSRIs represent the medication class that has been most frequently investigated in 
placebo-controlled trials, with a total of 18 RCTs conducted to date. It is primarily on the basis 




Paroxetine is registered by the FDA for the short-term treatment of PTSD. All 3 published 
randomised placebo-controlled trials of this medication have reported favourable results.  In 
the first two trials, improvements in symptom severity on the CAPS were detected after 4 
weeks of paroxetine, with medication effective for all 3 symptom clusters (Marshall et al., 
2001; Tucker et al., 2001). In one of these trials, almost a third of patients on paroxetine 
(29.4%) went into remission after 12 weeks of treatment (Tucker et al., 2001). A large 
placebo-controlled comparison of fixed doses of paroxetine (20 mg/d versus 40 mg/d) failed 
to detect a difference in treatment response as a function of dosage or comorbid depression 
(Marshall et al., 2001). Marshall et al. (2007) reported significant differences in treatment 
response on the improvement item of the Clinical Global Impressions scale (CGI-I) after 10 
weeks, with a third (14/21) of patients in a sample of 52 mostly Hispanic adults responding to 




Six RCTs of fluoxetine have been conducted to date. This includes the first published 
placebo-controlled trial of an SSRI for the treatment of PTSD, a 5 week trial in which 
significant reductions in PTSD symptom severity were observed in a sample of 64 patients 
on the CAPS (van der Kolk et al., 1994). This effect was not observed in a subsample from a 















In a second trial in civilian subjects (N = 54) differences in treatment response between the 
placebo and medication groups only reached significance for subjects classified as very 
much improved (Connor et al., 1999). Using a composite measure, almost half of the 
subjects on fluoxetine (41%) were regarded as displaying minimal levels of symptoms and 
non-disability by study endpoint. No differences were observed on any of the self or clinician-
rated symptom severity measures after 12 weeks of fluoxetine treatment in a small sample 
(N = 12) of combat veterans with high levels of comorbid depression (Hertzberg et al., 2000). 
In a larger sample of 54 predominantly male participants a statistically significant effect of 
medication emerged after 6 weeks on the observer-rated TOP-8 symptom severity scale 
(Connor et al., 1999; Martenyi et al., 2002b).  
 
A subsequent trial comparing treatment with 20 or 40 mg/d of fluoxetine in a sample 
composed primarily of women did not detect superiority of medication after 12 weeks 
between any of the comparison groups (N = 411)(Martenyi et al., 2007). Similar results were 
reported for a 8 week comparison of treatment with fluoxetine or eye movement 
desensitization and reprocessing (EMDR) (van der Kolk et al., 2007). No patients in the 





Sertraline is licensed by the FDA for the short and long-term treatment of PTSD. There have 
been a total of 7 published placebo-controlled RCTs of sertraline conducted to date. 
Evidence for the efficacy of sertraline has been mixed, with negative results reported for 
under-powered studies, or typically treatment-resistance populations (veterans). Significant 














designs. Brady and colleagues (Brady et al., 2000) detected differences on the CAPS after 
only 2 weeks of sertraline in 187 outpatients, with 70% of the reductions on the CAPS and 
the IES apparent after 4 weeks. Davidson et al. (2001b) reported significant differences on all 
primary severity measures after 12 weeks in an intent-to-treat sample of 202 outpatients.  
 
In contrast, however, two small 10 week sertraline, one in a sample of Israeli military 
veterans (N = 42) and the other in predominantly female outpatients (N = 35), both failed to 
detect an effect of medication on the total CAPS score (Tucker et al., 2003; Zohar et al., 
2002). Moreover, Tucker and colleagues (2003) also observed negative effects in the 
citalopram arm of their study, casting doubt on the power of the study to detect treatment 
effects. No differences on intent-to-treat analyses were observed for either drinking or PTSD 
severity outcomes in a 12 week fixed dose study of sertraline in 94 subjects with comorbid 
PTSD and alcohol abuse/dependence (Brady et al., 2005). Additionally,  a 12 week placebo-
controlled comparison of sertraline and the serotonin norepinephrine reuptake inhibitor 
(SNRI) venlafaxine in 538 mixed-trauma subjects did not detect differences between 
sertraline and placebo on the CAPS-SX, the primary outcome measure  (Davidson et al., 
2006b).   
 
In the final RCT of sertraline for PTSD, an equivalent number of treatment responders on the 
CGI-I were observed in the sertraline (36.9%) and placebo (41.5%) groups in a sample of 
169 combat veterans  after 12 weeks (Friedman et al., 2007).  The majority of patients 
treated with sertraline experienced treatment-emergent adverse events (86%), with diarrhoea 
and headaches being most common. Combat trauma was associated with a significantly 



















A single published RCT of citalopram (described above), failed to demonstrate an effect on 
PTSD symptom severity after 10 weeks compared to either sertraline or placebo in 33 
outpatients (Tucker et al., 2003). 
 
4.4.4  Tricyclic antidepressants (TCAs) 
 
Despite being one of the most established classes of antidepressants,  only 3 relatively small 
controlled trials of TCAs for PTSD have been published to date. In the earliest (cross-over) 
study, the TCA desipramine did not reduce PTSD symptom severity after 4 weeks of 
treatment in 18 male US war veterans with high levels of comorbid psychopathology, 
including affective disorder and substance abuse (Reist et al., 1989).  
 
This cross-over study was followed by a flexible-dose parallel group study of amitriptyline  in 
46 veterans, in which medication demonstrated superiority over placebo after 8 weeks of 
treatment. These effects of medication were restricted to self-rated PTSD severity scales, 
however (Davidson et al., 1990). Finally, an 8 week comparison of the TCA imipramine  and 
phenelzine detected a significant  reduction on the IES after 5 weeks of  imipramine (Kosten 
et al., 1991). However, a relatively larger proportion of patients on imipramine than 
phenelzine dropped out due to treatment-related side effects (17.4% versus 5.3%, 
respectively).   
 
4.4.5  Anticonvulsants 
 
The possibility that limbic hypersensitisation or kindling might underlie increased arousal to 
traumatic stimuli in PTSD suggests that anticonvulsants might be effective in treating this 














test this hypothesis (Hertzberg et al., 1999). Although a larger proportion of participants 
responded to treatment in the medication than placebo group (2/5 versus 1/4, respectively), 
the small sample (N = 15) precluded estimation of a treatment effect size.  
 
More recently, 232 patients from 38 centres in the US were treated for 12 weeks with the 
selective GABA reuptake inhibitor tiagabine (Davidson et al., 2007). No differences were 
observed in any of the efficacy outcomes assessed. Similar lack of efficacy was observed in 
40 outpatients on most outcomes after 12 weeks of treatment with topiramate (Tucker et al., 
2007). A reduction in overall PTSD symptom severity was detected on the self-rated TOPS-8 
following medication treatment, however. No effect of treatment was detected on any 
outcome measure after 8 weeks of placebo-controlled treatment with the selective GABA 
inhibitor divalproex in 85 US military veterans with PTSD (Davis et al., 2008). 
 
4.4.6   Antipsychotics 
 
Three small randomized controlled trials have evaluated the effectiveness of antipsychotic 
medication as monotherapy in treating PTSD. An initial trial of the atypical antipsychotic 
olanzapine was unable to det ct a treatment response in 15 mostly female patients with non-
combat PTSD over 10 weeks (Butterfield et al., 2001). Patients treated with olanzapine 
gained significantly more weight than those given placebo by study end (11.5 lb versus 0.9 
lb, respectively).  
 
Two small studies provide preliminary evidence that risperidone may be effective in treating 
PTSD in female patients, however. In a trial of 21 women with PTSD from childhood physical, 
sexual, verbal and emotional abuse, 8 weeks of risperidone  resulted in a significant 
reduction of symptom severity on the CAPS-2 (Reich et al., 2004). Almost half of the subjects 














risperidone over placebo was detected on the CAPS after 10 weeks of treatment in 20 
women exposed to domestic violence and sexual assault (Padala et al., 2006).  
 
4.4.7  Benzodiazepines 
 
Our search strategy retrieved a single RCT testing the effectiveness of benzodiazepine in 
treating PTSD. In a small controlled trial, sixteen outpatients were administered alprazolam 
or placebo for two 5 week periods in a cross-over fashion, separated by a 2 week placebo-
substitution washout period (Braun et al., 1990). Analysis of data from the 10 patients who 
completed the study revealed a significant reduction in depression symptoms only. 
 
4.4.8  Other medications 
 
A total of 5 placebo-controlled RCTs of medications with novel mechanisms of action have 
been conducted. In the first placebo-controlled trial inositol, a glucose isomer, was 
administered over four weeks in a cross-over fashion to 17 outpatients with mixed trauma, 
with no discernable effect of medication on the primary outcome (IES) amongst the 13 
subjects who completed the trial (Kaplan et al., 1996).  
 
The second trial compared the effectiveness of 8 weeks of treatment with mirtazapine or 
placebo in 26 subjects with PTSD, the majority of whom had comorbid depression (Davidson 
et al., 2003). A greater number of treatment responders were observed in the medication 
group, with mirtazapine also demonstrating an antidepressant effect. Davis et al. (2004) 
detected superiority of 12 weeks of nefazodone  to placebo in 42 combat veterans on the 
continuous total CAPS score. The high dropout rate amongst those treated with medication 















A 6 month study of the serotonin norepinephrine reuptake inhibitor venlafaxine assessed its 
effectiveness in patients sampled from 56 outpatient centres outside of the US (Davidson et 
al., 2006a). An improvement was observed on the CAPS-SX total score , as well as on 
measures of quality of life, functional disability, resilience to stress and comorbid depression.  
A subsequent trial by the same group detected significant reductions in symptom severity 
following venlafaxine treatment in 538 outpatients on the CAPS-SX total score. Differences 
were observed as early as 2 weeks following the initiation of treatment (Davidson et al., 
2006b). 
 
4.5  Meta-analysis of pharmacotherapy for PTSD 
 
This brief review highlights the inconsistency of the evidence for the efficacy of medication in 
treating PTSD.  Of the 37 short-term studies included in this review that conducted between-
group comparisons, only 12 detected a significant reduction in PTSD symptom severity on 
the CAPS or an alternate primary outcome measure (see Table 1). This divergence in 
findings was detected even amongst first line agents, with 9 of the 15 SSRI trials employing 
the CAPS unable to distinguish statistically between the effects of medication and placebo.  
 
Poor sensitivity to treatment effects may be partially due to variation in study methodology 
and the clinical characteristics of patient groups, as well as insufficient power to detect a 
treatment effect in small studies. The quantitative synthesis or meta-analysis of treatment 
outcome data allows one to maximise power in detecting an effect. Overall treatment effects 
are typically summarised in the form of a mean difference (MD) or effect size estimate that 
can be standardised to accommodate the use of different outcome scales (Cohen, 1988). 
 
A number of meta-analyses of medication treatment for PTSD have been conducted to date, 














as well as comparing treatment efficacy across agents (Penava et al., 1996; Stein et al., 
2006; Stewart and Wrobel, 2009; Van Etten and Taylor, 1998). Although the findings of these 
meta-analyses have in general supported the use of pharmacotherapy, and SSRIs in 
particular, in treating PTSD, their conclusions have been weakened by methodological 
shortcomings (listed in Table 3).  Accordingly, we conducted a meta-analysis of placebo-
controlled RCTs of PTSD in adults that was restricted to between-group comparisons of 
outcome data from validated scales.   
 
4.5.1  Methods of meta-analysis 
 
Primary outcomes included the reduction in total symptom severity on the Clinician 
Administered PTSD Scale and the number of subjects rated as “much improved” or “very 
much improved” on the improvement item of the Clinical Global Impressions scale (CGI-I) (or 
closely related measure). Secondary outcomes included the efficacy of medication in 
alleviating the severity of PTSD symptom clusters, as assessed by the respective subscales 
of the observer-rated CAPS and the self-rated DTS. Medication acceptability was estimated 
by calculating the total proportion of participants who withdrew from the RCTs due to 
treatment emergent adverse events.  
  
Weighted mean differences (WMD) for continuous measures and relative risks for categorical 
outcomes were obtained from a random effects model and were expressed in terms of the 
average and 95% confidence interval of the effect size for each subgroup. Treatment 
response on the CGI-l was converted into a number needed to treat (NNT) for each 
medication agent (see footnotes in Table 3 for the exact procedure).  
 
Efficacy analyses (detailed below) were conducted using the metafor package in the R 














(DerSimonian and Laird, 1986; Viechtbauer, 2010). Differences in the efficacy of classes of 
medication were assessed by means of Deeks' stratified test of heterogeneity (2001). 
Egger’s regression test of funnel plot asymmetry was employed in order to determine 
whether there was evidence of possible publication bias (Egger et al., 1997). A mixed-model 
meta-regression was conducted to determine the degree to which methodological (gender 
distribution and proportion of patients with combat-trauma) and clinical (duration of trial in 
weeks, number of sites, year of publication, and pharmaceutical funding) differences 
between trials might have systematically influenced variation in the reduction of PTSD 
symptom severity.  
 
4.5.2  Results of meta-analysis 
 
A total of 37 short-term RCTs (4 – 24 weeks), containing data for 5008 patients treated with 
medication for an average of 10 weeks, were included in the review (Table 1). These 
included data from unpublished industry-funded short-term RCTs of paroxetine (SKB627)  
and sertraline (Pfizer588) , published in the National Institute of Clinical Excellence PTSD 
guidelines (NICE, 2005).  In addition, 5 published (Connor et al., 2006; Davidson et al., 
2001a; Davidson et al., 2005; Marshall et al., 2007; Martenyi et al., 2002a) and 1 
unpublished RCTs (SKB650) included a maintenance component. The greatest number of 
trials assessed the effectiveness of the SSRIs (N = 20). There was little evidence from an 
Egger regression plot of publication bias across the 23 studies that were included in the 
meta-analysis (z = 1.12, p = 0.27; see supplementary material for regression plot). 
 
Medication treatment resulted in a significant reduction in PTSD symptom severity, with a 
reduction of about 6 points on the CAPS total score relative to placebo (N = 23, MD = -6.10, 
95%CI = -7.98, -4.23, n = 4112)(see Figure 1.). A moderate degree of variation was evident 














for which there was data (citalopram, fluoxetine, paroxetine and sertraline), evidence of 
efficacy was only available for paroxetine (N = 4, MD = -10.65, 95%CI = -14.16, -7.14, n = 
1100) and sertraline (N = 8, MD = -4.35, 95%CI = -6.76, -1.93, n = 1260). Paroxetine was 
significantly more effective than sertraline and fluoxetine in reducing symptom severity using 
a fixed effects model (chi-squared=10.37, p = 0.001 and chi-squared=3.08, p = 0.08, 
respectively). 
 
Pharmacotherapy was more likely to result in a global clinical response on the CGI-I than 
placebo (N = 16, RR = 1.4, 95%CI = 1.17, 1.66, n = 1821). A larger proportion of patients 
were responders on this scale in the medication (57.2%) than placebo (40.2%) groups. The 
corresponding NNT indicates that, relative to patients in the placebo groups, approximately 7 
to 10 patients have to be treated for an average of 11 weeks with medication in order for an 
additional patient to respond to treatment. 
 
Significant treatment effects were observed for the intrusion/re-experiencing, 
avoidance/numbing and hyperarousal symptoms on the CAPS. Comorbid depression but not 
anxiety were reduced following medication treatment (HAM-D: N = 10, MD = -2.31, 95%CI = 
-3.6, -1.02, n = 930). Significant improvements were also observed in functional disability 
following medication treatment (N = 10, MD = -1.87, 95%CI = -2.72, -1.02, n = 1852). Finally, 
a larger number of patients on medication withdrew from treatment due to adverse events 
than on placebo (N = 29, relative risk = 1.38, 95%CI = 1.10, 1.72, n = 4045), though the 
absolute proportion that withdrew was relatively small (9.5%).  
 
More recently published trials were more likely to report smaller reductions in symptom 
severity that older trials (coef = 1.32, z = 3.28, p = 0.001). Although the placebo response on 
the CAPS was relatively marked across trials (mean reduction of 26.8 points), there was little 














Instead, it is more likely a result of the fact that the more recent studies are small trials of 
novel psychotropics, for which there is limited evidence of effectiveness, and which are 
under-powered to detect treatment effects.   
 
A strong positive relationship was observed between response on the CAPS and number of 
centres at which a trial was conducted. The high correspondence between number of centres 
and sample size (rho = 0.92), suggests this finding may also result from increased power in 
the larger samples employed in multi-centre studies.  Surprisingly, no effect on outcome was 
detected for the source of funding, duration of trial, or proportion of females or veterans 




















4.6  Length of treatment 
 
The available pharmacotherapy evidence base suggests that treatment effects may emerge 
as early as 2 to 4 weeks for the SSRIs and the SNRI venlafaxine. Less is known about how 
long patients should be treated to achieve a maximal response, and when it is safe to 
discontinue pharmacotherapy without risking relapse.   
 
Davidson and colleagues administered 28 weeks of placebo or sertraline to patients who 
completed a 12 week placebo controlled trial of sertraline, and who responded to a 
subsequent 24 weeks of open-label treatment with this agent (50 – 200 mg/d) (Davidson et 
al., 2001a). Response to acute-treatment with sertraline was maintained in the majority of 
patients during open-label continuation, with more than half of the non-responders to 
sertraline (54%) during the acute phase responding during the continuation phase (Londborg 
et al., 2001). Relapse, defined as a composite measure consisting of reductions in clinical 
improvement scores, increasing PTSD symptom severity and investigators opinion of clinical 
deterioration, was 6.4 times as frequent in responders to continuation treatment who were 
subsequently randomised to placebo (26%) than sertraline (5%).  
 
Responders to medication in 12 week double-blind placebo-controlled trial of fluoxetine for 
PTSD were randomised to another 24 weeks of treatment with fluoxetine or placebo 
(Martenyi et al., 2002a).  Relapse was defined as an increase from baseline at week 12 of 
acute treatment by 40% on the TOP-8 score and an increase >= 2 on the CGI-S. Time to 
relapse was significantly longer in the medication than the placebo group, with a lower 
proportion of the 131 responders to acute-phase fluoxetine treatment relapsing (5.8%) after 
continuation with medication than placebo (16.1%). Patients who were randomised to 
fluoxetine continued to improve significantly on the clinical and PTSD severity scores, as well 















Davidson et al. (2005), randomized 62 subjects to 6 months continuation treatment with 
fluoxetine or placebo after the same period of open-label treatment (max: 60 mg/d) with 
fluoxetine. Relapse was defined as either an untoward clinical event (eg. psychiatric 
hospitilization) during the randomisation phase, or an increase of at least 2 points on the CGI 
since randomisation, or as no improvement or worsening of symptoms on the CGI relative to 
open-label baseline. Although a relatively strong effect of medication was observed in 
preventing relapse during the maintenance phase of the study, relapse rates were high for 
both participants who continued receiving a stable dose of fluoxetine (22%) as well as for 
those whom medication was discontinued medication (50%).  
 
The efficacy of maintenance treatment with the selective GABA reuptake inhibitor tiagabine 
was tested by randomising 18 completers of 12 weeks of open-label treatment with tiagabine 
(max dose: 16 mg) to ongoing medication treatment or placebo for an additional 12 weeks 
(Connor et al., 2006). No differences in clinical response were detected.  
 
The limited evidence reviewed above suggests that treatment with SSRIs may be beneficial 
over the long term. These agents also appear to be well-tolerated amongst those patients 
who have achieved stable doses, with no drug-related adverse events reported for more than 
20% of subjects in any of the relapse prevention studies reviewed.   
 
4.7  Treatment refractory cases 
 
A large proportion of patients with PTSD fail to respond to treatment with pharmacotherapy. 
For example, close to half of the patients (44.2%) in the 23 RCTs that provided information 















Despite the relatively high rates of treatment resistance, few rigorous trials of 
pharmacotherapy in non-responders to first-line treatments for PTSD have been conducted 
(Table 4). In a recent review, Ipser et al. (2006) identified only 4 RCTs that assessed 
augmentation strategies for treating PTSD in populations who were currently receiving 
psychotropic medication, and who could be defined as treatment resistant according to lack 
of response on the CGI-I or a validated measure of symptom severity (Bartzokis et al., 2005; 
Hamner et al., 2003; Raskind et al., 2003; Stein et al., 2002). These trials are briefly 
described below, as well as a subsequently published study of the antipsychotic risperidone 
that satisfied the inclusion criteria employed by Ipser et al. (2006)(Rothbaum et al., 2008).  
 
Dysregulation of the sympathetic system and the centrality of hyperarousal symptoms in 
PTSD suggest that agonists of adrenergic receptors might be effective treating refractory 
patients. A small 20 week double-blinded cross-over study of the efficacy of the alpha 1 
adrenergic antagonist prazosin in treating sleep disturbances in 10 patients with chronic 
PTSD  reported clinically significant improvement following medication treatment in PTSD 
and sleep symptoms (Raskind et al., 2003).  
 
Antipsychotic agents may be indicated as augmentation agents in treating PTSD, given the 
presence of psychotic symptoms in complicated cases of PTSD, and the possibility that the 
disorder is characterised by dysregulation of the dopaminergic system (Seedat et al. 2003). 
The first antipsychotic tested in an RCT for PTSD as part of an augmentation strategy was 
olanzapine (Stein et al., 2002). This agent was administered for the treatment of chronic 
PTSD in 21 war veterans who did not respond to a minimum of 12 weeks of prior treatment 
with an SSRI. Olanzapine significantly reduced symptom severity on the CAPS and sleep 
disturbance after 8 weeks of double-blind treatment, despite the absence of psychotic 















The efficacy of risperidone in treating PTSD has been assessed in three RCTs.  No effect of 
medication was observed on the CAPS following 5-weeks of treatment with risperidone in 37 
Vietnam veterans diagnosed with PTSD and psychotic symptoms (Hamner et al., 2003). 
However, a greater reduction was observed in the medication group in severity of psychotic 
symptoms, as measured using the PANSS (Kay et al., 1987). A subsequent placebo-
controlled trial of risperidone was conducted in 65 veterans with PTSD who were 
participating in a 5 week psychotherapy residential program (Bartzokis et al., 2005).  Patients 
with psychotic symptoms were excluded, and most of the study participants were being 
treated with antidepressants (88%). Superiority of medication was observed after 16 weeks 
in reducing PTSD symptoms on the total CAPS score, as well as anxiety and negative and 
positive psychotic symptoms.  
 
In one of the few trials to assess pharmacotherapy for treatment-resistant PTSD in a non-
veteran population, Rothbaum and colleagues (2008) administered add-on risperidone for 8 
weeks to 20 patients who failed to achieve a 75% reduction in total score on the CAPS after 
8 weeks of open-label treatment with sertraline. Many of the patients were reported as 
displaying psychotic symptoms. Virtually identical differences were observed on the CAPS at 
endpoint in the placebo and medication groups. Approximately a third of the patients treated 
with risperidone (4/11) dropped out due to possibly treatment-related adverse events.  
 
The majority of controlled trials of pharmacotherapy in combating anxiety disorders add a 
course of antipsychotics to ongoing treatment with SSRIs (Ipser et al., 2006). In general, 
findings from trials of PTSD appear to support the efficacy of this strategy, at least with 
respect to combat-related traumas. There is less evidence regarding the management of 
PTSD in civilian populations. Paradoxically, antipsychotic agents have thus far only 
demonstrated effectiveness in reducing PTSD symptoms in patients without psychotic 














refractory PTSD is consistent with findings from an RCT of this agent when used as 
monotherapy in treating sleep-related symptoms in PTSD patients (Taylor et al., 2008). 
 
 
4.8  Conclusion 
 
The results of a meta-analysis are only as valid as the quality of the individual trials from 
which they are composed. With this in mind the authors conducted an exhaustive search for 
eligible trials, and restricted the results of this review to RCTs, widely regarded as the most 
rigorous study design. Moreover, the test of publication bias provided little evidence that 
articles that reported positive results were disproportionally represented in the meta-analysis.  
 
The results of our review support the effectiveness of medication in in treating PTSD over the 
short-term, with the largest body of evidence of efficacy for the SSRIs and venlafaxine. The 
agents appear relatively fast-acting, with response reported as early as the first 2 to 4 weeks 
of treatment. Nevertheless, maximising response to medication might require treatment for 
substantially longer, with RCTs of paroxetine and fluoxetine observing substantial 
improvements in clinical response beyond 12 weeks of treatment (Martenyi et al., 2002a). No 
evidence of efficacy was available for the benzodiazepines, despite their continued popularity 
in clinical practice (Cloos and Ferreira, 2009). 
 
The current evidence-base supports the efficacy and tolerability of treatment with the SSRI’s 
over the longer-term. The finding that over a quarter of patients relapsed after discontinuation 
of fluoxetine treatment after up to 26 weeks of treatment (Davidson et al., 2001a) provides 
some support to the consensus that treatment of chronic PTSD with medication should be 
continued for at least a year. Of the two FDA approved agents for the treatment of PTSD, 














question the usefulness of including sertraline as the gold-standard comparator in RCTs 
comparing the efficacy of different medications (Chung et al., 2004; McRae et al., 2004; 
Saygin et al., 2002; Smajkic et al., 2001).  
 
War-trauma is commonly perceived as being prognostic of a poorer response to treatment, 
with 9 of the 11 trials that included a majority of trauma veterans failing to demonstrate 
efficacy for pharmacotherapy. The finding in a 12 week trial of fluoxetine of increased 
response in patients recently exposed to combat suggests that the salient characteristic with 
regards to medication response might be duration of PTSD, rather than combat trauma or 
gender, per se (Martenyi et al., 2002b).  Although inadequate information prevented a 
quantitative test of this hypothesis, the suggestion that combat trauma or gender are not 
influential determinants of study outcome is consistent with the results of the meta-regression 
analyses reported in this paper.  Indeed, our analyses suggest that certain study design 
features, such as sample size, might be more important in determining the size of the 
treatment effects observed. 
 
Neither of the dose-comparison studies of fluoxetine or paroxetine were able to detect 
significant differences in efficacy between higher and lower doses (Marshall et al., 2001; 
Martenyi et al., 2007). This is consistent with the general observation of a flat response curve 
for the SSRIs, and suggests that it might be prudent to initiate medication treatment at the  
low end of the recommended dose range,  with the aim of minimising  potential treatment-
related adverse events. Future research should address the comparative efficacy of doses of 
venlafaxine, as there is evidence in studies of depression that the efficacy of venlafaxine is 
dose-dependent (Stahl et al., 2005). It is notable that the maximum dose of venlafaxine in 
both of the RCTs of this agent in PTSD conducted to date were higher than the FDA 
guidelines for the licensed prescription of this medication for depression (Davidson et al., 















There has recently been interest shown in the treatment of PTSD with medications that 
employ extra-serotonergic mechanisms of action, including the anticonvulsants, atypical 
antipsychotics and venlafaxine. With the exception of risperidone and venlafaxine, the results 
of these trials have been disappointing. Positive results from small underpowered studies of 
risperidone need to be followed up with larger placebo-controlled trials. Similarly, although 
medications such as prazosin and the atypical antipsychotics  appear to hold promise as 
augmenting agents, much additional work is needed to determine how best to manage PTSD 
symptoms in treatment-refractory patients. Investigators are encouraged to design their 
clinical trials according to best-practice guidelines, and using gold-standard outcomes, such 























Table 1. Placebo-controlled randomised studies included in the review 
Medication  
agents 










Response criteria‡ Efficacy* Tx-related 
dropouts (%) 
       Drug Control    
MAOIs            
phenelzine Shestatzky  1988 5 13 -- 30-75 -- --  ↔ 44 
phenelzine Kosten 1991 8 37 100 15-75 68   28 CGI-I < 4 ↔ 17 
            
RIMAs           5 
brofaromine Katz  1995 14 60 76 50-150 55   26 no PTSD diagnosis ↔  
brofaromine Baker  1995 12 114 81 150 
(max) 
-- --  ↔ 18 
            
SSRIs            
citalopram Tucker 2003 10 35 29 20 - 50 -- --  ↔ -- 
fluoxetine v.d. Kolk  1994 5 64 66 20 - 60 -- --  ↑ -- 
fluoxetine Connor 1999 12 54 9 10-60 85   62 DGRP-I < 3 ↑ 0 
fluoxetine Hertzberg  2000 12 12 100 10-60 17   33 DGRP-I < 3 ↔ 17 
fluoxetine Martenyi†  2002 12/24 301 81 20-80 60   44 CGI < 3, TOP-8 <= 
50% 
↑ 3 
fluoxetine Davidson† 2005 24/24 62 50  -- --   3 
fluoxetine Martenyi 2007 12 411 29 20, 20 
-40 
41,39  38 CGI < 3, TOP-8 <= 
50%, no PTSD 
diag. 
↔ 4 & 13 
fluoxetine v.d. Kolk  2007 8 59 14 10-60 81   65 no PTSD diag. ↔ -- 
paroxetine Marshall 2001 12 376 32 20, 20-
40 
62,54   37 CGI-I < 3 ↑ 11 & 15 
paroxetine Tucker 2001 12 323 34 20-50 59   38 CGI-I < 3 ↑ 11 
paroxetine SKB627  12 322 46 20-50 -- -- -- -- -- 
paroxetine SKB650†ms  36 176 34 -- -- -- -- -- -- 
paroxetine Marshall† 2007 10/12 52 33 20-60 67   27 CGI-I < 3 ↔ 0 
sertraline Brady‡  2000 12/24/28 187 27 25-200 53   32 CGI-I < 3, CAPS < 
20 
↑ 5 
sertraline Davidson† 2001 12/24/28 208 22 25-200 60   38 CGI < 3 ↑ 9 
sertraline Zohar  2002 10 42 88 50-200 53   20 CGI < 3 ↔ 13 
sertraline Tucker 2003 10 33 29 50-200 -- --  ↔ -- 
sertraline Pfizer588  11 193 25 156 
(mean) 
-- -- -- -- -- 
sertraline Brady 2005 12 94 54 150 -- --  ↔ 0 













sertraline Friedman 2007 10 169 80 25-200 37   42 CGI-I < 3 ↔ 13 
            
TCAs            
desipramine Reist  1989 4 18 100 50-200 -- --  ↔ 7 
amitriptyline  Davidson  1990 8 46 100 50-300 50   17 CGI-I < 3 ↔ 12 
imipramine Kosten 1991 8 41 100 50-300 65   28 CGI-I < 4 ↔ 17 
            
ANTICONVULSANTS           
divalproex Davis 2008 8 85 98 500-
3000 
-- --  ↔ 7  
lamotrigine Hertzberg 1999 12 15 64 25-500 50   25 DGRP-I < 3 -- 18 
tiagabine Connor† 2006 12/12 18 -- 2 (BID) 
- 16 
-- --   0 
tiagabine Davidson 2007 12 232 34 4-16 49   54 CGI < 3 ↔ 8 
topiramate Tucker 2007 12 40 21 25-400 42   21 CAPS < 20 ↔ 20 
            
ANTIPSYCHOTICS          20 
olanzapine Butterfield 2001 10 15 7 5-20 60   60 CGI < 3 ↔ 8 
risperidone Reich  2004 8 21 0 0.5-8 -- --  ↑ 9 
risperidone Padala 2006 10 20 0 0.5-6 -- --  ↑  
            
BENZODIAZEPINE 
alprazolam Braun  1990 5 16 -- 1.5-6 -- --  ↔ 0 
            
OTHER             
inositol Kaplan 1996 4 13 62 12000 -- --  ↔ -- 
mirtazapine Davidson  2003 8 26 -- 15-45 65   22 SPRINT-I < 3 ↔  18 
nefazodone  Davis 2004 12 42 98 200-
600 
47   42 CAPS >= 30% 
improvement 
↑ 19 
venlafaxine Davidson 2006 12 358 -- 37.5-
300 
-- --  ↑ 10 
venlafaxine Davidson 2006 24 329 46 37.5-
300 
78   64 CAPS-SX >= 30% 
improvement at 12 
wks 
↑ 9 
*: significant differences in PTSD symptom severity in favour of medication is indicated by an upward pointing arrow (↑) and non-significant differences by a   
double-headed horizontal arrow (↔). Symptom severity data was collected for the CAPS, or from another primary efficacy measures where the CAPS was not 
employed.  
†: sample included in maintenance trial   
‡: CGI-I = Clinical Global Impressions Scale – Improvement item, DGRP-I – Duke Global Rating of PTSD – Improvement item, SPRINT-I = Short PTSD 














Table 2.  Meta-analyses of pharmacotherapy for PTSD 
Study  Year Interven tion  Databases * Date 
range 
Trials † PTSD Outcomes ‡ ES§ Limitations  







6 PTSD effect, or the “best 
overall measure of specific 
PTSD symptomatology”. 
0.41(--)a small number of studies; no explicit 
criteria for “best” measure of PTSD; 
variability of effect sizes not reported; 
combination of data from self and 
observer-rated scales; multiple data 
points for different studies  











1984-1996 16(19) (1) observer-rated  PTSD 
scales 





meta-analysis included open-label 
trials without controls; combination of 
wait-list, supportive psychotherapy 
and pill placebo as primary control 
group; likelihood of false positive 
findings increased through setting 
statistical threshold to 0.1; analyses  
limited to data from trial completers 












35(17)  CAPS-2 -5.76b  
(-8.16, 
-3.36) 
possible publication bias in the funnel 
plot for the CAPS 
Stewart 2009 All medication 
& 
psychotherapy 
psycINFO 1988-2006 13(10) Clinician and self-rated 
PTSD scales 
1a included open-label studies that did 
not control for placebo effect; pre-post 


















of the studies employed the 
medication as adjunctive agents to 
existing pharmacotherapy; multiple 
studies reporting on the same sample 
included 
*: AMED = Allied and Complementary Medicine Database, CCDAN-TR = Cochrane Collaboration Depression, Anxiety and Neurosis Trial Registry, CINAHL =  
Cumulative Index to Nursing and Allied Health Literature, PILOTS = Published International Literature on Traumatic Stress, SIGLE = System for Information on 
Grey Literature in Europe  
†: Total number of pharmacotherapy trials included in study, with the specific number of trials included in meta-analysis in parentheses 
‡: CAPS = Clinician Administered PTSD Scale, IES = Impact of Events Scale, DTS = Davidson Trauma Scale,  
§:  effect size estimates and 95% confidence intervals reported using standardised (a) or non-standardised  (b) mean difference metrics 
 
 
Table 3. Summary measures of effect size and statistical heterogeneity across medication agents 
Medication   Studies  Sample CAPS Effect & 95% CI* Heterogeneity † NNT‡ 
SSRIs 13 2642 -6.64 (-9.11, -4.16) Moderate 6-9 
Sertraline 7 1072 -4.84 (-7.37, -2.31) Minimal 7-11 
Paroxetine 3 888 -12.17 (-15.68, -8.65) Minimal 4-7 
Fluoxetine 2 356 -4.76 (-10.79, 1.27) Minimal 8-12 
Citalopram 1 33 -13.41 (-34.73, 7.91) na -- 
Brofaromine 2 178 -5.06 (-15.93, 5.81) Moderate 16-25 
Venlafaxine 2 687 -8.11 (-12.30, -3.92) Minimal -- 
Divalproex 1 82 -0.70 (-11.69, 10.29) na -- 
Nefazodone 1 41 -5.60 (-21.26, 10.06) na -- 
Risperidone 1 21 -11.00 (-30.55, 8.55) na -- 
Tiagabine 1 202 -0.50 (-7.60, 6.60) na 25-40 
Topiramate 1 38 -14.00 (-36.33, 8.33) na -- 
*: effect sizes reported as (non-standardised) mean differences 
†:Heterogeneity classified as minimal, moderate and large, based on an I2 statistic of less than 30%, between 30% and 50%, and over 50%, respectively.  
‡: The number needed to treat (NNT) was calculated from the risk ratio estimates of treatment response, defined as “much improved” or “very much improved” 
on the Clinical Global Impressions Improvement item (or related scale). The NNT is based on a high and low estimate of response in the control group of 0.25 
and 0.4, respectively, calculated by  rounding the limits of the interquartile range for the placebo group response rate in the included studies to the nearest 5 
















Table 4. Randomised placebo-controlled augmentation studies  
Medication 
agents  












Min. Severity Outcome scales* 
Alpha adrenergic agonists 
prazosin Raskind 2003 10 10 9.5 100 100 70 CAPS distressing 
dreams item => 6 
CAPS, CGI-I 
Antipsychotics           
olanzapine Stein 2002 8 21 15 100 100 100 -- CAPS, CGI-I, CES-
D PSQI 
risperidone Hamner 2003 5 40 2.5  100 100 54 PANSS >= 60 PANSS, CAPS 
 Bartzokis 2005 16 65 1-3 100 100 92 CAPS => 65 CAPS, HAM-D, 
HAM-A, PANSS-P 
 Rothbaum 2008 8 20 .05-2 20 0 100 CAPS => 50 CAPS, DTS, 
PANSS, BDI, CGI-I 
           
* CAPS: Clinician Administered PTSD Scale; BDI: Becks Depression Inventory; CES-D: Center for Epidemiologic Studies Depression Scale; CGI-I: Clinical 
Global Impression scale – Improvement item; DTS: Davidson Trauma Scale; HAM-A: Hamilton Anxiety scale; HAM-D: Hamilton Depression scale; PANSS: 
Positive and Negative Syndrome Scale ; PANSS-P: Positive and Negative Syndrome Scale; PSQI: Pittsburgh Sleep Quality Index 













4.9  Supplementary Material 
 
 
4.9.1  Inclusion criteria for meta-analysis 
 
Inclusion of studies in this review was restricted to all placebo-controlled randomised 
controlled trials (both published and unpublished) of pharmacotherapy for adults (18 
– 64 years) diagnosed with PTSD, according to DSM-III+ or ICD-9+ criteria. 
Assessment of RCTs for inclusion in this review was conducted independently by 2 
raters. Concurrent treatment of the majority of patients with medication (=> 50%) as 
part of standard care were grounds for exclusion. Concurrent psychotherapy was 
permitted, on the condition that it was (a) not trauma-focused, or (b) had been 
initiated at least 3 months prior to the beginning of the trial. RCTs of medication 
prophylaxis for PTSD were not eligible. Finally, studies were restricted to those in 
which the objective was to treat all symptom clusters defining PTSD, rather than 
specific subsets, such as sleep disturbances.  
 
Eligible RCTs were identified in February, 2010 by systematically searching the  
following databases:  MEDLINE, EMBASE, the Cochrane Central Register of 
Controlled Trials, the Cochrane Collaboration Depression, Anxiety and Neurosis 
Controlled Trials Register and the National PTSD Center Pilots database. Database-
specific search queries were designed, and included the terms "posttraumatic stress 
disorder" and "randomized controlled trial" (see the supplementary material for full 
syntax). Unpublished studies were located  by searching the bibliographies of 
published articles, and by contacting experts in the field.  Where study data was 













reports on the same trial, the reviewers contacted investigators by email in an 
attempt to obtain more information. 
 




Searched on 11 February, 2010  
 
1. ((serotonin or norepinephrine or noradrenaline or dopamine or neurotransmitter) adj 
(uptake or reuptake or re-uptake)).mp. 
2. (5-hydroxytrypotophan or Acetylcarnitine or Alaproclate or alprazolam or Amersergide or 
Amiflamine or Amineptine or Amitriptyline or Amoxapine or anticonvulsant* or Antidepress* or 
antipsychotic* or anxiolytic*).mp. 
3. (Befloxatone or Benactyzine or benzodiazepine* or Brofaromine or Bupropion or 
Butriptyline).mp. 
4. (Caroxazone or cck-4 or Chlorimipramine or Chlorphenamidine or Chlorpoxiten or 
Cilosamine or Cimoxatone or Citalopram or Clomipramine or clonidine or Clorgyline or 
Clovoxamine or cyproheptadine or d-cycloserine).mp. 
5. (Deanol or Demexiptiline or Deprenyl or Desipramine or Desvenlafaxine or Dibenzipin or 
Diclofensine or divalproex or dopamin* or Dosulepin or Dothiepin or Doxepin or 
Duloxetine).mp. 
6. (Escitalopram or Etoperidone or Femoxetine or Fenfluramine or flumazenil or Fluotracen 
or fluoxetine or Fluparoxan or fluphenazine or Fluvoxamine or Furazolidone).mp. 
7. (haloperidol or Harmaline or Harmine or hydrocortisone or Idazoxan or Imipramine or 
inositol or Iprindole or Iproniazid or Isocarboxazid or lamotrigine).mp. 
8. (Lithium carbonate or Lithium compounds or Litoxetine or Lofepramine).mp. 
9. (MAOI* or Maprotiline or medicat* or Medifoxamine or Melitracen or Metapramine or 
metyrapone or Mianserin or Milnacipran or Minaprine or Mirtazapine or Moclobemide or 
Monoamine Oxidase Inhibitor* or monocrotophos).mp. 
10. (naloxone or naltrexone or Nefazodone or Nialamide or Nomifensine or noradrenerg* or 
norfenfluramine or Nortriptyline or Noxiptiline or olanzapine or Opipramol or Oxaflozane or 
Oxaprotiline).mp. 
11. (Pargyline or Paroxetine or pharmacother* or Phenelzine or pheniprazine or Piribedil or 
Pirlindole or Pivagabine or Pizotyline or prazosin or procaine or propanolol or Prosulpride or 
Protriptyline or psychotropic*).mp. 
12. (quetiapine or Quinupramine or quipazine or Reboxetine or risperidone or Ritanserin or 
Rolipram).mp. 
13. (selegiline or seroto* or Sertraline or Setiptiline or SNRI* or SSRI* or sulpiride).mp. 
14. (Teniloxine or Tetrindole or Thiazesim or Thozalinone or tiagapine or Tianeptine or 
Toloxatone or Tomoxetine or topiramate or Tranylcypromine or Trazodone or tricyclic* or 
Trimipramine or tryptophan).mp. 
15. (Venlafaxine or Viloxazine or Viqualine or yohimbine or Zimeldine).mp. 
16. or/1-15 
17. posttraumatic stress disorder/ 
18. ((post-traumatic or post traumatic or posttraumatic) and disorder*).tw. 
19. PTSD.tw. 
20. or/17-19 
21. major clinical study/ 



















29. ((singl$ or doubl$ or trebl$ or tripl$) adj3 (blind$ or mask$ or dummy)).mp. 
30. (control$ adj3 (trial$ or study or studies$)).tw. 
31. ((animal or nonhuman) not (human and (animal or nonhuman))).de. 
32. or/21-30 
33. 32 not 31 
34. 16 and 20 and 33 
35. (2004$ or 2005$ or 2006$ or 2007$ or 2008$ or 2009$ or 2010$).yr. 
36. (2004$ or 2005$ or 2006$ or 2007$ or 2008$ or 2009$ or 2010$).em. 
37. or/35-36 
38. 34 and 37 
39. from 38 keep 1-773 
40. ((serotonin or norepinephrine or noradrenaline or dopamine or neurotransmitter) adj 
(uptake or reuptake or re-uptake)).mp. 
41. (alprazolam or amitriptyline or brofaromine or citalopram or desipramine or fluoxetine or 
imipramine or inositol or lamotrigine or olanzapine or mirtazapine or nefazodone or 
paroxetine or phenelzine or risperidone or sertraline or venlafaxine or anticonvulsant* or 
antipsychotic* or benzodiazepine* or noradrenerg* or dopamin* or seroton* or SNRI* or 
SSRI* or tricyclic* or anxiolytic* or pharmacother* or medicat*).mp. 
42. 40 or 41 
43. 20 and 33 and 37 and 42 
44. from 43 keep 1-631 
45. 39 not 44 





Searched on 11 February, 2010  
 
((serotonin or norepinephrine or noradrenaline or dopamine or neurotransmitter) adj (uptake 
or reuptake or re-uptake)) or 5-hydroxytrypotophan or Acetylcarnitine or Alaproclate or 
alprazolam or Amersergide or Amiflamine or Amineptine or Amitriptyline or Amoxapine or 
anticonvulsant* or Antidepress* or antipsychotic* or anxiolytic* or Befloxatone or Benactyzine 
or benzodiazepine* or Brofaromine or Bupropion or Butriptyline or Caroxazone or cck-4 or 
Chlorimipramine or Chlorphenamidine or Chlorpoxiten or Cilosamine or Cimoxatone or 
Citalopram or Clomipramine or clonidine or Clorgyline or Clovoxamine or cyproheptadine or 
d-cycloserine or Deanol or Demexiptiline or Deprenyl or Desipramine or Desvenlafaxine or 
Dibenzipin or Diclofensine or divalproex or dopamin* or Dosulepin or Dothiepin or Doxepin 
or Duloxetine or Escitalopram or Etoperidone or Femoxetine or Fenfluramine or flumazenil or 
Fluotracen or fluoxetine or Fluparoxan or fluphenazine or Fluvoxamine or Furazolidone or 
haloperidol or Harmaline or Harmine or hydrocortisone or Idazoxan or Imipramine or inositol 
or Iprindole or Iproniazid or Isocarboxazid or lamotrigine or Lithium carbonate or Lithium 
compounds or Litoxetine or Lofepramine or MAOI* or Maprotiline or medicat* or 
Medifoxamine or Melitracen or Metapramine or metyrapone or Mianserin or Milnacipran or 
Minaprine or Mirtazapine or Moclobemide or Monoamine Oxidase Inhibitor* or 
monocrotophos or naloxone or naltrexone or Nefazodone or Nialamide or Nomifensine or 
noradrenerg* or norfenfluramine or Nortriptyline or Noxiptiline or olanzapine or Opipramol or 













pheniprazine or Piribedil or Pirlindole or Pivagabine or Pizotyline or prazosin or procaine or 
propanolol or Prosulpride or Protriptyline or psychotropic* or quetiapine or Quinupramine or 
quipazine or Reboxetine or risperidone or Ritanserin or Rolipram or selegiline or seroton* or 
Sertraline or Setiptiline or SNRI* or SSRI* or sulpiride or Teniloxine or Tetrindole or 
Thiazesim or Thozalinone or tiagapine or Tianeptine or Toloxatone or Tomoxetine or 
topiramate or Tranylcypromine or Trazodone or tricyclic* or Trimipramine or tryptophan or 





Searched on 2 February, 2010  
 
(randomized controlled trial[pt] OR controlled clinical trial[pt] OR randomized[tiab] OR 
placebo[tiab] OR randomly[tiab] OR trial[tiab] OR groups[tiab]) AND (Stress Disorders, Post-
Traumatic/drug therapy* OR "posttraumatic stress disorder" [tw] OR "post traumatic stress 
disorder" [tw] OR PTSD [tw]) AND (alprazolam [tw] OR amitriptyline [tw] OR brofaromine [tw] 
OR citalopram [tw] OR desipramine [tw] OR fluoxetine [tw] OR imipramine [tw] OR inositol 
[tw] OR lamotrigine [tw] OR olanzapine [tw] OR mirtazapine [tw] OR nefazodone [tw] OR 
paroxetine [tw] OR phenelzine [tw] OR risperidone [tw] OR sertraline [tw] OR venlafaxine [tw] 
OR anticonvulsant* [tw] OR antipsychotic* [tw] OR benzodiazepine* [tw] OR noradrenerg* 
[tw] OR dopamin* [tw] OR serotonin* [tw] OR SSRI* [tw] OR tricyclic* [tw] OR anxiolytic* [tw] 
OR Psychotropic Drugs [mh] OR Anticonvulsants [mh] OR Benzodiazepines [mh] OR 
Monoamine Oxidase Inhibitors [mh] OR Neurotransmitter Uptake Inhibitors [mh] OR Drug 





Searched on 2 February, 2010  
 
 Query: (control* OR random*) AND (PTSD OR "posttraumatic") AND (alprazolam OR 
amitriptyline OR brofaromine OR citalopram OR desipramine OR fluoxetine OR imipramine 
OR inositol OR lamotrigine OR olanzapine  OR mirtazapine  OR nefazodone  OR paroxetine  
OR phenelzine OR risperidone  OR sertraline  OR venlafaxine  OR anticonvulsant*  OR 
antipsychotic*  OR benzodiazepine*  OR noradrenerg*  OR dopamin*  OR serotonin*  OR 
SSRI*  OR tricyclic*  OR anxiolytic*  OR Psychotropic Drugs OR Anticonvulsants OR 
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4.9.3  Test of publication bias 
 
Egger’s regression test of funnel plot asymmetry was employed in order to determine 
whether there was evidence of possible publication bias (Egger 1997). The analysis was 
conducted using the metabias procedure in the meta package in the R statistical language. 
There was no evidence of publication bias (t = 1.2859, df = 21, p > = 0.05), with the intercept 
of the linear regression model close to zero (see plot below). 
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5. IMAGING META-ANALYSIS OF RESPONSE INHIBITION AND THE GO/NOGO 
PARADIGM 
 
5.1  Preface 
 
Employing a laboratory measure of motor response inhibition as a proxy for impulsivity has 
numerous advantages over using self-rated impulsivity questionnaires, including the ability to 
identify neural correlates of inhibitory behaviour. In addition,  comparing the standard version 
of the GNG paradigm with the affective version of this paradigm by means of a brain imaging 
meta-analysis would help identify commonalities of, and differences betwee , impulsivity and 
affect regulation in terms of their underlying neural circuitry. These findings can then be 
related to the neural systems known to be involved in PTSD. 
 
Accordingly, we decided to conduct a meta-analysis comparing the effects of methodological 
differences between GNG tasks on brain activation, and to determine the extent to which 






















5.2  Introduction 
 
Adaptive social behaviour presupposes the ability to selectively inhibit inappropriate 
behaviour in a context-dependent fashion. The importance of this ability in everyday 
functioning, and evidence that it is impaired in a range of psychiatric conditions including 
ADHD and borderline personality disorder, has led to increasing interest in its neural 
underpinnings.  A wide variety of behavioural paradigms are available to investigate 
psychological constructs thought to underlie inhibitory behaviour. These include tasks 
assessing interference suppression (Stroop task, Flanker), stimulus response associations 
(Stimulus – response contingency, Simon task), and inhibition of motor responses 
(Antisachade, Go/NoGo (GNG) task, Stop-Signal task).   
 
Technologies for the in-vivo imaging of brain activation, such as functional magnetic 
resonance imaging (fMRI) and positron emission tomograph (PET), offer great potential for 
elucidating those regions of the brain that are critical for behavioural inhibition. Studies 
comparing common regions of activation in the same participants across a range of tasks 
measuring inhibition have identified the right inferior frontal gyrus (rIFG) (Bunge, et al. 2002; 
McNab, et al. 2008; Rubia, et al. 2001), right dorsolateral prefrontal cortex (DLPFC) (Rubia, 
et al. 2001; Zheng, et al. 2008), anterior cingulate cortex (ACC) (Rubia, et al. 2001; Rubia, et 
al. 2006; Wager, et al. 2005), and the basal ganglia (Rubia, et al. 2006; Wager, et al. 2005) 
as forming part of an inhibitory network.  
 
Activation of the frontal cortex and basal ganglia in these tasks is consistent with one of the 
most influential models of the neurocircuitry of motor inhibition (Casey, et al. 2002).  This 
model proposes the involvement of a frontal-striatal loop in which representations of stimulus 
response are maintained in the frontal cortex, and guide the basal ganglia in inhibiting 
inappropriate behaviours through modulating motor output via the thalamus (Casey, et al. 













findings, the validity of this model has not been unanimously accepted. For instance, failure 
to detect consistent involvement of the striatum in a qualitative synthesis of results from 11 
fMRI motor inhibition studies led Aron and Poldrack (2005) to question the involvement of 
the basal ganglia in response inhibition. Wager and colleagues (2005) in turn proposed an 
insular-prefrontal-cingulate inhibitory model, on the basis of common neural activation in 
healthy subjects on three inhibition tasks that are selectively dependent on different aspects 
of inhibition (Go/NoGo, Flanker, Stimulis Response Compatibility task).   
 
One strategy to identify a characteristic pattern of brain activation associated with response 
inhibition would be to focus on the findings of studies employing the same paradigm.  The 
GNG task is one potential candidate, given the frequency within which it is employed in both 
research and clinical settings. Adopting this strategy also has the advantage of not conflating 
brain activity that is responsive to systematic differences between inhibitory tasks. A recent 
ALE meta-analysis of 48 GNG and 21 stop-signal studies concluded that despite 
considerable overlap in the brain circuitry activated by these tasks, the neural activation they 
elicit is not identical (Swick et al. 2011). As stated by Swick and colleagues (2011), "While 
the functional signicance of this difference is an important empirical question […], it is clear 
that these two tasks are not equivalent, and caution is required when generalizing GNG or 
SST findings" (p1663). A similar conclusion can be reached on the basis of a comparison of 
the neural correlates of performance on the GNG and antisaccade task (Chikazoe, et al. 
2007). 
 
In the classic GNG task participants are presented with a series of distinct stimuli on a 
computer screen, one or more of which are designated as targets (``Go'' trials).  Subjects are 
instructed to press a response button as quickly as possible when presented with the 'Go' 
stimuli, and to withhold responding on presentation of other distractor stimuli (``NoGo'' trials). 
The GNG is typically designed to reduce interference from ambiguous sensory stimuli, and 













inhibition. The GNG has also been cited as having reasonable temporal stability, relative to 
other behavioural inhibition tasks (Horn, et al. 2003).  Finally, findings of a correlation 
between performance and neural activation on the GNG and self-rating measures of 
impulsivity in healthy subjects (Brown, et al. 2006; Chuah, et al. 2006; Horn, et al. 2003) 
underscore the validity of the GNG as a measure of impulse-control deficits.  
 
Studies employing the GNG paradigm to delineate neural correlates of inhibitory behaviour 
have tended to detect diffuse patterns of brain activation in response to successful 
inhibitions. A search through the literature reveals reports of activation in a multitude of 
regions during successful inhibitions, including the right inferior frontal gyrus (rIFG, eg. 
Garavan 1999, Horn 2003), the dorsolateral prefrontal cortex (DLPFC, eg. Braver 2001, 
Fassbender 2004), the anterior cingulate cortex (ACC – eg. Borgwardt 2008, Brown 2006), 
the pre supplementary motor association areas (pre-SMA – eg. Kelly 2004, Rubia 2001), the 
orbitofrontal cortex (OFC – eg, Falconer 2008, Passamonti 2008), the inferior parietal cortex 
(eg. Chuah 2006, Hester & Murphy 2004), the basal ganglia (putamen – eg. Fassbender 
2004, Wager 2005; caudate – eg. Menon 2001, Rubia 2006), the insula (eg. Garavan 1999, 
McNab 2008), the thalamus (eg. Passamonti 2008, Watanabe 2002), the occipital cortex (eg. 
Bonnet 2009, Langenecker 2007), and the cerebellum (eg. Laurens 2003, Zheng 2005). 
 
This wide-spread pattern of activation is suggestive of activation that is idiosyncratic to 
particular implementations of the GNG paradigm, rather than core to the inhibition of the 
motor response itself. Attempts to identify task features that tap into the core construct of 
inhibition have unfortunately been hampered by the complexity of these tasks, lack of 
standardisation between different implementations of the same task, and failure to base task 
design on theoretical considerations. Accordingly, differences in task performance may 













opportunity to employ different strategies to achieve comparable performance (Chambers, et 
al. 2009).  
 
Furthermore, given the complexity of the cognitive processes that are likely to be recruited 
by even the simplest behavioural tasks, one cannot simply adopt a “vote-counting” approach 
to identify an inhibitory network by tallying those regions that are most frequently activated 
across studies. The right inferior frontal gyrus is instructive in this regard. The rIFG is one of 
the most frequently identified brain regions in studies of motor inhibition. Its function as an 
“inhibition module” appears to receive support from   lesion and transcranial magnetic 
stimulation studies that have mapped differences in performance on motor-inhibition tasks to 
disruption of the rIFG (Aron, et al. 2003; Chambers, et al. 2007). Nevertheless,  a number of 
recent quantitative syntheses of coordinates from  GNG studies have failed to observe 
consistent activation of the rIFG (Simmonds, et al. 2008; Swick, et al. 2011). In a meta-
analysis of 10 GNG tasks, Simmonds et al. (2008) explained their negative finding with 
respect to the frontal operculum (Brodmann Area 47), a part of the rIFG that is regarded as 
particularly crucial to response inhibition, as possibly resulting from their decision to 
deliberately restrict their analysis to studies employing a baseline reference condition for the 
NoGo trials, as opposed to the more commonly employed Go trial reference condition. 
 
The finding by Simmonds and colleagues (2008) highlights the sensitivity of study results to 
the procedures employed by individual teams of investigators. Differences in activation occur 
even with the introduction of relatively small differences in the jittering of trials for the same 
task (Goghari and MacDonald 2008). There are a number of potential sources of variability 
that might explain poor reliability in identifying activation of a particular region of interest in 
response to successful inhibitions. These include differences in subject characteristics, the 













contrasts employed in the final analyses. Some of the more significant sources of 
heterogeneity in study findings will be described below. 
 
The choice of the reference condition used for statistical contrasts has been highlighted as 
influential in determining the clusters of activation that are reported by imaging studies 
(Simmonds, et al. 2008). The majority of studies compare successful inhibitions on NoGo 
trials to correct responses to Go trials. Go and NoGo trials differ on a number of dimensions, 
however. Go trials are associated with the presence of motor activity and are frequently 
presented at a higher frequency than NoGo trials, in order to establish a prepotent response 
tendency. Differences in activation between Go and NoGo trials are therefore potentially 
confounded by attentional effects associated with the presentation of infrequent stimuli (the 
`”oddball” effect). Indeed, overlap in many of the same brain regions involved in response 
inhibition, including the right IFG (see Laurens 2005), have been demonstrated in the past 
using the oddball paradigm. The fronto-striatal model of inhibition also identifies inhibitory 
processes as a precursor to the release of a motor response (Chambers, et al. 2009). The 
possible overlap in the neural substrate involved for both response inhibition and execution 
has therefore led to concerns regarding the validity of the subtraction paradigm when 
comparing activation coincident with Go  and NoGo trials (Simmonds, et al. 2008).   
 
Differences in the extent to which specific versions of the GNG task make demands on 
working memory can also influence where brain activity is observed. Variants of the GNG 
task in which the response required depends on the context in which it appears (complex 
GNG tasks) place a greater load on working memory than tasks in which the identity of the 
target trials remains constant (simple GNG tasks). Although studies employing complex 
Go/NoGo tasks frequently identify the right DLPFC and parietal lobe as critical to response 
inhibition, these same brain regions are implicated in working memory functioning (in the 













both working memory and response inhibition systems are likely to be involved in successful 
performance on the GNG task. This is suggested by the finding of an overlap between 
performance on this task and working memory capacity (Nyberg et al. 2009), as well as the 
observation, in a conjunction analysis of response inhibition and working memory tasks, of 
common signal in the rIFG, the right middle frontal gyrus and the right parietal lobe (McNab, 
et al. 2008). 
 
The analytic strategy employed with regard to imaging data can have consequences for 
activation patterns that are observed. In fMRI studies employing the Go/NoGo paradigm as a 
blocked design, investigators typically attempt to isolate brain activity specific to motor 
inhibition by subtracting the blood oxygen level dependent (BOLD) signal in blocks of Go 
trials from blocks combining both trial types. In contrast, in event-related designs, the 
hemodynamic response function is convolved with specific inhibitory events. Authors have 
previously observed that left lateralisation of neural activity appears more frequently in 
blocked than event-related GNG designs (Fassbender, et al. 2004; Rubia, et al. 2001). The 
inclusion of errors in blocked designs might also be expected to result in activation of the 
ACC, given the postulated role of this region in conflict monitoring and error processing 
(Botvinick, et al. 2004).  
 
Finally, inhibition-related brain activity has to be interpreted in light of the nature of the 
stimulus employed. A subset of GNG studies employ affective words or facial expressions as 
stimuli in order to test hypotheses regarding the influence of emotion on inhibitory function 
(Amin, et al. 2006; Berkman, et al. 2009; Elliott, et al. 2004; Elliott, et al. 2000; Elliott, et al. 
2002; Goldstein, et al. 2007; Hare, et al. 2005; Hare, et al. 2008; Protopopescu, et al. 2005; 
Roiser, et al. 2009; Schulz, et al. 2008; Shafritz, et al. 2006; Wessa, et al. 2007). The 
indication from performance and brain imaging data that greater inhibitory demands are 













consequences in terms of  the magnitude of the BOLD response,  the recruitment of 
additional brain regions (or both)(Shafritz, et al. 2006). Employing linguistic stimuli also 
poses challenges in the interpretation of the hemispheric lateralization of brain activity in 
particular (Lutcke and Frahm 2008). 
 
This paper shall attempt to isolate the neural circuitry underpinning motor response inhibition 
through applying meta-analytic techniques to whole-brain coordinate data from fMRI studies 
of the GNG task. By synthesising data from studies employing different versions of a specific 
task (or different analytic strategies), a meta-analysis allows one to identify neural activity 
that does not depend on particular idiosyncratic methodological characteristics of a specific 
study. Conversely, by comparing data from studies grouped by design feature, one can 
identify activity that is specific to that feature, and use this information to identify the function 
of the underlying brain regions. This should assist in selecting between different models of 
neural circuitry thought to underlie response inhibition.  
 
We have utilized state-of-the-art meta-analytic methods in the service of these aims, and in 
recognition that the usefulness of a meta-analysis in answering a particular question 
depends to a large extent on the relevance and quality of the included studies. Therefore, in 
addition to conducting the most comprehensive search of the literature conducted thus far to 
identify all eligible GNG studies, we have attempted to optimize the validity of our results, 
both by controlling for variability in the precision of the data contributed by individual studies 
through using a random effects model (unlike Swick et al. 2011), and by restricting studies to 
those that employed GNG tasks (unlike Levy et al. 2011). 
 
5.3  Method 
 
A comprehensive search strategy was devised to identify eligible studies for inclusion in the 













between June and October, 2009 using the following search terms: ``functional magnetic 
resonance imaging'',  ``response inhibition'' and ``nogo`` (please contact the authors for 
more information).  Additional studies were identified by searching the EMBASE database in 
January, 2009. In addition, the contact authors of the included studies were emailed for 
missing data, and queried regarding additional published and unpublished studies. 
 
All fMRI studies of healthy subjects performing the GNG task were included, on the proviso 
that the study reported stereotactic coordinates from whole-brain analyses of activation 
associated with inhibitory responses. Studies from the clinical literature were included, 
provided they included a control group without psychopathology. Coordinates representing 
brain regions that were deactivated during successful inhibitions were not included in the 
meta-analytic component of the review (eg. Amin 2006). Studies were restricted to those that 
employed task features designed to establish a prepotent motor response, such as the 
presentation of a majority of target trials. Only studies employing versions of the GNG using 
visual stimuli were included.  Given evidence of the maturation of the frontal cortex during 
adolescence (Hare, et al. 2008), and changes  in brain systems underlying attentional 
functioning in later adulthood (Segalowitz and Dywan 2009), studies were limited to those 
which reported data for participants aged between 18 and 65 years of age, inclusive. Finally, 
studies that did not control for within-subject variance by means of random or mixed-effects 
analyses were excluded. 
 
Two raters independently extracted data for each study on task design and sample 
characteristics, stereotactic (x, y, z) coordinates, and performance using a customised data-
extraction form designed in accordance with the Brainmap database format (Fox and 
Lancaster 2002; Laird, et al. 2005b).  An omnibus comparison of brain activation during 
successful inhibition was conducted across all of the studies included in this review. Where 













those employing Go trials as baseline, as the majority of event-related studies provided data 
in this form.  Data from block-designed tasks were restricted to analyses employing Go-only 
blocks as baseline or in which the BOLD signal was regressed on the proportion of Go trials 
across conditions.   
 
Investigations of the impact of methodological differences on activation patterns were also 
conducted. Task design-related methodological criteria of interest included (1) the use of Go 
trials versus baseline as reference condition, (2) the use of blocked versus event-related 
designs, (3) the employment of simple versus complex GNG paradigms, and (4) the use of 
different types of stimuli. The latter comparison contrasted linguistic (including letters and 
words) versus other stimuli (including shapes, arrows and images of objects), as well as 
affective (including emotional facial images and words) versus non-affective stimuli.   
 
 In order to increase the likelihood of detecting differences resulting from working memory 
load, simple variants of the GNG task were defined as those in which each of the trial types 
was represented by a single invariant stimulus. Employing multiple letters as Go stimuli in 
the simple GNG task has been associated with differences in brain activation when  
compared to use of a single target stimulus, and represents a potential confound (Bonnet, et 
al. 2009; Laurens, et al. 2005). As all of the complex GNG tasks employed event-related or 
mixed designs (incorporating elements of both block and event-related designs), the 
comparison of blocked versus event-related designs was restricted to simple Go/NoGo 
tasks, to avoid confounding design with task complexity. The comparison of stimuli type 
(linguistic, affective) were restricted to studies employing the simple GNG task, for the same 
reason,. 
 
Data from studies which reported stereotactic (x, y, z) coordinates were aggregated as part 













statistical parametric map (SPM) of brain activity through the quantitative synthesis of whole-
brain coordinate data across multiple studies. The likelihood that activation in particular 
voxels occurs by chance can subsequently be determined through reference to an 
empirically derived probabilistic map of brain activity (Laird, et al. 2005a; Turkeltaub, et al. 
2002). ALE makes optimal use of the voxel-wise resolution of the study-level data, 
overcomes between-study heterogeneity in the positioning of activated voxels introduced 
through measurement error, and bypasses reliance on subjective and error-prone 
anatomical labeling (Laird, et al. 2005c). Moreover, ALE is fully automated and conclusions 
drawn from it can be statistically defended through reference to a null hypothesis distribution. 
 
With the exception of subtraction analyses (detailed below) all ALE SPMs were generated by 
GingerALE 2.0 (Eickhoff, et al. 2009), part of the suite of software provided by the 
developers of the Brainmap database (http://www.brainmap.org). These SPMs were 
smoothed with study-specific Gaussian kernels, with the smoothing parameter (Full Width 
Half Maximum (FWHM)) weighed by the study sample size. The best-fitting icbm2tal 
algorithm (Lancaster, et al. 2007) was used to transform coordinates from MNI to Talariach 
space prior to data synthesis. Following recommendations in the GingerALE manual, 
coordinate data that was reported in Talairach coordinate space following conversion by the 
authors from MNI using the Brett transform was ''unbretted`` prior to this step (Laird 2009).  
The coordinates from separate studies with overlapping samples (eg. (Menon, et al. 2001; 
Mobbs, et al. 2007a), (Kaladjian, et al. 2007; Kaladjian, et al. 2009; Mazzola-Pomietto, et al. 
2009)  and (Passamonti, et al. 2008; Passamonti, et al. 2006)) were restricted to those from 
the study with the largest sample size in order to minimize dependency in the data (Menon 
et al. 2001, Kaladjian et al. 2007, Passamonti et al. 2008, respectively). 
 
Inferential statistics were derived by comparing SPMs for the experimental contrast with null 













approximates non-parametric permutation analysis. The False Discovery Rate (FDR) 
method was applied as a correction for multiple comparisons, given its ability to maximise 
sensitivity while minimising false positive results (Laird, et al. 2005a). All random-effects ALE 
maps were thresholded at p < 0.05, with a smoothing parameter of 15 mm, and a minimum 
cluster size of 160mm2. Preliminary evidence indicates that a FWHM of 15mm is optimal in 
replicating image-based mega-analyses (Salimi-Khorshidi, et al. 2009). Of the coordinates 
provided by authors in response to requests for additional data, only those that passed a 
significance threshold of p < 0.05, corrected at the cluster level, were included in the meta-
analysis.    
 
Subtraction analyses between groups of studies were conducted using a fixed-effects 
method implemented in GingerAle 1.2, as random effects analyses of this kind are not 
currently supported. The interpretation of comparisons between groups of studies in 
subtraction analyses are confounded by (a) differences in the size of the dataset for each 
group, and (b) failure of the fixed-effects model used to account for between-study variability.  
Accordingly, the following procedure was implemented in order to obtain an estimate of the 
reliability of these findings with respect to particular clusters: 100 pairwise comparisons were 
conducted on coordinates from 6 randomly selected experiments in each of the groups being 
contrasted (eg. 6 experiments in each of the complex versus simple GNG groups). The 
number of times in which particular cluster labels were identified was subsequently tabulated 
across all 100 permutations, and correlated with the extent of the cluster (in mm3) reported in 
the results from the analysis employing coordinates from all eligible studies. The pair-wise 
analyses were conducted using a batch file implementing the command-line interface to 
GingerALE version 1.2 (FWHM = 15mm, 1000 random permutations, minimum cluster 















Basic descriptive and inferential statistics were computed for performance data. The mean 
reaction time on Go trials was calculated, as were the error rates for NoGo trials identified as 
targets (“commission errors”) and Go trials that were not identified as targets (“omission 
errors”). The increased precision afforded by larger sample sizes was factored into the 
between-group comparisons by weighing each study's error rates and reactions times by 
their sample sizes. Correlations between the ratio of Go to NoGo trials and errors of 
commission were also calculated, so as to determine the extent to which increasing the 
relative frequency of Go to NoGo trials increases the difficulty of inhibiting motor responses. 
This was in light of concerns that  inhibitory brain circuits  are not reliably activated when the 

































* Number in parentheses refers to the number of reports that were unique to 
that particular database   
 
Figure 1. Flowchart of selection process for eligible studies 
 
A total of 877 papers were initially retrieved through the search strategy (please refer to 
Figure 1 for a breakdown by sou ce). Fifty one studies were considered eligible for inclusion 
in the review, with a combined sample size of 946 healthy subjects (46% female) (Table 1). 
The average age of the subjects was 29.2 years (SD = 6.3). Ten of the studies included in 
this review employed the affective version of the Go/NoGo task (N = 185), and included 
either facial images (N= 6) or emotive words as stimuli (Table 2). 
 
With regards to the studies employing the non-affective Go/NoGo task (heretofore referred 
to as the “standard GNG”), the majority employed event-related designs (N = 25), with the 
remainder presenting the trials types in blocks (N=10), or combining blocked and event-
related designs (N=6). The simple version of the Go/NoGo was used in 30 of these studies, 













(2003) included both simple and complex versions of the task). Twenty six of these studies 
compared activation in response to NoGo versus Go trials, with 14 and 5 studies employing 
signal from baseline or oddball trials as comparators, respectively. Stimulus presentation 
times varied from 200 to 1400 ms, with the inter-stimulus interval ranging from 0 to 29 
seconds. A tendency to respond was established in block-design studies by the inclusion of 
a block comprised exclusively of Go trials, with the majority of event-related trials (22/25) 
achieving a similar effect by including a high ratio of Go to NoGo trials (average ratio = 
79%). 
 
One potentially eligible supra-modal comparison of  auditory and visual variants of the 
Go/NoGo task did not detect significant activation on the NoGo trials (relative to Go trials) for 
either modality, and was therefore not included in this review (Laurens, et al. 2005). 
Coordinates from a combined analysis of fMRI data for adults and adolescents in an 
affective Go/NoGo paradigm were included in the meta-analysis, as the influence of age was 
controlled for statistically (Hare, et al. 2008).   
 
Table 1. Study characteristics for the standard GNG paradigm 
 
Study ID  Year N* Imaging/analysis Specs † Desig n Type Stimuli  Baseline  Go 
/NoGo 
Ratio  
Asahi  2004 17 1.5T, GE EPI, T2*, TR=4s, 
TE=55ms, flip angle=90, 
fov=256, smoothing=8mm 
Block Simple Letters Go Block 50% 
Bonnet 2009 16 1.5T Gyroscan Philips, T2*, 
TR=2s, TE=60ms, flip 
angle=90, fov=230mm, 
smoothing= 10x10x3.5mm  
Block Simple Shapes Go Block 70% 
Booth  2003 12 1.5T General Electric, 
single shot EPI, TR=3s, 
TE=4ms, flip angle=90, 
fov=22cm, smoothing=7mm 
Block Simple Shapes Go Block 50% 
Borgwardt 2008 15 1.5T Signa, T2*, TR=1.8s, 
TE=40ms, flip angle=90, 
smoothing=7.2mm 
Event Simple Arrows Oddball-
Go 
78% 
Braver  2001 14 1.5T Siemens, TR=2.5s, 
TE=50ms, flip angle=90, 















Brown 2006 58 3T Siemens Allegra, TR=2s, 
TE=25ms, fov = 20cm, 
smoothing=6mm 
Block Simple Letters Go 50% 
Bunge  2002 19 3T Sigma, GE spiral 
sequence, TR=1s, 
TE=30ms, flip angle=60, 
fov=24cm, smoothing=6mm 
Event Simple Shapes Neutral 75% 
Chikazoe  2009 25 1.5T, gradient EP, TR=4s, 
TE=50ms, flip angle=90, 
smoothing=8mm 






Chuah 2006 27 3T Allegra, Gradient EPI, 
TR=2s, fov=192, 
smoothing=8mm 
Mixed Complex Letters Fixation 90% 
Cojan 2009 24 1.5T Intera, GRE EPI, 
TR=2.5s, TE=40ms, flip 
angle=80, fov=250mm, 
smoothing=8mm 
Event Simple Shapes Go 75% 
deZubicaray  2000 8 1.5T GE, T2, TR=3s, 
TE=40ms, flip angle=90, 
smoothing=6mm 
Block Simple Shapes Go Block 60-78 
Dibbets  2009 17 1.5T Philips, T2*, TR=1.75s, 
TE=27ms, flip angle=90, 
fov=224x120x225mm, 
smoothing=8mm 
Event Complex Letters Go 86% 
Falconer  2008 23 1.5T Siemens Magnetom, 
T2*, TR=3s, TE=40ms, flip 
angle=90, fov=24cm, 
smoothing=8mm  
Event Simple Coloured 
letters 
Go 75% 
Fassbender  2004 21 1.5T Siemens, EPI T2*, 
TR=2s, TE=50ms, flip 
angle=90, fov=256mm, 
smoothing=3mm 
Mixed Simple Numbers Baseline 89% 
Fassbender 2006 17 1.5T Siemens, EPI T2*, 
TR=2s,  flip angle=90, 
fov=240mm, 
smoothing=3mm 
Event Complex Letters Baseline 94 




Event Complex  Letters Tonic 76% 




Event Complex Letters Tonic 94% 




Mixed Complex Letters Tonic 90% 
Goghari 2009 12 3T Siemens, EPI, TR=2s, 
TE=28, flip 
angle=90,fov=224mm, 














Hester  2009 16 4T Bruker Medspec varian, 
TR=2s, TE=30ms, 
fov=384mm, flip angle=90, 
smoothing=3mm 
Event Complex Letters Tonic 92% 
Hester  2004a 10 1.5T Siemens VISION, T2*, 
EPI, TR=2s, TE=50ms, 
fov=256mm, 
smoothing=3mm 
Mixed Complex Letters Tonic 93% 
Hester  2004b 15 1.5T GE Signa, blipped 
gradient-echo EP, TR=2s, 
TE=40ms, fov=24cm, 
smoothing=3mm 
Mixed? Complex Letters Tonic 88% 
Horn  2003 21 1.5T Philips Gyroscan, T2*, 
single-shot EPI, TR=3.1s, 
TE=50ms, flip angle=90, 
fov=230mm, 
smoothing=8mm 
Block Simple Letters Go Block 50% 
Kaladjian 2007 30 3T MedSpec, T2*, FID EP, 
TR=3s, TE=35ms, flip 
angle=83, fov=19.2cm, 
smoothing=9mm  
Event Simple Letters Go 50% 
Kaladjian  2009 10 3T Brucker, T2*, FID EP, 
TR=3s, TE=35ms, flip 
angle=83, fov=19.2cm, 
smoothing=9mm  
Event Simple Letters Go 50% 




Mixed Complex Letters  Tonic 92% 
Langenecker  2007 17 3T GE Signa, TR=2s,  
fov=24cm 
Event Complex Letters Baseline 83% 
Laurens  2003 16 1.5T GE, TR=3s, TE=40ms, 
flip angle=90, fov=24cm, 
guassian smoothing=8mm 
Event Simple Letters Go 84% 
Lawrence 2009 21 1.5T GE Signa, T2*, 
TR=1.8s, TE=40ms, flip 
angle=90, 
smoothing=7.2mm 
Event Simple Shapes Go/ 
oddball  
76%/88% 
McNab  2008 14 1.5T GE Signa, T2*, spiral 
EP, TR=2.1s, TE=40, flip 
angle=76, fov=220mm, 
smoothing = 6mm 
Event Simple Shapes Go/ 
oddball  
75% 
Menon  2001 14 1.5T GE Signa, TR=2s, 
TE=40ms, fov=240mm, flip 
angle = 89, 
smoothing=4mm 
Block Simple Letters Go/Rest 50% 
Mostofsky  2003 48 1.5T ACS-NT (Phillips), 
single shot EPI, TR=2.5s, 
TE=40ms, flip angle=90, 
smoothing=7x7x9 
Event Both spaceships Fixation 82% 
(simple) 













TR=3s, TE=50ms, flip 
angle=90,  smoothing=6mm 
Roth  2007 14 1.5T  GE Signa, TR=2.5s, 
TE=40ms, fov=24cm, flip 
angle=90, 
smoothing=10mm 
Event Simple Shapes Go 25/50/75% 
Rubia 2001 12 1.5T GE Signa, T2*, 
TE=40ms, TR=3300ms,  
smoothing=3mm 
Block Simple Objects Go Block 50% & 
70% 
Rubia 2006 23 1.5T GE Signa, T2*, 
TR=1.8s, TE=40ms, flip 
angle=90,  
smoothing=7.2mm 
Event Simple Arrows Go 76%/88% 
Schmitz  2006 12 1.5T GE Signa, T2*, 
TR=1.8s, TE=40ms, flip 
angle=90, fov=240mm, 
smoothing=10mm 
Event Simple Arrows Oddballs 76%/88% 
Vollm  2004 8 1.5T GE Phillips, T2*, 
TR=5sec, TE=40ms, 
smoothing=10mm 
Block Simple Letters Go Block 50% 
Wager  2005 14 3T GE Signa, spiral 
sequence, TR=1s, 
TE=30ms, flip angle=90, 
fov=24cm, 
smoothing=10mm 
Event Simple Letters Go 50% & 
80% 
Watanabe 2002 11 1.5T Siemens, GE-EPI, 
TR=2s, TE=60ms, flip 
angle=90, fov=256mm, 
smoothing = 12mm 
Event Simple Shapes Correl + 
Go 
-- 
Zheng  2008 20 1.5T Siemens, TR=3s, 
TE=40ms, flip angle=90, 
fov=200mm, smoothing = 
9mm 
Event Simple Letters Go 75% 
* Number of participants in healthy subject groups only 























Table 2. Study characteristics for the affective GNG paradigm 
 
Study I D Year 
N* 
Imaging/analysis Specs † Design  Stimuli  Source  Conditions  
Amin  2006 
20 
3T Siemens Trio, SPGR, TR=1.5s, 
TE=30ms, flip angle=80,fov=220mm, 
smoothing=8mm 






Berkman 2009 14 3T Allegra Siemens, T2*, TR=2s, 















Goldstein 2007 14 3T GE, T2* EPI, TR=1.2s, TE=30ms, 
flip angle=70,fov=240, 
smoothing=7.5mm   






Hare 2005 10 3T, spiral in-and-out seq., TR=2.5s, 
TE=30ms, flip angle = 90, 
fov=200mm, smoothing=4mm 





Hare 2008 48 3T, spiral in-and-out seq., TR=2.5s, 
TE=30ms, flip angle = 90, 
fov=200mm, smoothing=6mm   




Protopopescu 2005 12 3T GE Signa, GE EPI, TR=1.2s, 
TE=30ms, flip angle=70, fov=240mm, 






Schulz 2008 23 3T Siemens Allegra, T2*, TR=3s, 






Shafritz 2006 13 1.5T GE, T2*, TR=1.5s, TE=60ms, flip 











Wessa 2007 19 1.5T GE, T2*, TR=2.4s, TE=35ms, flip 
angle=90 







* Number of participants in healthy subject groups only 
† TR = repetition time, TE = echo time, fov = field of view 




5.4.1  Performance data 
 
The average speed of response to target trials in studies employing the standard GNG 













committed (1.7% (N = 20) versus 15.2% (N=32), respectively), supporting the effectiveness 
of these tasks in testing inhibitory ability (Wilcoxon signed-rank test z = 3.8, p < 0.01). 
Complex versions of the standard GNG were more difficult than simple versions of the task, 
as indicated by a greater proportion of commission errors (28.5% versus 12.1% respectively, 
Wilcoxon-Mann-Whitney  z = 2.3, p < 0.05). The mean reaction time and percentage of 
omission errors did not differ significantly for simple (mean = 394.4ms and 1.5%, 
respectively) versus complex (mean = 402ms and 2.4%, respectively) versions of the task. 
There was no evidence that the proportion of trials that required a response in event-related 
trials had an influence on the number of incorrect responses on NoGo trials (Spearman rho = 
0.12, p > 0.05, n = 21)4. 
 
Subjects were slower on average in responding to target trials in GNG tasks that employed 
affective stimuli (mean = 567ms, SD=71.5ms, n = 7), than in the standard GNG tasks (mean 
= 395.8ms, SD = 74.3ms, n=32)(Wilcoxon-Mann-Whitney test z = 3.7, p < 0.01). No 
difference was observed between the commission and omission error rates on the 6 studies 
that provided this data for affective versions of the GNG task (9.8% versus 7.6%, 
respectively, Wilcoxon signed-rank test z = 1.2, p > 0.05). The comparison of performance 
metrics for happy and fearful target trials in the 3 studies that employed stimuli of both 
valences was insufficiently powered  to detect differences on either reaction time (552.6ms, 
SD=99.7ms versus 591.6ms, SD=85.7ms, respectively) or commission error rate (8.7%, 




                                                            
4 The results of this analysis were similar when the two studies that employed cueing methods to 













5.4.2  Omnibus comparison 
 
As anticipated, synthesizing coordinate data across all 41 (484 foci) of the standard GNG 
tasks produced a diffuse pattern of activation, with the largest clusters observed in the right 
cerebral hemisphere. These included the frontal (BA 6, 9, 10) and parietal cortices, the ACC, 
and the insula/rIFG (see Table 3). Activation was specific to the right hemisphere for the 
cingulate cortex (posterior and anterior) and thalamus, with bilateral representation in the 
dorsal striatum (putamen & caudate), as well as in the cerebellum and temporal, parietal and 






Figure 2. Activation map for correct inhibitions on the standard and affective versions of the 

















Table 3.  Activation clusters for the inhibition condition on the standard Go/NoGo task 
 




Value (103) X Y Z 
1 Frontal, Middle, inferior &  precentral R 6, 9, 10 14928 39 23 31 4.407 38 36 22 
2 Parietal, supramarginal gyrus R 40 4416 45 -47 37 4.024 46 -46 36 
3 Insula/rIFG R 47 4104 34 17 2 4.825 34 16 2 
4 Parietal, superior, precuneus &  angular R 
7, 31, 
39 3848 24 -67 40 3.285 20 -70 42 
5 Frontal, medial, superior (left); cingulate gyrus R 6, 8, 32 3776 2 17 44 4.158 2 12 46 
6 Insula and putamen L 13 1960 -23 10 6 3.016 -32 22 4 
7 Frontal, IFG and precentral) L 6, 9 1864 -45 6 35 3.589 -46 8 32 
8 Frontal, middle L 9 1456 -33 38 30 2.795 -32 38 30 
9 Caudate R  1296 14 5 11 3.024 14 6 10 
10 Frontal, middle, inferior & sub-gyral R 10 1152 35 48 5 2.55 32 52 6 
11 Temporal, superior R 22 968 51 -47 10 2.871 50 -46 12 
12 Parietal, inferior L 40 928 -44 -42 41 2.768 -44 -40 38 
13 Temporal, fusiform gyrus L 37 800 -38 -61 -12 2.751 -38 -62 -12 
14 Temporal, superior L 39 536 -50 -56 32 2.378 -48 -56 32 
15 Frontal, medial R&L 6 496 0 -3 58 2.173 -6 -4 58 
16 Cingulate gyrus R 23 432 2 -20 27 2.182 2 -20 26 
17 Frontal, middle L 10 296 -35 50 12 2.409 -36 50 12 
18 Frontal, precentral L 6 248 -38 -12 46 2.095 -38 -12 46 
19 Cerebellum, culmen L  240 -33 -51 -25 2.026 -34 -50 -24 
20 Cerebellum, culmen R  224 31 -51 -25 1.967 32 -54 -24 
21 Parietal, precuneus L 7 152 -24 -67 40 2.106 -24 -68 40 
22 Parietal,  superior L 7 128 -36 -70 46 2.104 -36 -70 46 
23 Thalamus R  112 14 -10 14 1.996 14 -10 14 
* Coordinates for the weighted centre of mass for the cluster  
 † The most extreme t statistic for the voxels in the cluster          
































                Table 4. Number of experiments (foci) contributing to group comparisons 
 
Comparison 1st  Group 2nd  Group 
 
Baseline  
fixation 14 (172)  
go 26 (314)  
oddball 5 (86)  
Design  
block vs. event* 9 (100) 20 (204) 
complex vs simple 12 (181) 14 (108) 
linguistic vs. other* 13 (133) 16 (180) 
affective vs standard 6 (57) 41 (484) 
                         a. Foci that fell outside of talairach mask in GingerALE are not included in the table 
                         * Experiments were restricted to those from the simple Go/NoGo task paradigm, to  








A = fixation baseline, B = Go trial baseline, C = Oddball trial baseline 
 
Figure 3. Comparison of activation for NoGo trials using different baseline conditions 
 
The extent of activation observed was inversely proportional to the specificity of the baseline 
condition employed, with the most widespread activation observed with the fixation baseline 
(24 clusters), followed contrasts with the Go (17 clusters) and Oddball (10 clusters) 
conditions. Regions activated for the fixation but not other baseline contrasts included the 













more evident for this contrast, with no  relative differences in recruitment of this region for 
inhibition relative to Go trials. Right frontal cortex activation was more prominent for the 
fixation and go baseline contrasts than the oddball contrast. Finally, activation of the frontal 
operculum portion of the right IFG (BA 47) was only observed for studies comparing NoGo 
with Go trials.  
 
5.4.4  Subtraction analyses 
 
Substantial differences in agreement when comparing all of the coordinate data with those 
contrasts that were equated for sample size were observed for many of the group 
comparisons. The correlation between the number of times a particular region was activated 
in the 100 pairwise contrasts and  cluster size for that region in the full-sample analyses was 
large for the simple versus complex GNG and the standard versus affective GNG contrasts 
(rho = 0.92, p < 0.01; rho = 0.81, p < 0.05, respectively), but less robust with regards to the 
comparison of tasks using linguistic versus other stimulus types, or those using event-related 
versus blocked-design analytic strategies (rho = 0.13 and 0.09, respectively). Indeed, for all 
4 contrasts in the full-sample analyses, most of the regions where statistically significant 
between-group differences were observed favoured the group with the larger number of foci 
(event-related experiments, complex GNG tasks, linguistic stimuli, and standard GNG, 
respectively). With the exception of the comparison between experiments employing simple 
and complex GNG tasks, this pattern of results disappeared when groups were equated for 
sample size, suggesting that differences in the number of studies and/or coordinates within 
each group may be influencing the results of the full-sample analyses.   
 
Accordingly, we decided to limit the presentation of the results of the full-sample analyses to 
the simple-complex GNG contrast. Discussion of the results of the other methodological 













permutation analyses. Reliable activation is defined within the context of particular 
comparisons as identification of   regions through their Talairach labels in at least a third of 
all permutation analyses or in the top quartile with regards to frequency of “hits”, whichever 
led to the smaller number of activated regions. Clusters for which the average peak 
statistical threshold was below the critical t value for a two-tailed t-test (t = 1.96) were 
excluded, in order to eliminate regions that failed to consistently favour one group over the 
other across the pairwise contrasts.  
 
Simple versus complex GNG tasks 
 
The most marked changes in brain activation with the additional cognitive demands imposed 
by the complex version of the GNG task were in the inferior parietal lobes, bilaterally (Table 
5). Other areas that were preferentially activated were primarily lateralised to the right 
hemisphere (with the exception of the putamen), and included the frontal cortex, 
caudate/claustrum, cingulate gyrus and occipital lobe. 
 
Table 5.  Areas that were more consistently activated for complex than simple GNG tasks 
 
# Label Hemi  BA Volume  
 (mm 3) 
Weighted 




X Y Z‡ 
1 Parietal, Inferior R 40 6936 43 -46 40 9.24 42 -44 38 
2 Putamen L  5392 -21 6 5 7.46 -16 4 6 
3 Frontal, Middle R 46 4496 41 33 23 8.13 40 34 22 
4 Parietal, Inferior L 40 4144 -45 -42 43 7.97 -44 -42 42 
5 Caudate and claustrum R  4104 15 7 8 6.27 14 8 10 
6 
Temporal, Middle & 
Superior 
R 21, 
22 1528 50 -40 2 5.21 50 -48 8 
7 Limbic, Cingulate R 23 1488 2 -22 27 5.25 2 -22 26 













9 Occipital, Superior R 19 256 35 -76 30 4.51 34 -76 30 
10 Temporal, Fusiform gyrus L 20 160 -49 -32 -15 4.18 -48 -32 -16 
11 Limbic, Cingulate L 32 144 0 18 41 4.08 0 18 40 
* Coordinates for the weighted centre of mass for the cluster † The most extreme t statistic for the 
voxels in the cluster          





Block versus event-related designs 
 
Activations were more prominent for blocked than event-related designs, in keeping with the 
increased power attributed to blocked designs in detecting task-coupled changes in BOLD 
response. Greater activation in blocked-designs was most consistently observed bilaterally 
in the IFG and the precuneus, in the right middle frontal gyrus, temporal cortex, and 
cerebellum, and in the left occipital cortex (Table 6). Greater activation was observed for the 
left superior frontal gyrus (BA 9) and right superior temporal gyrus (BA 39) for event-related 





































Table 6. Differential activation for block-design versus event-related GNG tasks 
 
Region Hemi  BA Frequency * 
Avg. Cluster 
size (mm3) (SD)  
† 
Avg. Peak 
Threshold (SD)  
‡ 
X Y Z§ 
Block > Event-related 
Frontal, Middle R 9 80 3647 (2542) 3.558 (3.35) 44 22 30 
Frontal, Inferior R 47 80 727 (453) 2.388 (2.69) 40 20 -14 
Occipital, Inferior L 19 59 687 (326) 3.677 (0.29) -38 -76 0 
Frontal, Medial L 8 59 1839 (997) 4.126 (0.65) 0 28 40 
Frontal, Inferior L 47 56 2475 (768) 3.675 (0.02) -42 18 -8 
Parietal, Precuneus R 7 53 1711 (1541) 3.256 (1.8) 18 -70 46 
Cerebellar Tonsil R   45 423 (272) 3.048 (0.26) 30 -42 -36 
Parietal. Precuneus L 7 45 357 (146) 3.071 (0.88) -14 -66 48 
Temporal, Middle R 37 44 1217 (957) 3.633 (0.67) 50 -62 6 
Frontal, Inferior  L 45 40  3.624 (0.15) -46 16 4 
Event-related > Blocked 
Frontal, Superior L 9 40 1562 (1173) -4.03 (0.8) -36 36 28 
Temporal, Superior R 39 37 1079 (887) -3.47 (2.29) 48 -56 28 
* Frequency refers to the number of times a particular cluster was identified across 100 permutations 
for 6 pseudo- randomly selected studies in each group being compared. 
 † Calculated across occurrences of the cluster identified in the  permutation analysis 
 ‡ Average and standard deviation of peak t statistic (103) for occurrences of cluster in the permutation 
analysis 
  § Calculated as the mode of the coordinates for that cluster across the permutation analyses 
        
 
Linguistic versus non-linguistic stimuli 
 
In comparing data from all of the eligible studies in terms of the nature of the trial stimuli, 
greater activation for linguistic stimuli was observed in the amygdala (left),  insula 
(bilaterally), and frontal operculum portion of the IFG (bilaterally). The only one of these 
regions that was reliably activated when sample size was controlled for was the right IFG 
(BA 47). Non-linguistic stimuli, on the other hand, activated the cerebellum (left), brain-stem 
(right), cingulate gyrus (right), and claustrum (right) exclusively. When sample size was 
equated, the right claustrum was still observed as being more active in response to non-
linguistic than linguistic stimuli. 
 














  Table 7. Differential activation for GNG tasks that differ in linguistic content of stimuli* 
 
Region Hemi BA Frequency * 
Avg. Cluster  
size (mm3) † 
Avg. peak 
threshold (SD) ‡ X Y 
Z§ 
Linguistic > Non-linguistic 
Frontal, Superior gyrus L 8 52 969 (799) 3.355 (0.61) -6 32 46 
Frontal, Inferior gyrus R 47 49 1122 (811) 3.755 (1.11) 38 20 -14 
Temporal, Middle gyrus R 39 35 1329 (949) 3.912 (0.59) 50 -60 8 
         
Non-linguistic > Linguistic 
Claustrum R  51 1777 (1684) -3.7 (2.08) 28 20 4 
Medial Frontal Gyrus L 6 38 2667 (1363) -4.31 (0.9) -4 -6 58 
Inferior Frontal Gyrus L 9 35 777 (581) -3.47 (0.68) -48 8 26 
* Frequency refers to the number of times a particular cluster was identified across 100 permutations 
for 6 pseudo- randomly selected studies in each group being compared. 
† Calculated across occurrences of the cluster identified in the  permutation analysis 
 ‡ Average and standard deviation of peak t statistic (103) for occurrences of cluster in the permutation 
analysis 




Affective versus Standard versions of the Go/NoGo 
 
Coordinate data could only be included for 6 experiments from 5 of the 10 included studies. 
Reasons for excluding data from the Affective GNG studies included the lack of a Go-only 
comparison group for a blocked design study (Elliott, et al. 2000), the reporting of 
deactivated coordinates (Amin, et al. 2006) or between-group contrasts only (Protopopescu, 
et al. 2005; Silbersweig, et al. 2007; Wessa, et al. 2007), and failure to obtain coordinate 
data (Shafritz, et al. 2006). 
 
Studies employing versions of the Go/NoGo task containing emotional stimuli were more 
likely to observe BOLD signal in the right cingulate, insula and the left amygdala. On the 
other hand, the parietal lobe (precuneus and inferior parietal) as well as the middle frontal 















Table 8. Differential activation for comparison of standard and affective versions of the GNG 
task 
Region  Hemi BA Frequency*  
Avg. Cluster 
size (mm3) † 
Avg Peak  
threshold (SD) ‡ X Y Z
§ 
Affective > Standard         
Limbic, Cingulate gyrus R 23 94 744 (377) 3.221 (2.13) 8 -24 32 
Insula L 13 93 2269 (943) 4.517 (0.6) -34 20 8 
Limbic, Amygdala L  62 533 (210) 3.244 (0.1) -28 0 -16 
Temporal, Superior gyrus R 13 59 2069 (1113) 3.754 (0.6) 48 -44 14 
Insula R  42 3627 (1013) 4.99 (0.7) 32 20 0 
Frontal, Inferior gyrus R 9 37 716 (637) 2.997 (1.07) 40 6 30 
Temporal, Fusiform gyrus R 37 35 425 (259) 2.809 (0.18) -40 -60 -8 
Frontal, Superior gyrus R 10 33 234 (87) 2.738 (0.17) 28 58 24 
Standard > Affective         
Frontal, Middle gyrus R 9 42 1658 (1562) -3.36 (2.33) 28 38 34 
Parietal, Precuneus R 7 36 1597 (1339) -3.6 (1.43) 18 -70 42 
  * Frequency refers to the number of times a particular cluster was identified across 100 permutations    
    for 6 pseudo- randomly selected studies in each group being compared. 
  † Calculated across occurrences of the cluster identified in the  permutation analysis 
  ‡ Average and standard deviation of peak t statistic (103) for occurrences of cluster in the  
    permutation  analysis 
   § Calculated as the mode of the coordinates for that cluster across the permutation analyses 
 
 
5.5  Discussion 
 
This study represents the largest quantitative review of the neural correlates of successful 
motor inhibition using a single paradigm to date, collating coordinate-data from a total of 51 
fMRI studies (946 subjects). The finding of a substantially higher commission than omission 
error rate on average for the standard GNG studies included in this review appears to 
support the adoption of this paradigm as a measure of motor inhibition for the MRI scanner.  
 
Bilateral activation was observed across (standard) GNG studies in the frontal, temporal and 
parietal cortices, with the largest cluster in these meta-analyses detected in the right middle 
and inferior frontal cortex (extending to the precuneus). This prominence of right-
hemispheric activation is consistent with findings in  other imaging meta-analyses of the 













Nee, et al. 2007; Simmonds, et al. 2008). Mirroring the  findings from the most recent of 
these meta-analyses, we detected a largely right-lateralised pattern of concordance in 
fronto-parietal regions in response to successful inhibitions on the GNG, as well as bilaterally 
in the insula/putamen (Simmonds, et al. 2008). Greater activation was also observed in the 
thalamus, as well as the right insular cortex, extending to the pars opercularis of the rIFG 
(BA47). These findings concur with those reported for a mega-analysis of fMRI data from 5 
studies (126 participants) utilizing the stop-signal paradigm, in which the only network out of 
20 identified using independent components analysis that correlated significantly with 
inhibitory performance contained the bilateral  IFC/frontal  opercular/insular  cortices,  and  
the  bilateral striatum, pallidum, and thalamus (Congdon, et al. 2010). 
 
The findings of this review are largely in agreement with recent versions of the fronto-striatal 
model of motor inhibition, in which inhibitory behaviour is subserved by a neural network that 
includes the basal-ganglia, the rIFG, the supplementary motor area (SMA) and preSMA 
(Chambers, et al. 2009). This neural circuit is distinct from the inhibitory connections 
between the ventral ACC and nucleus accumbens that are conceptualized as crucial in 
predicting impulsive behavior associated with deficits in reward processing (Fineberg, et al. 
2010). In the fronto-striatal model the inhibition of a motor response is achievable by means 
of two routes, both of which result in inhibition of excitatory projections from the thalamus to 
cortical motor areas. The first is a relatively slow indirect pathway in which activation of the 
striatum via cortical motor projections (dorsal motor cortex, preSMA, SMA, M1) results in the 
down-regulation of the global pallidus pars externa (GPe) by means of inhibitory 
(GABAergic) connections, further reducing the inhibition of GPe afferents (globus pallidus 
pars interna (GPi)/reticular substantia nigra (SNr) and the subthalamic nucleus) that send 














The second route by which motor inhibition might occur is through a so-called “hyperdirect 
pathway” in which the subthalamic nucleus is activated directly via excitatory connections 
from the rIFG, in turn resulting in stimulation of excitatory glutamatergic connections to the 
internal segment of the globus pallidus/recticular substantia nigra, and the activation of 
inhibitory projections to the thalamus. The differential delays associated with the indirect and 
hyperdirect pathways  resonates with  evidence that it may be easier to distinguish between 
correct inhibitions and commission errors on the temporal than the spatial plane (Garavan, et 
al. 2002). 
 
The ventrolateral prefrontal cortex (VLPFC), and in particular the rIFG, has been identified as 
a core component of the fronto-striatal model of motor inhibition. The importance of this 
region for motor inhibition has recently been questioned however, with a number of scholars 
arguing that the preSMA may be more critical for inhibition (Simmonds, et al. 2008).  
Activation of the insula/rIFG could potentially arise from incidental differences between trial 
types (eg. greater frequency of Go trials & greater difficulty of NoGo trials), rather than 
response inhibition per se. Indeed, activation of the pars opercularis, the region of the IFC 
encompassed by this cluster, was determined to be sensitive to reference condition, and was 
only detected in this review in comparisons with Go trials. This finding may partially explain 
discrepancies in the results reported in the two most recently published ALE meta-analyses 
of motor inhibition, in which Levy et al. (2011) discovered robust activation of both the right 
opercular and triangular regions of the rIFG, despite failure to detect rIFG involvement in a 
larger (N = 48) meta-analysis of the GNG (Swick et al. 2011). Levy and colleagues (2011) 
based their findings on an activation map produced by combining stop-signal and GNG tasks 
(N = 45), and, tellingly, restricted the latter to those using Go trials as a reference condition. 
 
Although it may be tempting on the basis of the finding in our review  to interpret the role of 













been observed in individual studies employing oddball comparators, in which frequency 
effects have been accounted for (Borgwardt, et al. 2008; McNab, et al. 2008).  The possibility 
should also be considered that failure to detect activation of the rIFG when combining data 
from the 5 studies employing the oddball paradigm may be attributable to the limited power 
of this comparison. Finally, findings from other paradigms, such as the recent demonstration 
in a target-detection task that   activation of the rIFG was not dependent on the frequency of 
targets (Hampshire, et al. 2009), also argues against describing the role of the rIFG as 
primarily one of novelty – detection.  
 
The IFG is a large region of the brain, incorporating the pars opercularis, pars orbitalis, and 
pars triangularis. One possible explanation for the conflicting characterizations of the role of 
the IFG therefore is that it may incorporate multiple subregions, each with specialised 
functions. Indeed, task-specific activation patterns within the rIFG, visible on the millimetre 
scale, suggest caution in regarding this structure as monolithic in function (Goghari and 
MacDonald 2009; Hirose, et al. 2009). Treating the entire rIFG as a single region of interest 
carries with it the possibility that inhibitory effects might be diluted to below the level of the 
statistical threshold applied. The functional fractionation of the IFG is apparent in the 
distinction made by Chikazoe and colleagues (Chikazoe 2010; Chikazoe, et al. 2009) 
between the posterior IFG, inferior frontal junction (IFJ), and the insula/IFG. These authors 
argue that whereas the pIFG is specialised for inhibitory functioning, the IFJ is involved in 
processing infrequent stimuli. This is supported by the finding that the pIFG responds 
preferentially to infrequent NoGo trials, while the IFJ responds to both NoGo and infrequent 
Go or oddball trials, regardless of type (Chikazoe, et al. 2009) (however, see Braver 2001).  
 
Levy et al. (2011) recently attempted to decompose the functional structure of the right 
VLPFC using meta-analytic methods, by comparing the results of tasks designed to measure 













response stopping (the GNG and stop-signal task). The authors concluded, on the basis of 
bilaterally-activated IFJ across all tasks that the function of this structure might better be 
interpreted with respect to the detection of task-relevant stimuli. Activation of the par 
opercularis and pars triangularis regions on the other hand was modulated by the inhibition 
but not the reorientation tasks, indicating that the function of these components of the IFG 
might be more closely tied to inhibition. The finding that the pars triangularis was activated 
by tasks where there was uncertainty regarding the identity of upcoming trials (GNG tasks 
with equiprobable trial types), and not where a dominant response was established by the 
task design (all stop-signal tasks and GNG tasks with a majority of Go trials) led  the authors 
to conclude that one of the functions of this structure might be to resolve decision-level 
conflict in circumstances characterised by high levels of uncertainty.  
 
Levy et al. (2011) interpreted the role of the right pars opercular activation as one of updating 
action plans, despite evident specificity of this region for the inhibition as opposed to 
orienting tasks, partly on the basis of evidence of its invariance with respect to the difficulty 
of inhibitions. This concurs with the suggestion that the rIFG constitutes a general purpose 
relevance-detection mechanism that  signals the dorsal frontal cortex for task-set 
maintenance (Hampshire, et al. 2010). Indeed, evidence in support of this hypothesis  is 
particularly strong for the frontal operculum, as  the cluster of activation incorporating the 
insula and frontal operculum has been related to a diverse range of cognitive functions that 
have been subsumed under the category of awareness (Craig 2009). Its involvement across 
a variety of tasks has led to the suggestion that the insula/rIFG forms part of a core task-set 
system along with the dorsal ACC/medial superior frontal cortex (Dosenbach, et al. 2006), 
and that it may form part of a network including the VMPFC and ACC in assigning salience 
to stimuli (Sridharan, et al. 2008).  Although the insula has been implicated in many studies 
as central to inhibition (Garavan, et al. 1999; Swick, et al. 2011; Wager, et al. 2005), and was 
the only region (after correction for multiple comparisons) to correlate significantly with 













inhibition may therefore be part of its broader function in flagging stimuli as relevant to the 
requirements of a particular task. This is consistent with the hypothesis that the insula forms 
part of a frontal-striatal attentional network that is integral to inhibitory performance via its 
connections with  the  prefrontal cortex and anterior cingulate gyrus (Schmitz, et al. 2006). 
 
The findings of this review provide support for the involvement of the preSMA in inhibition 
(Fassbender, et al. 2004). This agrees with the meta-analytic observation that the 
SMA/preSMA was activated in both GNG and the stop-signal task paradigms (Swick, et al. 
2011). Using a novel triangularisation technique, Aron et al. (2007) demonstrated a structural 
network linking the preSMA, sub-thalamic nucleus (STN) and the right IFC that 
corresponded closely with functional activation patterns in a subsequent modified stop-signal 
task. The same pathways were activated for delayed responses and correct inhibitions.  The 
finding of effective connectivity between the preSMA and the rIFG was confirmed recently in 
the analysis of BOLD data from a stop-signal paradigm using Granger Causality Analysis 
(Duann, et al. 2009). In this study activation in preSMA and PMC directly predicted activation 
of the caudate and STN, respectively, whereas the rIFC exerted influence on the basal 
ganglia indirectly via its connectivity with the preSMA. These connectivity patterns were 
stronger for correct than failed inhibitions. Duann et al. (2009) go on to suggest that their 
findings necessitate the re ision of the fronto-striatal model of motor inhibition, as they are 
not consistent with the existence of the hyperdirect pathway between the IFC and the 
subthalamic nuclei. 
 
The issue of the specificity of the rIFG and preSMA to inhibitory control has generated much 
debate. A recent study employing the stop-signal paradigm detected great activation of the 
pre-SMA during better inhibitory performance (Chao, et al. 2009), with failure to find parallel 
activation of the rIFG interpreted by the authors as reflecting its role in the orientation of 
attention. The authors noted, however, that it is difficult to separate the contribution of the 













preparation (Zubicaray 2000, p1288). This latter interpretation of the role of the preSMA is 
consistent with the finding that this region responds to both target and inhibition trials 
(Hampshire, et al. 2010). Although the ACC/preSMA has been identified as a component of a 
core cognitive control network, the exact role of the preSMA vis-a-vie response inhibition still 
needs to be determined (Cole and Schneider 2007; Dosenbach, et al. 2006). 
 
Concurrent activation of the dorsal ACC was also observed for successful inhibitions in this 
review. Increasing reliance on the ACC has been observed with maturation from 
adolescence to adulthood (Rubia, et al. 2006), and it has been posited to be crucial to 
conflict monitoring and error detection (Braver, et al. 2001). The dorsal portion of the ACC 
has reciprocal connections to the frontal cortex as well as afferent connections to the 
associative premotor and primary motor regions, and is therefore particularly well situated to 
coordinate cognitive-motor interactions (Mohanty, et al. 2007; Paus 2001). It is conjectured, 
based on evidence of functional connectivity, that the dACC may recruit the DLPFC and 
parietal cortex to exert greater attentional control in response to conflicts between task 
requirements and behavioural tendencies (Carter, et al. 2000; Mohanty, et al. 2007). For 
instance, Mohanty and colleagues (2007) demonstrated that over 70% of the variance in 
DLPFC activation during the incongruent word-colour condition of a Stroop task was 
explained by activation of the dACC.  
 
Finally, there was a small cluster of activation in the right thalamus on correct inhibitions. The 
thalamus plays a pivotal role in models of motor response inhibition. Afferent connections to 
the thalamus from the prefrontal cortex and ACC, regions of the brain putatively involved in 
task-set maintenance, conflict resolution and response selection, implicate the role of the 
thalamus as gatekeeper for motor control on the level of response execution. The GNG task 
is considered to be a relatively selective measure of response execution compared to other 













by  Wager et al (2005) of a correlation between activation of the thalamus and performance 
on the GNG but not other measures of interference resolution, such as the Flanker and 
Stimulus Response Compatibility task (Wager, et al. 2005). 
 
5.5.1  Effect of differences in task design on inhibition-related brain activation 
  
There was no evidence in this study that manipulating the ratio of Go to NoGo trials in event-
related studies resulted in differences in task performance. The absence of fronto-parietal 
activation in studies in which the number of trial types has been kept equivalent could be 
interpreted as evidence that inhibitory function is not being tested in these studies (Braver, et 
al. 2001; Konishi, et al. 1998) This rests on the assumption that the fronto-parietal network 
identified in this and other studies is a core component of inhibition. However, Simmonds et 
al. (2008) phrase the involvement of the fronto-parietal circuitry in terms of its function in the 
maintenance and manipulation of stimulis-response associations rather than inhibitory 
function per se. Indeed, we were able to confirm that the fronto-parietal circuit was activated 
to a greater extent in complex versions of the GNG, where dynamic stimulis-response 
associations place a greater burden on these regions in updating working memory.  
 
The choice of the reference condition used for assessing the neural correlates of inhibition 
appears to have substantial effects on patterns of brain activity. A more diffuse pattern of 
activation was observed when NoGo trials were compared to baseline rather than Go trials. 
Specifically, regions that have been implicated in motor control, including the bilateral inferior 
parietal cortex and the putamen were evident only when baseline was used as a reference 
condition. This is in line with accounts that describe inhibition as involving the triggering of a 
“kill switch” for a motor response that has been initiated (Chambers, et al. 2009). In this 
scenario, use of Go trials as a reference condition would mask this motor-related activity. 













hemisphere, consistent with a contralateral response to the use of a right button-box in the 
majority of studies.  
 
There was substantial overlap between areas that were preferentially activated for complex 
GNG tasks and for studies that compared inhibition to a baseline reference (left putamen, 
bilateral inferior parietal lobe, left fusiform gyrus). Although discrepancies in the size of the 
clusters were observed, there was almost complete correspondence in the location of the 
peak coordinates. This can be attributed to a confound between reference condition and 
working memory load, with the vast majority of the studies conducting NoGo > Go 
comparisons employing simple GNGs (25/26), and over 70% of the studies using baseline 
comparisons employed complex GNGs (10/14). Nevertheless, the inferior parietal cortex has 
been consistently identified with working memory performance (Berryhill and Olson 2008; 
Muller and Knight 2006), suggesting that it would be recruited to a greater extent for 
conditions requiring updating of a stimulus-response set.  
 
Brain regions that were uniquely activated for the complex - simple GNG contrast included 
the ACC, as well as the right medial posterior cingulate cortex (BA 23), an area that has 
been linked to self-monitoring processes (Blakemore, et al. 1998). Previous studies have 
detected a shift of activation from the right DLPFC to the ACC with increasing task difficulty 
(de Zubicaray, et al. 2000; Garavan, et al. 2002), a phenomenon that is interpreted as 
reflecting a transition from a more deliberative to a more 'urgent' response style (Garavan, et 
al. 2002). Activation of the ACC in this review is consistent with this interpretation, with a 
greater number of commission errors being detected for complex than simple GNG tasks. 
 
Blocked study designs and analytic procedures are frequently employed, as they are 
regarded as more sensitive than event-related designs to differences in BOLD signal 













isolate trial-specific activation, (b) remove  error responses, and (c)  characterize the shape 
of the hemodynamic response. In comparing blocked versus event-related GNG tasks in this 
review, more activation was detected in blocked-design studies in the right parietal and 
temporal hemispheres, as well as bilaterally in the frontal cortex (BA 9, 47). Interestingly, a 
relatively large cluster (average extent: 2475 mm3) was observed in the left lobe for the 
inferior frontal gyrus (BA 47). Though the function of the left IFG has been discussed in 
terms of the inhibition of conflicting verbal information (McNab, et al. 2008) and interference 
resistance (Nelson, et al. 2009), a neurophysiological study recently demonstrated 
impairments in motor inhibition in patients with lesions in the left IFG (Swick, et al. 2008). 
One possibility is that the right-lateralised network identified in event-related designs is an 
artifact of the lower sensitivity of these designs to detect signal changes.  
 
5.5.2  Effect of differences in stimulus type on inhibition-related brain activation 
 
Relative to the standard GNG, we observed a high error rate on the affective GNG (average 
of 8.7% over both trials types), as well as a slower reaction time for the Go trials. This 
concurs with evidence from the literature that it is more difficult to inhibit responses to 
emotional than non-emotional stimuli in healthy individuals (Schulz, et al. 2007; Verbruggen 
and Houwer 2007).This  may also underlie the finding that the ACC was the most 
consistently activated region in response inhibition in studies employing this paradigm, given 
the central role it is posited to play in monitoring conflict (Botvinick, et al. 2004). Hare et al. 
(2005) have postulated that one source of conflict that occurs in the affective GNG is 
between task instructions and the approach or withdrawal orientation associated with 
positive and negative emotions, respectively. Although we had insufficient power to replicate 
Hare et al.’s (2005) finding of a higher commission error rate for happy faces and a slower 
reaction time for fearful targets in this review, the differences that were observed were in the 














Clusters that were most consistently activated in the affective relative to the standard GNG 
included the right cingulate gyrus, the insula (bilaterally), the left amygdala, and the right 
temporal and frontal lobes.  The amygdala has frequently been associated in the literature 
with emotional processing, and fear conditioning in particular. Its association with exposure 
to negative affect has led to an initial emphasis on its involvement in fear processing. For 
instance, previous meta-analyses of imaging studies employing emotional stimuli have 
generally detected greater activation for fearful than happy stimuli (Murphy, et al. 2003; 
Phan, et al. 2002). The characterization of the amygdala as a threat-detection module is 
consistent with the finding that this structure is frequently activated amongst anxiety 
disordered patients in stimulus exposure paradigms (Freitas-Ferrari, et al. 2010; Shin, et al. 
2006). The inverse association between prefrontal and amygdala activation typically 
observed in these paradigms supports a model in which the prefrontal cortex moderates 
amygdala activation, and finds its anatomical basis in the bidirectional neural pathways 
between the OFC/ventromedial prefrontal cortex (vmPFC) and the amygdale. 
 
The role of the amygdala is likely to be more complex than suggested by the naïve frontal-
limbic model, however. For instance, Mobbs et al.  (2007b) were able to demonstrate 
specificity of subdivisions within the amygdala to the physical and psychological proximity of 
a virtual predator. The exclusivity of the amygdala's role in relation to fear/threat has also 
been questioned, with  a region-of-interest meta-analysis observing greater activation of the 
amygdala for happy than fearful faces (Sergerie, et al. 2008). The finding of the sensitivity of 
the amygdala to the task-relevance of emotional faces, rather than their emotional valence 
per se (Santos, et al. 2011),  and its activation in response to non-affective stimuli in GNG 
paradigms and other measures of executive functioning (Pourtois, et al. 2010), suggests that  
the amygdala may possess a more general function  in detecting the behavioural 














Finally, it should be noted that although previous studies have detected associations 
between behavioural performance and amygdala activation using the affecive GNG 
paradigm (eg. Hare et al. 2005), this  paradigm is not necessarily optimized for detection of 
activity in  the amygdala. In fact, there is evidence that the executive component of affective 
inhibitory control, mediated by the frontal cortex, may inhibit activitation of the amygdala 
(Berkman, et al. 2009). Nevertheless, the possibility that deficits in the frontally-mediated 
regulation of the limbic lobe (including the amygdala) could serve as an endophenotype for 
affective disorders suggests that the affective GNG might have application in clinical 
populations. Even more tantalizing are indications that this task could serve to discriminate 
between competing diagnoses, as suggested by a series of studies conducted by Rebecca 
Elliot on patients with unipolar and bipolar depression (Elliott, et al. 2004; Elliott, et al. 2002).  
In these studies, ventral regions of the ACC were selectively responsive to sad as opposed 
to happy target words in depressed patients, with the converse finding observed in normal 
controls (Elliott, et al. 2002). Although patterns of activation were similar in manic patients, 
they were observed in response to both happy and sad words, suggesting a general deficit 
in emotion regulation in this clinical population (Elliott, et al. 2004).   
 
The finding in this review that the use of affective stimuli was associated with bilateral insula 
activation concurs with evidence that this structure might be involved in the explicit 
discrimination of stimuli based on their emotional content (Gorno-Tempini, et al. 2001; Iaria, 
et al. 2008).  Shafritz et al (2006) argue that the insula may be important in the integration of 
emotions in decision-making processes. It therefore follows that the processing of 
information conveyed by these emotions may  fall within the more general function proposed 
for the insula of achieving homeostasis through monitoring a person’s internal physiological 
states (via interoception – see Craig 2002). This is reminiscent of the central role postulated 
by proponents of the somatic marker hypothesis for affective feedback in explaining complex 













insula reported for anxiety prone individuals (Stein, et al. 2007) as well as individuals who 
experience unusually strong emotions in response to affective stimuli (Iaria, et al. 2008).  
 
Finally, this review provides some evidence that the nature of the stimuli that are employed 
in the standard GNG paradigm may impact on the brain regions that are activated. Tasks 
employing shapes or objects as stimuli as opposed to letters were more likely to detect 
activation in the right claustrum, a thin layer of cells lying subcortically between the putamen 
and the insula. Although the exact function of this structure is not known, it is speculated that 
it might be important in the cross-modal integration of features of an object (Crick and Koch 
2005). Its activation in this instance is therefore arguably incidental to the properties of the 
stimuli employed. 
 
 5.5.3  Limitations 
 
Conducting subgroup analyses of groups separated on a single factor does not control for 
confounding effects of other factors that might be differentially represented in the two groups. 
In this review, there was substantial overlap between reference condition, working memory 
load and experimental design (blocked versus event-related). This made teasing apart the 
effects of these different design factors on brain function challenging. Although the 
development of brain imaging meta-analysis approaches that allow one to regress the 
effects of a continuous covariate on brain activation may go some way towards addressing 
this concern (e.g. Signed Differential Mapping (Radua and Mataix-Cols 2009)), possible 
confounding variables should ideally be considered at the design stage. This is particularly 
the case when one considers the subtlety of some of the proposed interactions, such as that 
between specific stimulus types and the brain areas involved in mediating the relationship 
between  working memory and inhibition (McNab, et al. 2008).   
 













there was a far greater amount of data for correct responses, affording us the opportunity to 
interrogate the effects of methodological features on variance in brain activation. This 
decision also receives partial justification from evidence that activation patterns elicited by 
correct and incorrect inhibitions may be more distinguishable in the temporal than the spatial 
domain (Garavan, et al. 2002). However, even with the adoption of this strategy, conclusions 
drawn from comparisons in this review still need to be considered in light of quite severe 
sample-size constraints (particularly with respect to the affective GNG comparison). 
 
This review examined brain activation associated with motor inhibition in healthy 
participants, and did not address the literature employing the GNG paradigm in clinical 
samples. Nevertheless, collating data from fMRI studies in healthy populations can be seen 
as a first step in providing a  frame of reference for the identification of  clinically-relevant 
brain activity patterns  in patient samples. Diffuse non-task-specific activity in clinical 
populations is frequently interpreted as a compensatory response to hypoactivation of 
regions, such as the rIFG, that have been regarded as more pertinent to the task at hand in 
normally functioning individuals, particularly in the context of equivalent behavioural 
performance (Schmitz, et al. 2006). The finding in Kana et al. (2007)   that differences 
between schizophrenia patients and healthy controls only manifested in a version of the 
GNG containing a substantial working memory component highlights the importance of 
matching the design features of the task employed to the particular patient sample . 
 
It was unfortunately not possible to distinguish on a neural level between the effects of 
different emotions, due both to heterogeneity in the stimulus sets that were employed and 
the contrasts that were performed. The relationship between emotional valence and 
activation of the amygdala in the context of inhibition might have been particularly 
informative, given controversy over the generality of activation in this region. The specificity 













exposure to sad emotions (Shafritz, et al. 2006), and the caudate in connection with positive 
emotions (Hare, et al. 2005) awaits confirmation from future research.   
 
Despite the limitations of this review, we were able to address a number of the shortcomings 
of previous quantitative syntheses of imaging data for motor inhibition tasks, as described by 
Simmonds et al. (2008). With the exception of Levy et al. (2011), previous meta-analyses 
assigned the same weighting to coordinate data contributed by different studies, despite 
substantial inter-study differences in the sample size and statistical thresholds employed. By 
way of illustration, 2 of the 48 GNG studies included in Swick et al. (2011)(Konishi, et al. 
1999; Konishi, et al. 1998) contained an average of 6 participants, but from an analytic point 
of view were considered equivalent to a  study contributing data from 48 participants 
(Mostofsky, et al. 2003).  In addition, we took pains to exclude studies reporting on the same 
sample, in an  attempt to minimize dependency in the data. Notably, recent meta-analyses 
have included data from as many as 5 studies containing overlapping sample, partially 
undermining the strength of the conclusions drawn (Levy and Wagner 2011; Swick, et al. 
2011).  
 
This review employed a version of the  ALE algorithm that adjusted the extent of smoothing 
applied to coordinate foci on a study-by-study basis, using a Gaussian full-half-width-
maximum (FWHM) kernel proportional to the sample size (Eickhoff, et al. 2009). In this way 
bias introduced through small under-powered studies with overly lenient statistical thresholds 
was minimized. Activation was also restricted to biologically plausible regions through the 
use of a grey matter mask. Finally, the effects of variation in the number and clustering of 
foci between studies was explicitly controlled for through the use of a random-effects model. 
This allows us to extrapolate our findings beyond the particular studies included in this 
review. The generalisability of our findings was further strengthened by restricting inclusion 













5.6  Conclusion 
 
Inhibitory behaviour can be decomposed into a tightly integrated set of interacting cognitive 
components, including stimulus detection, response selection and response execution. 
Moreover, differential study-specific demands will be made on neural substrates involved in 
task-set maintenance, attention and conflict resolution, depending on the characteristics of 
the task and population tested. A potential consequence of the inclusion of extraneous 
cognitive components in tasks such as the GNG are reduced correlations between 
performance and brain activation. Individuals may also compensate for inefficient response 
inhibition by monopolising memory or selective attention demands, in line with their strengths 
(Wager, et al. 2005). 
 
It is therefore striking that, this variability in task design notwithstanding, we were able to 
detect consistent involvement of brain regions regarded by many as critical for motor 
inhibition, such as the rIFG, preSMA, ACC, insula and basal ganglia. Furthermore, by using 
novel meta-analytic strategies to collate data across multiple studies that employ different 
GNG paradigms, we were also able to observe a substantial impact of differences in task 
design and analytic strategy on the reported distribution of fMRI coordinates. Most striking 
was the observation that the rIFG, a region that has frequently been identified with motor 
response inhibition, was reliably activated only when inhibitory trials were compared to Go 
trials. Differences in task demands may also explain the preferential recruitment of the 
inferior parietal (implicated in working memory) in the complex variant of the GNG paradigm.    
 
The nature of the stimuli associated with the instruction to withhold or execute a motor 
response was also determined to have a substantial and systematic impact on patterns of 
brain activity. This was the case both for aspects of task design that can be regarded as 
incidental to the main aims of the studies included in this review (use of linguistic versus 













interest (affective versus non-affective stimuli). Relatively greater activation of the amygdala 
when affective stimuli were employed highlights the importance of preliminary attempts to 
disentangle the contribution of inhibitory process and affect regulation to limbic activation 
(Shafritz, et al. 2006), especially in light of the increasing recognition of a strong relationship 
between emotion regulation and impulse control (Cyders and Smith 2008).   
 
Evidence of task-specific differences in brain response within the same paradigm 
emphasizes the importance of an explicit and systematic consideration of the impact of task 
design during the planning stages of an fMRI study. This is underscored by consideration of 
the functional overlap of different brain regions as described in the research literature, in 
combination with the conceptual challenges in separating behavioural domains (eg. emotion 
regulation and impulse control).  Although the emergence of structural and functional 
connectivity studies that adopt a systems approach to understanding communication 
between different brain regions should help to impose constraints on the role of particular 
regions vis-a-vie one another, investigators are encouraged to seek guidance in the design 
of these tasks and the interpretation of the resulting data by consulting mechanistic accounts 
of motor inhibition, such as provided by the fronto-striatal model. The full potential of brain 
imaging studies as sensitive indicators of differences in inhibitory control will only be realized 
if investigators are cognizant of how task features may affect brain activation, and design 
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6. EARLY PSYCHOLOGICAL TRAUMA INFLUENCES LATER EMOTION RECOGNITION:  




This study assessed the effects of the partial mu-opioid agonist buprenorphine on the 
emotional behaviour of University students with a history of early life adversity. Exogenous 
opioid agents are routinely employed as analgesics, and the opioid system has been 
implicated in animal and clinical research in the modulation of the affective component of 
physical pain, as well its emotional and social analogues  (Panksepp, 2003; Zubieta et al., 
2003). Accordingly, one of the central hypotheses of this study was that the administration of 
buprenorphine would result in improved social interaction and a reduction of fearful 
responses, as evidenced in a series of affective tasks, and that this would be particularly 
apparent in a traumatised sample that was likely to demonstrate enhanced reactivity to, and 

























6.2  Introduction 
 
There is substantial evidence that early psychological trauma is associated with later deficits 
in affect regulation and the processing of aversive emotions. A number of studies indicate 
that childhood adversity is associated with altered recognition of anger and fear faces 
(Masten et al., 2008; S. D. Pollak, Cicchetti, Hornung, & Reed, 2000; Seth D Pollak & Kistler, 
2002; Seth D Pollak & Tolley-Schell, 2003; Scrimin, Moscardino, Capello, Altoè, & Axia, 
2009).  Using a facial morphing paradigm to assess adult responsiveness to angry, happy 
and sad faces, Gibb et al (2009) found that a history of childhood trauma increased both 
attention to angry faces and the accuracy with which anger was recognized (Gibb, Schofield, 
& Coles, 2009).   
 
An immediate question is the nature of the neural circuitry and molecular systems which 
mediate such changes. Several converging lines of evidence point to involvement of the 
opioid system in affect regulation, as well as in mediating response to psychological trauma.   
Animal research has demonstrated that mu-opioids are secreted during formation of social 
attachments such as the infant-mother bond, and that they have a role in regulating 
separation distress or “social pain” (Panksepp, 2003).  Furthermore, there is evidence   that 
the opioid system plays an important role in mediating affective components of physical pain 
(Bruehl, Burns, Chung, & Chont, 2009; Stein, van Honk, Ipser, Solms, & Panksepp, 2007).  
Finally, empirical research indicates that the opioid system may play a compensatory role in 
response to psychological trauma, and that this may be compromised in posttraumatic stress 
disorder (Kraus et al., 2009; Liberzon et al., 2007). 
 
Despite this growing body of evidence on the role of the opioid system in emotional 
regulation and trauma, there is little data on whether administration of an opioid agent is able 
to normalize dysregulated systems in those exposed to early adversity.  Given the putative 













responsive to threat via up-regulation of localized mu-opioid receptors (Liberzon et al., 
2007), one hypothesis is that  exogenous administration of opioids would lower the threshold 
at which emotions such as fear and anger are detected. Tests of this hypothesis would be 
useful in strengthening our understanding of the role of the opioid system in stress and 
emotional regulation, and may also provide proof of principle evidence for the use of opioid 
agents in related clinical settings.   
 
The emotion recognition paradigm is frequently used in approaches that employ 
pharmacological challenges to investigate the involvement of specific neural systems in 
affective behaviour.  For instance, findings of impaired performance in  recognising angry 
faces after acute treatment with 15mg of diazepam have been interpreted as implicating 
activation of benzodiazepine receptors in  orbitofrontal cortex (Blair & Curran, 1999; Blair, 
2003). Similarly, the reduction of accuracy in recognising fear and anger after acute 
treatment with citalopram and reboxetine was discussed in terms of their specific effects on 
serotonin and noradrenergic neurotransmitters, respectively (Harmer, Shelley, Cowen, & 
Goodwin, 2004).  These studies provide a useful paradigm for investigating the effects of the 
opioid system on emotion processing. 
 
 We hypothesized that administration of an opioid agonist would normalize responses to fear 
and anger in an emotion recognition paradigm, in subjects with a history of early adversity. 
Data on whether responses to these emotions is facilitated or disrupted is sparse and 
somewhat contradictory, however. Although Gibb et al. (2009) reported increased accuracy 
in recognising angry faces following childhood trauma exposure, an unpublished study that 
stratified 162 adults by childhood physical trauma history did not reveal any differences in 
error rates for the recognition of angry faces  (Gapen, 2009). Moreover, a number of studies 
using the dot-probe attention task have reported findings that are perhaps more consistent 
with avoidance of threatening emotions in adults who were abused as children (Fani, 














Therefore, one of the aims of this study is to provide greater clarity on the direction of the 
effect that early trauma history has on the processing of negative emotions.  
 
6.3  Method 
 
The study was approved by the Ethics Committee of the Faculty of Health Sciences at the 
University of Cape Town, and complied with ethical guidelines established by the Declaration 
of Helsinki (World Medication Association, 2000).  Subjects were required to sign an 
informed consent form prior to participation. Subjects completed a range of measures to 
assess eligibility (see below). Those who qualified were provided with 0.2mg of 
buprenorphine or placebo on separate testing occasions, during which the emotion 
recognition task was conducted.   Subjects were asked to eat a light meal two hours prior to 
testing, and then to fast until testing was complete.  
 
6.3.1  Subjects 
 
878 students from the University of Cape Town were recruited using study flyers. Students 
were eligible for inclusion in this study if they were free of psychopathology (as assessed on 
the Mini-International Neuropsychiatric Interview (MINI) (Sheehan et al., 1998) and 
depressive symptoms (as defined by a score of 13 or less on the Beck’s Depression 
Inventory (Beck, Ward, Mendelson, Mock, & Erbaugh, 1961)).   
 
A smaller group (n=47) of traumatised and non-traumatised participants were identified from 
scores on the short form of the Child Trauma Questionnaire (CTQ).  This is a  validated self-
rating scale  consisting of 28 items scored using a 5-point response format (ranging from 
never true to very often true)(Bernstein et al., 2003). The CTQ contains 5 items each 













emotional neglect, and 3 items included to assess validity.  Participants who obtained a 
rating of at least "moderate to severe" on one or more of the CTQ subscales were rated as 
traumatised.  The control group consisted of participants with at most a single low to 
moderate severity rating on any of the CTQ subscales.  In order to be included in the study, 
subjects had to be classified in the same trauma group across two administrations of the 
instrument.  Invalid response patterns, defined as obtaining a rating of "questionable validity" 
on either administration of the CTQ, or "some denial/minimization" on both administrations, 
were grounds for exclusion.    
 
6.3.2  Medication Administration 
 
The administration of medication was blinded, with the order of placebo/medication 
administration determined in a randomised and counterbalanced fashion.  The dose of 
buprenorphine used was 0.2mg, in order to minimize nausea.  Behavioural tasks were given 
120 minutes after medication administration. 
 
6.3.3  Emotion recognition task 
 
A modified version of the emotion recognition task developed by Montagne et al. (Barbara 
Montagne, Kessels, Haan, & Perrett, 2007) was used.  In this task subjects are presented 
with sequences of faces that dynamically morph from neutral to one of a series of prototype 
emotions (see Figure 1). The participant is subsequently asked to identify the emotion 
displayed. Dynamic facial displays of emotion are more readily recognised than the static 
images that have traditionally been employed in studies of emotion recognition, with this 















Participants were presented with the image of a face with a neutral expression on a 17 inch 
colour computer monitor. On pressing the Enter key the faces morphed into one of 4 
emotions (angry, fearful, happy, sad) in increments of 2 percent intensity. The intensity of the 
final image in the sequence ranged from 20 to 100% of a protoype image, across 9 intensity 
levels presented in consecutive order  (20%, 30%, 40%, 50%, 60%, 70%, 80% and 100%). 
Each intensity level contained 4 randomly presented trials per emotion, for a total of 144 
trials. After the image was presented, the subject was instructed to press a key between 1 
and 4 that corresponded to the order of the emotion labels displayed under each face. 
Depending on the intensity of the emotion, the presentation time varied between 
approximately 1 and 3 seconds, with no time-limit imposed on the response time.  Each 
participant was given 4 practise trials at the beginning of the task. 
 
The stimuli used consisted of grayscale images of faces of two male and two female actors. 
One of the actors was selected from the Eckman library (Ekman & Friesen, 1976) and 3 
were selected from the Karolinska Directed Emotional Faces libraries (Lundqvist, Flykt, & 
Ohman, 1998(Oosterhof & Todorov, 2008)). The images were selected on basis of the 
highest mean ratings provided by 12 subjects on a 9 point scale for each emotion. The 
morphed images were created with the WinMorph software 
(http://www.debugmode.com/winmorph/), and  presented using Eprime 1.2 (Psychology 






















Figure 1. Example of dynamic display of angry emotions during the facial morphing task  
6.3.4  Additional Measures 
 
Differences between the trauma groups in accurately identifying emotions on the facial 
morphing task might partially be accounted for by group differences in (a) the threshold for 
discriminating between emotions or for responding in favour of particular emotions,  (b)  
symptoms of anxiety or depression,  (c) subjective mood states, and (d) forms of impulsivity 
that are sensitive to affect. Therefore, in addition to a self-rating measure of emotional 
awareness and clarity, we also analysed data from measures of these factors to aid in the 
interpretation of the results of the emotion recognition task. 
 
Self-rating measures of clarity in identifying emotions and emotional awareness were 













(Gratz & Roemer, 2004).  The DERS has demonstrated adequate test-retest reliability and 
convergent validity with other measures of affect regulation (Gratz & Roemer, 2004), and 
has been effective in identifying differences in a diverse range of healthy and clinical 
populations (Fox, Axelrod, Paliwal, Sleeper, & Sinha, 2007; Fox, Hong, & Sinha, 2008; Glenn 
& Klonsky, 2009; Orgeta, 2009). 
 
The potential contribution to task performance of impulsive traits that are influenced by an 
individual’s emotional state were assessed using the self-rated UPPS-P Impulsive Behaviour 
Scale (Lynam, Smith, Cyders, Fischer, & Whiteside, 2007). The 12-item urgency subscale 
provides a measure of the “tendency to act rashly in response to distress” (Cyders & Smith, 
2008) (p808), and has consistently predicted impulsive behaviour in substance abusing and 
gambling populations (Anestis, Selby, & Joiner, 2007; Billieux, der Linden, & Ceschi, 2007; 
Fischer, Anderson, & Smith, 2004).  
 
Differences between the trauma groups on anxiety and depression symptoms were 
assessed using the Beck Depression Inventory (Beck et al., 1961) and the State-Trait 
Anxiety Inventory (Spielberger, Gorsuch, & Lushene, 1970), respectively. Both of these are 
well validated instruments that are frequently employed in research settings. The effects of 
medication on subjective experiences of mood were assessed both at the beginning of the 
testing session and  the end using visual analogue mood scales (VAMS) (Stern, Arruda, 
Hooper, & Wolfner, 1997). Although originally designed for testing aphasia patients, the 
VAMS has demonstrated reliability in normal populations. Changes in task-relevant mood 
were assessed using subscales for fear, anger, happiness and sadness. In addition, VAMS 
scales measuring how tired and energetic the subjects were provided some indication of the 














6.3.5  Data Analysis 
 
The effect of medication and trauma status on accuracy in identifying fearful and angry faces 
was tested using generalized estimating equation models (GEEs) .GEEs allow testing for the 
effects of predictor variables on emotion identification accuracy, while controlling for common 
variance introduced through repeated measurements. Between-group differences in the time 
taken to correctly recognise angry and fearful faces was tested using  multivariate 
regression, employing restricted Maximum Likelihood Estimation (REML). Both random 
effects GEE and REML procedures were implemented in Statistica (version 10) 
(www.statsoft.com). 
 
Separate GEE models were fitted for accuracy in recognising angry and fearful faces. The 
models included the following dependent variables (coding between parentheses): the order 
in which medication or placebo was administered for that subject (placebo first vs. placebo 
second), whether a particular trial came from a medication or placebo session (medication 
vs. placebo), the intensity of the emotion displayed (levels 1 to 9), trauma status of the 
subject (traumatised vs. non-traumatised), and gender (male vs. female). Interactions terms 
for these variables were also included in the models, with the highest order term testing for 
4-way interactions between intensity level, medication status, trauma status and gender. 
 
Non-parametric signal-detection measures of perceptual discriminability (d-prime) and 
response bias were calculated separately for anger and fear (Donaldson, 1992). In this 
context perceptual discriminability refers to an individual's ability to distinguish between 
particular emotions, whereas response bias refers to the internal threshold at which a person 
indicates that they detected an emotion. The computation formulae for discriminabilty (A') 
and response bias (B"D), as implemented in the R statistical language (version 2.10; R 














A' = 1/2 + [(H – FA)(1 + H - FA)]/[4H(1 - FA)]. 
B"D = [(1 - H)(l - FA) - HFA]/[(1 - H)(l - FA) + HFA]. 
 
, where H = hit rate or number of correct responses, and FA = false alarms, or number of 
incorrect responses. Response bias scores are constrained to fall between -1 and 1, with a 
score of 0 indicating no bias, negative scores indicating more liberal tendencies to respond, 
and positive scores reflecting tendencies to withhold responses. A discriminabilty score of 
0.5 indicates chance performance, with near perfect performance reflected by scores 
approaching 1. Differences between trauma groups on these metrics were compared using 
Wilcox Rank Sum tests. 
 
Differences between the trauma groups on the scores from the respective subscales of the 
DERS and UPPS-P questionnaires were assessed using independent t-tests, or the 
Wilcoxon Mann-Whitney test where assumptions of normality were violated. Relationships 
between scores on these questionnaires and di ferences in accuracy or reaction time as a 
function of medication were assessed using Pearsons correlations, or non-parametric 
equivalents, where indicated. Between-group differences in changes in the VAMS mood 
scores from the beginning to the end of the testing session were determined using repeated-
measures analysis of variance, with medication as a within-group factor.  These analyses 





















6.4  Results 
 
6.4.1  Subjects 
 
A total of 47 participants completed at least one behavioural testing session, with data from 
40 subjects included in the analysis.  Approximately equal numbers of subjects were 
classified as traumatised (n = 18) or non-traumatised (n = 22).  
 
There was little overlap in the CTQ total scores for the subject groups (range: non-trauma -
36.5, 45; trauma - 44.5, 68) (Table 1).  Fifteen of the trauma group experienced some form of 
abuse, with only 3 participants in this group exclusively exposed to neglect. The trauma 
group obtained substantially higher scores on the awareness subscale of the DERS (W = 
73.5, p < 0.05).  The groups were comparable in terms of ag  and gender, as well as on 
depression and anxiety symptomatology.  No between-group differences were observed on 
the urgency subscale of the UPPS-P. Similarly, trauma status had no apparent effect on the 
scores for any of the visual analogue moods scales, including those for tiredness and energy 
























                 Table 1. Characteristics of participants 
 
 Trauma Non-Trauma Z score 
Sample   18 22 - 
Age 21.2 (3.8) 21.2 (3.8) -0.40 
Male 9 11               - 
CTQ total score 53.8 (6.9)   40.9 (2.3) t = -7.61** 
BDI 6.4 (4.6) 5.2 (4.8) W = 85 
STAI 39 (6.1) 38.1 (8.7) W = 129 
DERS Awareness 14.85 (3.31) 12.3 (3.53) W = 73.5* 
DERS Clarity 17.08 (1.44) 17.1 (1.65) W = 134 
UPPS-P  urgency 29 (5.97) 25.35 (5.76) W = 90.5 
                Statistical comparisons conducted using non-parametric Wilcoxon-Mann-Whitney test 
                Sample on BDI (Non-trauma  = 18, Trauma = 11), STAI (Non-trauma = 21, Trauma =14),  
                CSI avoidance (Non-trauma = 13, Trauma = 9), DERS and UPPS subscales  
                 (Non-trauma = 20, Trauma = 13) 
                *significant at p < 0.05 **significant at p < 0.01 
 
6.4.2  Emotion recognition performance 
 
Participants with a history of trauma were less accurate in recognising angry faces than 
those without such a history (Wald χ2 = 4.43, df = 1, p < 0.05) (Figure 2).  These differences 
in accuracy were associated with an overall bias against identifying faces as angry (BD = 
0.688 versus 0.412, Wilcox Rank Sum = 265.5, p-value < 0.02), with no between-group 
differences observed in the ability to discriminate between anger and the other emotions. A 
main effect of intensity level for angry faces (Wald χ2 = 178.71, df = 8, p < 0.01) was 
observed, with accuracy strongly predicted by emotional intensity (Pearson r = 0.934). 
Finally, there was  a significant correlation between emotional awareness (as assessed by 
the relevant subscale of the DERS), and accuracy in recognising anger (r = 0.42, p-value < 
0.05). No evidence was detected of an association between impulsivity scores and accuracy 















Figure 2. Comparison of accuracy in identifying aversive emotions between trauma groups 
and medication conditions  
 
Main effects on accuracy in recognising fearful faces were observed for session, intensity 
and gender.  As for anger, increases in the intensity of fearful expressions was strongly 
associated with performance improvements (Wald χ2 = 99.57, df=8, p < 0.01). Similarly, 
subjects’ performance improved significantly in the 2nd session relative to the 1st (Wald χ2 = 
34.27, df =1, p < 0.01). Males were less accurate overall in recognising fear than females 
(Wald χ2 = 3.86, df=1, p = 0.05).  An interaction was observed between trauma status and 
medication condition, with the trauma group experiencing an increase in accuracy following 
administration of buprenorphine, relative to placebo, and the converse pattern observed in 



















Figure 3. Interaction of childhood trauma and medication on accuracy for fear faces  
 
Similar patterns in the reaction time data were observed for both fear and anger. Increasing 
intensity of the angry and fearful emotions were associated with a reduction in response time 
(F8,542 = 46.383, p < 0.01 and F8,542 = 59.519, p < 0.01, respectively).  Reaction time in 
recognising fear  (F1,542 = 71.47, df = 8, p < 0.01) and anger ((F1,542 = 62.42, p < 0.01) ) 
was significantly reduced in the second session compared to the first. Subjects were slower 
in responding to the angry and fearful faces in the medication than placebo sessions (F1,542 
= 16.378, p<0.01 and F1,542 = 10.201, p<0.01, respectively). This finding appears to be due 
to faster responses in the trauma than the control group when on placebo, with the relative 
reaction time advantage for the trauma group disappearing once burprenorphine was 
administered (F1,542 = 12.065, p< 0.01 for anger and F1,542 = 14.119, p < 0.01 for fear, 
respectively).  Although no effect of gender was detected overall, females were faster than 
males in correctly identifying anger (F1,542 = 3.921, p < 0.05) in the buprenorphine 













6.5  Discussion 
 
This is the first study to compare the effects of exogenous opioids on emotion recognition in 
healthy adults with a history of childhood adversity.  The main findings of this study are  (1) 
that adults with a history of childhood adversity are less accurate in identifying anger and 
display deficits in emotional awareness, and (2), that administration of a single dose of 
buprenorphine reduced trauma-associated differences both in  the accuracy with which fear 
was identified, as well as the speed with which participants with a history of trauma were 
able to identify fear and anger. 
 
Adults with a history of trauma were less accurate in recognising angry faces than control 
participants,  reflecting a general tendency in this group to avoid identifying faces as angry. 
One interpretation of this finding is that early adversity may disrupt the processing of socially 
antagonistic emotions.  A similar interpretation was made of the finding of reduced sensitivity 
to angry faces in 13 patients with depersonalization personality disorder, a disorder that has 
been associated with severe psychological trauma, using a similar facial morphing paradigm 
(Montagne et al., 2007). Interpreting impairment in the ability to identify anger as resulting 
from avoidance is also consistent with the association we found between performance on 
the awareness subscale of the DERS and accuracy at identifying anger.   The DERS 
awareness subscale can be conceived of as a measure of the acknowledgement of primarily 
adverse emotions, as illustrated by the wording of its items (eg. “When I’m upset, I 
acknowledge my emotions”) (Gratz & Roemer, 2004). 
 
Additional support for interpreting poor accuracy in identifying angry faces in terms of 
avoidance mechanisms is provided by a study of 129 adults with a history of child abuse (as 
assessed on the CTQ) recruited from general medical clinics (Fani et al., 2011). 
Performance on the affective dot-probe task in this sample failed to discriminate between the 













p < 0.01) towards happy faces was observed in the trauma group.  This finding, in 
combination with the positive association between the happiness bias and symptoms of 
avoidance/numbing on the Modified PTSD Symptom Scale (Falsetti, Resnick, Resick, & 
Kilpatrick, 1993) led the researchers to suggest that their sample may have demonstrated 
avoidance of aversive stimuli in favor of positive stimuli.  
 
Our findings differ from the only published study of the long-term effects of childhood trauma 
on emotion recognition in healthy adults, which found that trauma exposure was linked to 
improvements in the accuracy with which angry faces were identified (Gibb et al., 2009). The 
authors suggested that increased accuracy in identifying anger may be due to an attentional 
bias in adults with childhood trauma, as detected on a dot-probe task included in the study.  
However, a recent publication using an identical dot-probe task to that employed in Gibb et 
al. (2009) found evidence of avoidance with respect to angry faces (Johnson et al., 2010).  
Methodological differences that may have contributed towards the discrepant findings 
reported between this study and that of Gibb et al. (2009), include differences in the task 
employed (dynamic versus static display), the  fact that our study employed a placebo-
controlled pharmacological challenge design, and the facial stimuli employed. 
 
As hypothesized, administration of a single dose of buprenorphine partially normalised 
responses of participants with a history of trauma to both fear and anger.  This finding 
appears to contradict observations reported in a recent publication (Carroll et al., 2011), in 
which the acute administration of opioids produced no discernable effect on the recognition 
of anger or fear amongst 20 patients in a pain-management setting.  However, this study did 
not contain a control group nor did it assess childhood adversity.  Furthermore, the authors 
also noted that the failure to detect an effect of opioid medication may have been attributable 














Instead, the observation that the effect of a partial mu-opioid agonist on responses to 
threatening emotions can be predicted by an adult’s early life history suggests that  a 
dysregulated opioid system may be mediating these effects.  In a PET study, Liberzon et al. 
(2007) found that the OFC was one of the few regions that differentiated  trauma exposed 
individuals with PTSD from those without PTSD in terms of opioid receptor occupancy 
levels, indicating possible compensatory failure in the clinical population. The observation 
that PTSD is frequently associated with the poor control of aggressive impulses is consistent 
with the characterisation of the OFC as one of the primary sites involved in regulating anger 
(Blair, 2003). These observations support a putative role for the opioid system in dampening 
responses to both physical pain and “social pain”, and provide proof of principle support for 
future research on the therapeutic use of opioid agents in patients with emotion 
dysregulation.  
 
Our data emphasize that gender differences are important in understanding the influence of 
trauma history on processing aversive emotions. Across conditions, women were 
significantly more accurate in recognising fear than men.   Moreover, women with a history of 
childhood trauma were significantly faster in recognising fear across placebo and medication 
sessions compared to women without a history of trauma (no effect was observed for anger). 
These findings are consistent with evidence from the literature for greater sensitivity 
amongst females to negative emotional expressions (Montagne, Kessels, Frigerio, de Haan, 
& Perrett, 2005; Thayer & Johnsen, 2000), particularly at low emotional intensities. 
 
Scores on self-rating scales of urgency, a form of impulsivity that is conceptualized as being 
moderated by negative effect (Whiteside & Lynam, 2001), did not differentiate between 
trauma and non-trauma groups, or correlate with the effects of medication on accuracy for 
either angry or fearful faces. This was despite recent findings that scores on the impulsivity 
and deliberation facets of the self-rated NEO PI-R personality scale predicted endogenous 













including the right anterior cingulate, ventral basal ganglia and basolateral amygdala, both at 
baseline and in response to a physical pain stressor (Love, Stohler, & Zubieta, 2009).  
 
Nevertheless, other individual differences may contribute to variance in the effect of opioids 
on the association between child trauma exposure and responses to negative emotions. 
There is evidence, for example, that the amygdala, a core component of brain circuitry 
involved in emotion regulation, is differentially active in individuals with the short variant of 
the serotonin transporter gene on exposure to emotional faces (Hariri et al., 2002; Hariri et 
al., 2005). Indeed, preferential avoidance of angry faces in the dot-probe task amongst 
women who had been physically abused as children was only observed for subjects with this 
genetic variant (Johnson et al., 2010). Ethnicity has also been identified as a possible 
determinant of responses to emotional faces. A meta-analysis reported that emotion 
recognition was more accurate in individuals from the same ethnic group as the actors 
whose faces are displayed (Elfenbein & Ambady, 2002).  Responses to the ethnic 
composition of faces was also cited by  Fani et al. (2011) in explaining the bias towards 
positive emotions that they observed in their mainly African American sample. This was 
interpreted by the investigators as possibly reflecting avoidance of neutral and angry 
Caucasian faces that were perceived as particularly threatening.  
 
A number of additional alternative explanations for this study’s findings should be 
considered.  There was evidence of improvements in task performance across testing 
sessions for both fear and anger faces. Although this may be indicative of possible learning 
effects, it is unlikely to explain trauma-specific increases in accuracy and reaction across 
sessions. The observation that trauma was associated with faster responses and worse 
accuracy might also suggest that these trauma-effects could be explained in terms of speed-
accuracy trade-offs. Specifically, it has been suggested that the selective effects of 
medication on the recognition of negative emotions in previous studies could represent an 













identifying negative emotions (Murphy, Norbury, O'Sullivan, Cowen, & Harmer, 2009). 
However, we failed to detect differences between trauma groups on the tiredness and 
energy visual analogue mood scales, indicating that this cannot account for the differences 
observed between the trauma groups.  
 
Overall, these data support our hypothesis of an association between the opioid system, 
early adversity, and modulation of facial processing.  In particular, early adversity may lead 
to neurochemical alterations that facilitate recognition of threatening emotions, and 
administration of opioid agonist may act to normalize such emotional processing.  Future 
research on emotion recognition should assess subjects for history of early adversity.  The 
findings here provide support for additional research on the opioid system and emotional 
dysregulation in clinical populations, including the use of opioid agents to ameliorate deficits 
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The primary aim of the review of pharmacotherapy for disruptive behavioural disorders in 
children and adolescents was to attempt to identify the involvement of serotonin in these 
disorders, and relate serotonergic abnormalities to the impulsivity and deficits in affect 
regulation that frequently characterise these disorders. Unfortunately, none of the 
randomised controlled trials included in our review, or in a recent review of 
psychopharmacology for aggression in children and adolescents with a primary psychiatric 
disorder (Nevels, Dehon, Alexander, & Gontkovsky, 2010) specifically tested the efficacy of 
agents that selectively target serotonergic systems. 
 
Instead, psychostimulants emerged as the class of agents most frequently tested in treating 
child and adolescent disruptive behavioural disorders, with evidence of efficacy for 
methylphenidate (Ritalin) being particularly apparent. The mechanism of action of the 
psychostimulants has typically been described in terms of their molecular effects on the 
dopamine neurotransmitter system (Del Campo, Chamberlain, Sahakian, & Robbins, 2011; 
Heal, Cheetham, & Smith, 2009). The majority of the evidence-base implicates dopamine 
with regards to impulsive acts that are reward-related, such as assessed using delayed 
discounting tasks, however, rather than motor inhibition, per se (Fineberg et al., 2010; Pine, 
Shiner, Seymour, & Dolan, 2010). For instance, in a recent review of the 
neuropsychopharmacology of action inhibition, Eagle and colleagues (2008) found little 
evidence for an association of either D1 or D2 genotypes with performance on the stop-
signal or GNG tasks. Moreover, the reviewers drew attention to the fact that those few 
studies that find an effect of non-stimulant dopaminergic challenges on nogo performance 
only do so when correct inhibitions are rewarded.  
 
Although there is little evidence that abnormal levels of dopamine have direct bearing on 













implicating the downstream involvement of serotonergic pathways in the effects of the 
methylphenidate on symptoms of impulsivity and aggression.  
 
Hints that the effects of methylphenidate on impulsivity may be mediated through non-
dopaminergic neurotransmission was provided by the finding in one study that 
methylphenidate reduced motor activity in a dopaminergic-knockout ADHD mouse model, 
despite high extra-cellular levels of dopamine in the brains of these animals (Giros, Jaber, 
Jones, Wightman, & Caron, 1996). Thakur and colleagues (2010) subsequently probed the 
implications of this and other findings from the animal literature for human subjects, by 
investigating the possibility that serotonergic function might explain the response of ADHD 
symptoms to methylphenidate in 157 children between the ages of 6 and 12. Using a 
randomised placebo-controlled design, they demonstrated that those subjects who were 
homologous for the long variant of the 5-HTTLPR polymorphism of the SLC6A4 gene 
serotonin transporter gene responded to 1 week treatment with 0.5mg/kg/day of 
methylphenydate but not placebo on the Connors Global Index for Parents (a scale 
composed of the factors of “emotional lability” and “restless-impulsive behaviour” - (Conners, 
1999)). The converse pattern was observed in individuals with a genotype (s/s) that is less 
efficient in the transcription of serotonin. The implication that serotonergic mechanisms might 
be mediating the effects of methylphenidate is further strengthened by parallel findings from 
a study of the treatment of borderline personality disorder with the SSRI fluoxetine, in which 
reduction of scores on the anger subscale of the OAM were only observed in carriers of the 
more efficient l/l 5-HTT polymorphism (Silva et al., 2010).  
  
The mood stabiliser lithium is frequently prescribed for the treatment of aggressive behaviour 
in youth, and our review indicated that it may be efficacious in this regard (see also Masi et 
al. 2009).  There is evidence that lithium treatment over the long term may be associated 
with the synthesis of 5-HTT, and that this may be at least partially responsible for its anti-













likely given evidence from the animal and human literature reviewed by Krakowski and 
colleagues (2003) that low levels of CNS serotonin are associated with aggressive 
behaviour.  
 
These observations in combination indicate that future investigations of the effects of 
serotonin in affecting anger regulation and impulsivity in ODD populations may be 
warranted. This is likely to be particularly important given the evidence that ODD may be a 
potential precursor to conduct disorders, which in turn is associated with antisocial 
personality disorder in adulthood (Biederman et al., 1996; Copeland, Shanahan, Costello, & 
Angold, 2009; Whittinger, Langley, Fowler, Thomas, & Thapar, 2007). 
 
A review of pharmacotherapy for PTSD in adults was subsequently conducted to determine 
whether the responsiveness of overall PTSD symptoms, as well as individual PTSD clusters 
to serotonergic agents could provide information on the interaction between serotonin and 
long-term dysregulations of affect following trauma exposure. Indeed, we detected significant 
treatment effects for medication overall on the total CAPS scores, with the majority of 
evidence for the SSRIs. Medication effects were also observed for the individual intrusion/re-
experiencing, avoidance/numbing and hyperarousal symptom clusters. In addition, effects of 
medication on mood were detected, with a reduction in symptoms of depression but not 
anxiety following pharmacotherapy.  
 
At the level of individual medication classes, however, no differences were observed 
between the SSRIs and the other medications on any of the symptom clusters. This is 
consistent with the finding of no differences across symptom clusters in a direct comparison 
of 12 weeks of treatment with the SSRI fluoxetine, the serotonin reuptake enhancer 
tianeptine, and the reversible monoamine oxidase inhibitor (RIMA), MAO-I moclobemide 
(Onder, Tural, & Aker, 2006). This was despite predictions by the authors that the effects of 













hyperarousal symptoms,  and moclobemide for re-experiencing and avoidance symptoms. 
 
A closer look at the agent-specific effects for SSRIs across the different symptom clusters 
(data extracted from PTSD pharmacotherapy meta-analysis) also reveals a substantial 
amount of consistency in the ranking of the effects of the particular agents, with paroxetine 
demonstrating the largest effect across all symptom clusters (Table 1).  
 
     Table 1. Agent-specific effects of serotonergic medications on PTSD symptom clusters 
 Intr usion  Avoidance  Hyperarousal  
 Sample  Effect  Sample  Effect  Sample  Effect  





3,728 -3.64 [-4.95, -
2.33] 
Fluoxetine 2; 599 -2.38 [-4.12, -
0.64] 
2; 598 -2.42 [-
4.57, -
0.27] 
2; 599 -2.32 [-3.95, -
0.69] 
Sertraline 5; 864 -0.99 [-2.08, 
0.09] 
5; 864 -3.32 [-
4.99, -
1.65] 
5; 864 -2.07 [-3.32, -
0.82] 
Citaloram 1; 35 1.66 [-6.31, 
9.63] 
1; 35 2.08 [-
7.76, 
11.92] 
1; 35 1.04 [-5.44, 
7.52] 
  Sample: No. of studies; participants 
  Effect: Random effect estimates of Weighted mean difference between medication and  
  placebo groups on the CAPS (point estimate, 95% confidence interval)  
 
One possible explanation for these null findings is that the temporal resolution of these trials 
may not be sufficient to distinguish between primary effects of medication, and secondary 
knock-on effects on other symptoms. This is suggested by separate pooled analyses of the 
SSRI sertraline and the serotonin – noradrenergic reuptake inhibitor (SNRI) venlafaxine in 
treating PTSD (Davidson, Landerman, Farfel, & Clary, 2002; D. J. Stein et al., 2009). Both of 
these studies observed a reduction in angry outbursts or irritability as early as 2 weeks after 
initiation of treatment across two RCTs, with improvements in other symptoms only observed 
later. Reductions following venlafaxine treatment in numbing symptoms measured using the 













observed after 6 to 8 weeks of treatment. This effect was explained as a possible 
serotonergic response that mediated subsequent reductions in other symptoms (D. J. Stein 
et al., 2009).  
 
The suggestion that medication effects in reducing overall PTSD symptom severity are 
mediated by serotonergic dampening of anger/irritability is consistent with evidence from 
longitudinal studies that reductions in symptoms of hyperarousal, of which anger and 
irritability is one component, may drive subsequent changes in avoidance/numbing and 
intrusion symptoms (Schell, Marshall, & Jaycox, 2004; Z. Solomon, Horesh, & Ein-Dor, 
2009). A similar temporal precedence has been observed for hyperarousal symptoms with 
respect to numbing symptoms in traumatised children (Weems, Saltzman, Reiss, & Carrion, 
2003). Conversely, studies have typically found that the association between anger and 
PTSD becomes stronger as the duration with which individuals have lived with PTSD 
increases (Ehlers, Mayou, & Bryant, 1998; Feeny, Zoellner, & Foa, 2000), suggesting that 
poorly regulated anger may be a crucial component in the maintenance of pathological 
responses to trauma.  
 
Assessing the direct effect of medication on affect might therefore provide further insight into 
the possible neurocircuitry involved in pathological responses to psychological trauma. 
Unfortunately, few of the clinical trials of PTSD included in the review reported on treatment-
associated changes in affect. Investigation of the association between impulsivity and affect 
regulation are rendered even more problematic, given the multidimensional nature of both 
constructs and the use by different research teams of a variety of (frequently non-validated) 
measures of these constructs. Investigations of the association of trauma-exposure and 
aggressive impulsivity are further complicated by the tendency of anger researchers to use 
implicit definitions of “aggression” versus “impulsivity”, or indeed, to use these terms 














In an attempt to introduce some conceptual clarity regarding the relationship between 
aggression and impulsivity, Garcia-Forero and colleagues (2009) recently compared scores 
on self-reported measures of trait impulsivity and trait aggression in  768 healthy participants 
(ages ranging between 12 and 72 years), using Spanish adaptations of the Barrat Impulsivity 
Scale (Mathias, Stanford, Marsh, Frick, & Moeller, 1991), and the Aggression Questionnaire - 
Refined (AQ-R; (Gallardo-Pujol & Andres-Pueyo, 2006)), respectively. They detected a 
maximum canonical correlation between the scales of 0.42, leading them to conclude that 
impulsivity and aggression are largely independent constructs. Nevertheless, correlations 
between individual subscales of the AQ-R and the total BIS score revealed the largest 
association between anger and impulsivity (R = 0.37), providing some support for the 
concept of affect-driven impulsivity.  
 
One potential useful strategy in investigating the relationship between affect regulation and 
impulsivity that would bypass the paucity of information on affect regulation in clinical trials of 
pharmacotherapy for PTSD, as well as the conceptual confusion regarding the definition of 
these constructs, is to operationalise affect regulation and impulsivity in terms of 
performance on laboratory tasks. Performance on these tasks is likely to be a more reliable 
measure than scores on self-report questionnaires, thereby reducing the contribution of 
random error to contradictory findings in the literature. Moreover, fMRI allows one to use 
blood oxygenation (fMRI) as a relatively high (spatial) resolution proxy for brain activation 
that coincides with task execution. Reviewing studies that employ fMRI within the context of 
behavioural testing may therefore help to elucidate those regions of the brain that form the 
functional substrate of the particular behavioural construct under investigation.  
 
The ALE review of fMRI studies employing the standard GNG paradigm identified motor 
inhibition as being served by a largely right-lateralised fronto-parietal circuit that included the 













paradigm (Buchsbaum et al., 2005; Nee et al., 2007; Swick et al., 2011). In addition, 
differences between the affective and standard versions of the task were evident in regions 
of the brain typically considered to be part of the “emotional brain”, and included the 
amygdala, cingulate and anterior insula.   
 
The GNG imaging meta-analysis was based on the largest number of studies to date, using 
methods that accommodate between study variability in sample size and precision. The 
results of this meta-analysis may therefore form a useful reference against which to compare 
activation patterns in the brains of individuals with a history of trauma or who have been 
diagnosed with impulsive disorders.  
 
Evidence that trauma-associated psychopathology may interfere with normal inhibitory 
processes was provided by Falconer et. al. (2008), who not only detected a higher 
commission error rate in 23 PTSD patients versus controls, but also reported a negative 
correlation between the severity of PTSD symptoms and activation of the rIFG, DLPFC, 
medial PFC and cerebellum, regions identified by the ALE meta-analysis as involved in 
motor inhibition in healthy individuals. Moreover, controlling for differences in performance, 
Falconer et al. (2008) observed greater activation of the right inferior frontal/VLPFC cortex in 
control subjects (including healthy controls and trauma-exposed non-PTSD subjects), with 
the PTSD patients recruiting the cuneus, cerebellum, putamen, parahippocampus and 
postcentral cortex to a greater extent than healthy controls. The finding that somatosensory 
and striatal regions of the brain were recruited to a greater extent during inhibitory 
performance in the PTSD group was interpreted by the authors as suggesting a state of 
hyperarousal in these participants, with concomitant increases in the processing of sensory 
stimuli. This would conceivably have placed greater demands on inhibitory control centres in 
the brain (hence the increased striatal activation), impairing the capacity of the cortex to 














Another fMRI study compared 14 healthy control children to 16 children with exposure to at 
least one criterion A interpersonal stressor, and with posttraumatic stress symptoms (PTSS), 
as assessed using the Clinician Administered PTSD scale for Children (Carrion, Garrett, 
Menon, Weems, & Reiss, 2008). The investigators hypothesised that increased activation 
would be observed in brain regions associated with hyperarousal states, such as the insula, 
with corresponding reductions in frontal regions associated with inhibition. Although no 
differences between groups in performance were observed, these hypotheses were largely 
upheld, with decreased activation observed in the middle frontal cortex in children with PTSS 
relative to healthy controls, as well as greater left inferior temporal and occipital activation 
(once depression was controlled for). Activation in the insula correlated with severity of 
PTSD symptoms, and particularly with hyperarousal and avoidance/numbing symptoms 
(Carrion et al., 2008).  
 
Although the literature on the effects of trauma exposure on motor inhibition, as assessed by 
the GNG paradigm, is sparse, the findings are largely in agreement with the argument that 
hyperarousal symptoms may account for inhibitory deficits following trauma exposure. 
Nevertheless, there are a number of caveats that need to be made with reference to this line 
of reasoning. Firstly, the extent to which inhibitory deficits and their functional correlates are 
related to trauma exposure versus a clinical diagnosis of PTSD merits further investigation. 
For instance, Falconer and colleagues (2008) discovered that the findings they observed 
with respect to abnormal patterns of brain activation in PTSD patients were not evident in 
trauma exposed non-PTSD subjects, who did not differ in any of the regions of interest from 
healthy controls. Secondly, greater attention should be paid to the possible influence of 
comorbid psychiatric conditions on inhibitory performance in patients with post-traumatic 
symptoms, particularly when the comorbidities are associated with increased impulsivity. 
This is indicated by the finding in Carrion et al. (2008) that a history of self-injurious 













with correct inhibitions in our ALE meta-analysis, including the insula, putamen, and inferior 
frontal cortex/operculum, all in the right hemisphere.  
 
Nevertheless, despite these caveats, in general these findings indicate that the GNG might 
be usefully employed to examine trauma-specific deficits. Moreover, the association of 
serotonin deficiencies with hyperarousal (including anger) are grounds for arguing that this 
paradigm might be particularly sensitive to the effects of serotonin in individuals who have 
been exposed to trauma. This argument is supported by our finding that SSRIs are effective 
in treating PTSD, as well as by the conclusion reached by Eagle and colleagues (2008), in a 
review of human and animal psychopharmacology research on motor inhibition, that 
performance on the GNG, as opposed to the stop-signal task, is specifically influenced by 
levels of serotonin.  
 
In the final component of this dissertation, we argued that the opioid system holds particular 
promise in explaining the relationship between trauma exposure and affective dysregulation. 
The possibility that the analgesic affects of endogenous opioids may be involved in down-
regulating responses to negative emotions is suggested by the observation that 
neuralcircuitry common to both pain and affect regulation, including the anterior insula, 
rostral ACC, amygdala, ventral striatum (such as the nucleus accumbens), OFC and peri-
aqueductal gray (PAG), are rich in mu-opioid receptors (Bruehl et al., 2009). The consistent 
observation across studies of a correlation between pain and the expression of anger 
(anger-out), as reviewed by Bruehl et al. (2009), has implications for the affective sequelea 
of psychological trauma, given the association of PTSD with poor anger control and lower 
pain thresholds (Kraus et al., 2009). The observation in our study that opioid administration 
improved the accuracy of recognising fearful faces in adults with a history of childhood 
trauma provides indirect evidence that the poor recognition of fear may be due to altered 














Our finding of a relationship between a person’s accuracy in recognising anger and their 
preparedness to acknowledge negative emotions suggests that non-acceptance of 
emotional responses might be crucial to the phenomenology of impaired emotional 
responses in those with a history of childhood abuse and/or neglect. Indeed, the intensity of 
negative emotions predicted posttraumatic symptoms in victims of childhood interpersonal 
abuse, but only via mediation through non-acceptance or fear of those emotions (Tull, 
Jakupcak, McFadden, & Roemer, 2007). Further evidence that the acceptance of negative 
emotions might be a crucial component of deficits in emotion regulation associated with 
trauma exposure is provided by the finding of a relationship between PTSD symptoms and 
anxiety sensitivity, defined as the fear of experiencing anxiety-related physical sensations 
(Federoff, Taylor, Asmundson, & Koch, 2000; Zahradnik, Stewart, Marshall, Schell, & Jaycox, 
2009).  
 
It might have been predicted that trauma history would have increased attentiveness 
towards threatening stimuli, rather than what appears to be avoidance responses. Indeed, 
this is what Gibb and colleagues (2009) observed in their study employing a similar 
paradigm to the one we employed (Gibb, Schofield, & Coles, 2009). Moreover, studies have 
typically found PTSD in adults to be associated with increased attention to threat (eg. see 
Weber et al. (2008) for a recent review).  
 
However, it should be noted that the findings of an attentional bias towards threatening 
stimuli in adults has most consistently been observed with respect to the allocation of 
attentional resources to trauma-specific sources of threat (Weber, 2008).  Additionally, it 
seems reasonable to speculate that trauma exposure during childhood and adulthood might 
differ with regards to their consequences for emotion regulation strategies. For instance, 
there is evidence that physical abuse can result in chronic hypoarousal of the autonomic 
nervous system in children, with behavioural correlates of emotional numbing and 













2005). This would be consistent with the speculative notion that emotional numbing and 
avoidance behaviour might be an adaptive response in children to abuse by caregivers who 






































This dissertation attempted to employ a range of methods to determine the extent to which 
there is evidence for a relationship between behavioural impulsivity and poor regulation of 
affect amongst individuals with a history of psychological adversity. We were able to 
ascertain, via a meta-analysis of randomised controlled pharmacotherapy trials, that there 
has been very little rigorous testing of the efficacy of serotonergic agents in treating 
disruptive behavioural disorders in children and adolescents. This, despite indications from 
the research literature that (a) the poor regulation of anger is a prominent feature of DBDs, 
(b) that anger may be mediated by insufficient levels of serotonin, and (c) by evidence that 
other commonly employed agents in treating these disorders, such as lithium and the 
stimulant, methylphenidate, may achieve their efficacy with respect to the affective aspects 
of these disorders by means of interactions with the serotonergic system.  
 
In contrast to the treatment literature for paediatric oppositional defiant disorder and conduct 
disorder, the selective serotonin reuptake inhibitors are regarded as first-line agents in the 
treatment of PTSD. However, a quantitative synthesis of treatment data from 
pharmacotherapy trials for PTSD revealed that despite predictions that the SSRIs should be 
particularly efficacious for hyperarousal and avoidance symptoms, there was little evidence 
from the RCT evidence base that this is actually the case. This may be a consequence of 
insufficient temporal resolution of the effects of SSRIs to discriminate between the primary 
and secondary effects of these agents. Indeed, there is some evidence that an early 
response of hyperarousal symptoms in general, and anger in particular, to agents that act via 
serotonergic pathways might predict subsequent improvement on re-experiencing and 
avoidance/numbing symptoms. Further medication studies in trauma-exposed individuals 














The GNG paradigm represents one potential method of discerning the effects of changes in 
affect on impulsive behaviour. The validity of this paradigm in isolating neural circuits 
regarded as crucial for the inhibition of motor responses was confirmed by means of an ALE 
meta-analysis of 51 studies employing different versions of the GNG task. This meta-
analysis demonstrated that variants of the GNG task that employ affective stimuli are able to 
elicit responses from limbic regions of the brain that have been implicated as hyperactive in 
patients with PTSD. Other studies using this paradigm in trauma-exposed populations have 
observed brain activation patterns consistent with an interpretation of the disruption of 
inhibitory circuits through sensory hyperarousal. These observations, in combination with 
preliminary evidence for the selectivity of SSRIs for hyperarousal symptoms, suggests that 
the affective GNG paradigm might be a suitable candidate for the reliable measurement of 
the effects of serotonergic agents on emotionally-driven impulsive behaviour in trauma-
exposed populations.  
 
Finally, the strategy of identifying neurotransmitter systems that may play a role in the 
aetiology of trauma-related disturbances in impulse control and affect regulation by studying 
the effects of pharmacotherapy was implemented in the final component of this dissertation. 
A placebo-controlled test of the hypothesis that mu-opioids would remediate any hyper-
sensitivity in adults with a history childhood adversity to aversive emotions revealed that 
acute treatment with buprenorphine normalised deficits in the recognition of fearful faces in 
the trauma group. In addition, we found evidence that poorer accuracy in identifying angry 
faces in the trauma group relative to the controls may be partly explained by the tendency 
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